EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Total documents retrieved: 111

Results Generated From:
Embase <1980 to 2022 Week 24>
Embase Weekly Updates (updates since 2022-06-10)

<1>
Accession Number
2015409833
Title
Efficacy and safety of a bridging strategy that uses intravenous platelet
glycoprotein receptor inhibitors for patients undergoing surgery after
coronary stent implantation: a meta-analysis.
Source
BMC Cardiovascular Disorders. 22(1) (no pagination), 2022. Article Number:
125. Date of Publication: December 2022.
Author
Wu F.; Ma K.; Xiang R.; Han B.; Chang J.; Zuo Z.; Luo Y.; Mao M.
Institution
(Wu, Ma, Xiang, Chang, Zuo, Luo, Mao) Department of Cardiology, The First
Affiliated Hospital of Chongqing Medical University, No. 1, Youyi Road,
Yuanjiagang, Yuzhong District, Chongqing 400016, China
(Han) College of Medical Informatics, Chongqing Medical University,
Chongqing 401135, China
Publisher
BioMed Central Ltd
Abstract
Background: Current guidelines indicate we can consider a bridging
strategy that uses intravenous, reversible glycoprotein inhibitors for
patients that required surgery following recent stent implantation.
However, no strong clinical evidence exists that demonstrates the efficacy
and safety of this treatment. Therefore, in this study, the efficacy and
safety of a bridging strategy that uses intravenous platelet glycoprotein
receptor inhibitors will be evaluated. <br/>Method(s): A meta-analysis was
performed on preoperative bridging studies in patients undergoing coronary
stent surgery. The primary outcome was the success rate of no major
adverse cardiovascular events (MACE). The secondary outcomes were the
success rate of no reoperations to stop bleeding. <br/>Result(s): A total
of 10 studies that included 382 patients were used in this meta-analysis.
For the primary endpoint, the success rate was 97.7% (95% CI 94.4-98.0%)
for glycoprotein IIb/IIIa inhibitors, 98.8% (95% CI 96.0-100%) for
tirofiban (6 studies) and 95.8% (95% CI 90.4-99.4%) for eptifibatide (4
studies). For secondary endpoints, the success rate was 98.0% (95% CI
94.8-99.9%) for glycoprotein IIb/IIIa inhibitors, 99.7% (95% CI 97.1-100%)
for tirofiban (5 studies), and 95.3% (95% CI 88.5-99.4%) for eptifibatide
(4 studies). <br/>Conclusion(s): The results of this study showed that the
use of intravenous platelet glycoprotein IIb/IIIa inhibitors as a bridging
strategy might be safe and effective for patients undergoing coronary
stent implantation that require surgery soon after.<br/>Copyright &#xa9;
2022, The Author(s).

<2>
Accession Number
2014496019
Title
The effect of pulsatile versus non-pulsatile flow during cardiopulmonary
bypass on cerebral oxygenation: A randomized trial.
Source
Asian Cardiovascular and Thoracic Annals. 30(4) (pp 441-448), 2022. Date
of Publication: May 2022.
Author
Moosaeifar S.; Mousavizadeh M.; Najafi Ghezeljeh T.; Hosseinian A.; Babaee
T.; Hosseini S.; Mestres C.A.
Institution
(Moosaeifar) Department of Critical Care Nursing and Midwifery, Iran
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Mousavizadeh, Hosseinian, Babaee, Hosseini) Heart Valve disease Research
Center, Rajaie Cardiovascular, Medical and Research Center, Iran
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Najafi Ghezeljeh) Center for Nursing Care Research, Department of
Critical Care Nursing and Midwifery, Iran University of Medical Sciences,
Tehran, Iran, Islamic Republic of
(Mestres) Department of Cardiac Surgery, University Hospital Zurich,
Zurich, Switzerland
Publisher
SAGE Publications Inc.
Abstract
Background: The present study aims to compare regional oxygen supply
determined by Near-Infrared Spectroscopy in the course of pulsatile
perfusion with non-pulsatile perfusion during cardiopulmonary bypass in
patients undergoing valvular heart surgery. <br/>Method(s): In this
prospective randomized single-blinded trial, we enrolled adult subjects
aged 18-65 years scheduled for elective valvular heart repair/replacement
surgery with non-stenotic carotid arteries, employing a consecutive
sampling method. Eligible patients were then randomly assigned in a 1:1
ratio to pulsatile or non-pulsatile perfusion during aortic cross-clamp.
The primary outcome was regional cerebral oxygenation monitored by
Near-Infrared Spectroscopy in each group. <br/>Result(s): Seventy patients
were randomly assigned, and each group comprised 35 patients. Mean age was
46.8 and 46.5 years in pulsatile and non-pulsatile groups, respectively.
There were no significant between-group differences in regional cerebral
oxygen saturation at different time points of cardiopulmonary bypass
(p-value for analysis of variance repeated measures: 0.923 and 0.223 for
left and right hemispheres, respectively). Moreover, no significant
differences in regional cerebral oxygen saturation levels from baseline
between pulsatile and non-pulsatile groups at all desired time points for
the left (p = 0.51) and right (p = 0.22) hemispheres of the brain were
detected. <br/>Conclusion(s): Pulsatile perfusion during cardiopulmonary
bypass does not offer superior regional cerebral oxygenation measured by
Near-Infrared Spectroscopy than non-pulsatile perfusion during
cardiopulmonary bypass. Nonetheless, the efficacy of pulsatile flow in the
subgroup of patients in whom cerebral blood flow is impaired due to
carotid artery stenosis needs to be explored and evaluated by this method
in future studies.<br/>Copyright &#xa9; The Author(s) 2021.

<3>
Accession Number
2017940646
Title
The role of aromatherapy with lavender in reducing the anxiety of patients
with cardiovascular diseases: A systematic review of clinical trials.
Source
Journal of HerbMed Pharmacology. 11(2) (pp 182-187), 2022. Date of
Publication: 2022.
Author
Amin A.; Gavanrudi M.R.; Karami K.; Raziani Y.; Baharvand P.
Institution
(Amin) Cardiovascular Research Center, Lorestan University of Medical
Sciences, Khorramabad, Iran, Islamic Republic of
(Gavanrudi) Faculty of Pharmacy, Ayatollah Amoli Branch, Islamic Azad
University, Amol, Iran, Islamic Republic of
(Karami, Baharvand) Social Determinants of Health Research Center,
Lorestan University of Medical Sciences, Khorramabad, Iran, Islamic
Republic of
(Raziani) Department of Nursing, Komar University of Science and
Technology, Kurdistan Region, Sulaymaniyah, Iraq
Publisher
Nickan Research Institute
Abstract
Most studies have shown the positive effects of lavender inhalation in
decreasing anxiety in patients with cardiovascular diseases. We aimed to
systematically review the role of aromatherapy with lavender in these
patients. By PRISMA standards, we explored the studies on the role of
aromatherapy with lavender in reducing the anxiety of patients with
cardiovascular diseases in English databases through the words and terms
"aromatherapy", "lavender", "lavandula", "anxiety", "cardiovascular
diseases". Out of 16 647 papers, 12 papers up to January 2022 encountered
the inclusion criteria for involving in this systematic review. The
majority of studies (7 studies, 70%) were used Spielberger Standard
Questionnaire as a measurement scale for their studies. Lavender
aromatherapy was mostly used for myocardial infarction (3 studies, 30%)
and coronary artery bypass graft (CABG) surgery (3 studies, 30%) patients.
We concluded that aromatherapy with lavender essential oil significantly
ameliorated the anxiety signs in some cardiovascular diseases, e.g., CABG
surgery, myocardial infarction, and cardiac ischemia; however, more
studies are required in this field to obtain more specific
evidence.<br/>Copyright &#xa9; 2022 Nickan Research Institute. All rights
reserved.

<4>
Accession Number
2017687537
Title
Efficacy of Date Palm Pollen in the Male Sexual Dysfunction after Coronary
Artery Bypass Graft: A Randomized, Double-Blind, Clinical Trial.
Source
Evidence-based Complementary and Alternative Medicine. 2022 (no
pagination), 2022. Article Number: 5032681. Date of Publication: 2022.
Author
Hooshang H.; Farahani A.V.; Rezaeizadeh H.; Forouzannia S.K.; Alaeddini
F.; Ashraf H.; Karimi M.
Institution
(Hooshang) Department of Persian Medicine, School of Persian Medicine,
Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Farahani) Clinical Cardiac Electrophysiology, Department of Cardiology,
School of Medicine, Cardiac Primary Prevention Research Center,
Cardiovascular Diseases Research Institute, Tehran Heart Center,
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Rezaeizadeh) Traditional Medicine, Department of Persian Medicine, School
of Persian Medicine, Cardiac Primary Prevention Research Center,
Cardiovascular Diseases Research Institute, Tehran University of Medical
Sciences, Tehran, Iran, Islamic Republic of
(Forouzannia) Department of General Surgery, School of Medicine, Research
Center for Advanced Technologies in Cardiovascular Medicine,
Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Alaeddini) Department of Research, Tehran Heart Center, Tehran University
of Medical Sciences, Tehran, Iran, Islamic Republic of
(Ashraf) Cardiology Sina Hospital, Tehran University of Medical Sciences,
Tehran, Iran, Islamic Republic of
(Karimi) Traditional Medicine, Department of Persian Medicine, School of
Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran,
Islamic Republic of
Publisher
Hindawi Limited
Abstract
Background. Bypass graft surgery of the coronary artery has a significant
effect on the creation and development of sexual dysfunction among male
patients. The previous studies have demonstrated that date palm pollen
(DPP) increases the count and quality of sperm. Additionally, it has been
shown that DPP has a protective effect against myocardial infarction and
cardiac remodeling. Therefore, this is the first study investigating the
impact of DPP (Phoenix dactylifera L.) on managing male sexual dysfunction
after coronary artery bypass graft. Methods. This randomized,
double-blind, placebo-controlled clinical trial was conducted on 60
patients (DPP group n = 30, control group n = 30) of Iranian men after
coronary artery bypass graft. Two parallel groups were randomly generated
from the study participants. The intervention group was prescribed 3 grams
of the powder of DPP twice a day (9 AM and 9 PM) for two months, while the
control group received the same prescription of the placebo powder.
Results. The DPP consumption significantly increased the International
Index of Erectile Function (IIEF) (from 23.21 to 46.57) and the Hurlbert
Index of Sexual Desire (HISD) (from 59.39 to 64.45) scores over time in
the intervention group. However, there were no significant changes in the
control group. Conclusion. Daily intake of 6 g DPP for two months
exhibited beneficial effects on the symptoms of male sexual dysfunction in
patients who have undergone coronary artery bypass graft
(CABG).<br/>Copyright &#xa9; 2022 Hamed Hooshang et al.

<5>
[Use Link to view the full text]
Accession Number
2017651747
Title
Colchicine for Patients With Coronary Artery Disease: A Systematic Review
and Meta-analysis.
Source
Journal of Cardiovascular Pharmacology. 79(4) (pp 420-430), 2022. Date of
Publication: 11 Apr 2022.
Author
Shrestha D.B.; Budhathoki P.; Sedhai Y.; Khadka M.; Pokharel S.; Yadav S.;
Patel T.; Elgendy I.; Mir W.A.Y.; Patel N.K.
Institution
(Shrestha, Mir) Department of Internal Medicine,, Mount Sinai Hospital,
Chicago, IL, United States
(Budhathoki) Department of Internal Medicine, Bronxcare Health System,
Bronx, NY, United States
(Sedhai) Department of Internal Medicine, Division of Hospital Medicine,
Virginia Commonwealth University,, School of Medicine, Richmond, VA,
United States
(Khadka, Pokharel, Yadav) Nepalese Army Institute of Health Sciences
(NAIHS), Kathmandu, Nepal
(Patel) P Department of Internal Medicine, Division of Cardiology,
AdventHealth - AdventHealth Medical Group at East Orlando, Orlando, FL,
United States
(Elgendy) Department of Internal Medicine, Weill Cornell Medicine-Qatar,
Doha, Qatar
(Patel) Department of Internal Medicine, Division of Cardiology, VCU
Pauley Heart Center, Virginia Commonwealth University, School of Medicine,
Richmond, VA, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Several randomized controlled trials have studied the role of colchicine,
a potent anti-inflammatory drug, to prevent adverse cardiovascular events
in patients with coronary artery disease (CAD). In this meta-analysis, we
aimed to determine the role of colchicine in patients with CAD in clinical
outcomes and mortality. We searched PubMed, PubMed Central, Scopus, and
Embase for randomized controlled trials/experimental studies evaluating
the role of colchicine in patients with CAD. After assessing the
eligibility for inclusion, risk-of-bias assessment, and data extraction
from the included studies, a narrative synthesis was conducted. Of 17
studies included for the qualitative analysis, 11 studies reported that
inflammatory markers such as C-reactive protein and cytokines were reduced
in the colchicine group, suggesting an anti-inflammatory role of
colchicine in CAD. Quantitative analysis with pooling of data from 9
studies using a fixed-effect model showed 28% lower odds of acute
myocardial infarction [odds ratio (OR) 0.72, 95% CI 0.59-0.86; n =
11,712], 52% lower occurrence of stroke (OR 0.48, 95% CI 0.30-0.76), and
37% reduction in odds of coronary revascularization procedure in the
colchicine group (OR 0.63, 95% CI 0.52-0.76; n= 11,258). However, the odds
of gastrointestinal adverse events were 50% higher in the colchicine group
(OR 1.50, 95% CI 1.01-2.23; n = 12,214). In conclusion, colchicine is
associated with a lower risk of acute myocardial infarction, stroke, and
coronary revascularization. However, there is some increased risk of
gastrointestinal adverse events with the use of colchicine.<br/>Copyright
&#xa9; 2022 Lippincott Williams and Wilkins. All rights reserved.

<6>
Accession Number
2017123210
Title
Randomised open-label trial comparing intravenous iron and an
erythropoiesis-stimulating agent versus oral iron to treat preoperative
anaemia in cardiac surgery (INITIATE trial).
Source
British Journal of Anaesthesia. 128(5) (pp 796-805), 2022. Date of
Publication: May 2022.
Author
Kong R.; Hutchinson N.; Hill A.; Ingoldby F.; Skipper N.; Jones C.;
Bremner S.; Bruce C.; Wright J.; Lewis M.; Newman S.; Chevassut T.;
Hildick-Smith D.
Institution
(Kong, Hutchinson, Hill) Department of Anaesthesia, Royal Sussex County
Hospital, Brighton, United Kingdom
(Ingoldby, Skipper) University Hospitals Sussex NHS Foundation Trust,
Clinical Research Facility, Cardiac Research, Brighton, United Kingdom
(Jones, Bremner, Bruce) Brighton and Sussex Clinical Trials Unit, Brighton
& Sussex Medical School, University of Sussex, Brighton, United Kingdom
(Wright) Brighton and Sussex Medical School, Brighton, United Kingdom
(Lewis) Department of Cardiac Surgery, Royal Sussex County Hospital,
Brighton, United Kingdom
(Newman) School of Health Sciences, University of London, London, United
Kingdom
(Chevassut) Department of Haematology, Royal Sussex County Hospital,
Brighton, United Kingdom
(Hildick-Smith) Department of Cardiology, Royal Sussex County Hospital,
Brighton, United Kingdom
Publisher
Elsevier Ltd
Abstract
Background: Preoperative anaemia is a risk factor for adverse
postoperative outcomes after cardiac surgery. Iron deficiency is a
frequent cause of low preoperative haemoglobin. An effective treatment for
preoperative anaemia associated with iron deficiency has not been
determined. <br/>Method(s): We conducted a single-centre, open-label,
pragmatic randomised trial, enrolling 156 elective cardiac surgery
patients who had low preoperative haemoglobin (100-130 g L^-1)
with iron deficiency (serum ferritin <100 mug L^-1 or
transferrin saturation <30%) to compare intravenous ferric derisomaltose
1000 mg and darbepoetin 200 mug subcutaneously (intervention group) with
oral ferrous sulphate 600 mg daily (control group). The primary outcome
was transfusion of at least one unit of allogeneic red cells during
surgery and within the following 5 days. Secondary outcomes included the
change in haemoglobin concentration between randomisation and surgery, red
cell transfusion volume, postoperative blood loss, pre-specified
postoperative complications, length of hospital stay, and in-hospital
death. <br/>Result(s): The odds of red cell transfusion were lower in the
intervention group compared with the control group (adjusted odds
ratio=0.33; 95% confidence interval [CI], 0.15-0.75; P=0.008). Of the
secondary outcomes, the only significant difference was the increase in
haemoglobin between randomisation and surgery, intervention vs control 9.5
g L^-1 (95% CI, 6.8-12.2; P<0.001). <br/>Conclusion(s): In
patients with a low preoperative haemoglobin and iron deficiency,
preoperative treatment with a single dose of ferric derisomaltose and
darbepoetin decreased the proportion of participants who received a
perioperative blood transfusion as a consequence of a greater increase in
haemoglobin compared with treatment with oral ferrous sulphate. Clinical
trial registration: ISRCTN Number: 41421863; EUDRACT number:
2011-003695-36.<br/>Copyright &#xa9; 2022 British Journal of Anaesthesia

<7>
Accession Number
638215930
Title
Aortic valve intervention for aortic stenosis and cardiac amyloidosis: A
systematic review and meta-analysis.
Source
Future Cardiology. 18(6) (pp 477-486), 2022. Date of Publication: June
2022.
Author
De Campos D.; Saleiro C.; Botelho A.; Costa M.; Goncalves L.; Teixeira R.
Institution
(De Campos, Saleiro, Botelho, Costa, Goncalves, Teixeira) Centro
Hospitalar e Universitario de Coimbra-Hospital Geral, Quinta Dos Vales,
Sao Martinho do Bispo 108, Coimbra 3041-801, Portugal
(Goncalves, Teixeira) Faculdade de Medicina, Universidade de Coimbra, R.
Larga 2, Coimbra 3000-370, Portugal
(Goncalves) Coimbra Institute for Clinical & Biomedical Research (ICBR),
Azinhaga Santa Comba, Celas, Coimbra 3000-548, Portugal
Publisher
Future Medicine Ltd.
Abstract
Aortic stenosis with cardiac amyloidosis (CA-AS) is common in the elderly.
We provide an overview and a meta-analysis of outcomes after aortic valve
(AV) intervention. The primary end point was all-cause mortality. Weighted
pooled analysis showed a non-significant higher risk of death in CA-AS
patients following surgical or transcatheter AV replacement. After
transcatheter AV replacement, the risk of death in CA-AS patients was
comparable to that associated with aortic stenosis alone (risk ratio:
1.23; 95% CI: 0.77-1.96; p = 0.39; I2 = 0%). An AV intervention is
possibly not futile in CA-AS and should not be denied to patients with
this condition. Plain language summary Dual presentation of aortic
stenosis (AS) and cardiac amyloidosis (CA) is common in the elderly.
Patients with CA-AS face a dismal prognosis. Clinical outcomes after an
aortic valve intervention are conflicting. Our data showed that there is
no increased risk of death in CA-AS patients compared with patients with
only AS after an aortic valve replacement. In particular, our analysis
unveils that following less invasive percutaneous aortic valve
replacement, rates of death of patients with concomitant CA were not
significantly different from those in patients who had AS without CA.
Based on this data, an aortic valve substitution procedure should not be
withheld in patients with CA. <br/>Copyright &#xa9; 2022 Future Medicine
Ltd.

<8>
Accession Number
638215923
Title
Evaluating the effect of multivalvular disease on mortality after
transcatheter aortic valve replacement for aortic stenosis: A
meta-analysis and systematic review.
Source
Future Cardiology. 18(6) (pp 487-496), 2022. Date of Publication: June
2022.
Author
Siddiqi T.J.; Usman M.S.; Ahmed J.; Shahid I.; Ahmed W.; Alkhouli M.
Institution
(Siddiqi, Usman) Department of Medicine, University of Mississippi,
Jackson, MS 39216, United States
(Ahmed) Department of Medicine, Dow University of Health Sciences, Karachi
74200, Pakistan
(Shahid) Department of Medicine, Ziauddin Medical University, Karachi
7500, Pakistan
(Ahmed) Medical College, Aga Khan University, Karachi 74800, Pakistan
(Alkhouli) Department of Cardiovascular Medicine, Mayo Clinic, Rochester,
MN, United States
Publisher
Future Medicine Ltd.
Abstract
Aims: To determine the prognosis of multivalvular disease in patients
undergoing transcatheter aortic valve replacement (TAVR) for severe aortic
stenosis. <br/>Method(s): Patients undergoing TAVR for aortic stenosis
with covariate-adjusted risk of mortality associated with concomitant
valve disease (mitral regurgitation [MR], mitral stenosis [MS] or
tricuspid regurgitation [TR]) were included. <br/>Result(s):
Moderate-to-severe MR was associated with increased mortality at 30 days
(hazard ratio [HR]: 1.60; 95% CI: 1.11-2.30; p = 0.01) and 1 year (HR:
1.87; 95% CI: 1.22-2.87; p = 0.004). The presence of all-grade MS did not
impact 30-day or 1-year mortality (HR, 30 days: 1.60; 95% CI: 0.71-3.63; p
= 0.26; and HR, 1 year: 1.90; 95% CI: 0.98-3.69; p = 0.06); however, an
increased risk of 1-year mortality (HR: 1.67; 95% CI: 1.03-2.70; p = 0.04)
was observed with severe MS compared with no MS. Moderate-to-severe TR had
a higher risk of all-cause mortality at 1 year (HR: 1.49; 95% CI:
1.24-1.78; p < 0.001) compared with no or mild TR. <br/>Conclusion(s):
Moderate-to-severe MR or TR, and severe MS, significantly increase
mid-term mortality after TAVR. Plain language summary Transcatheter aortic
valve replacement (TAVR) is a minimally invasive heart procedure to
replace a thickened aortic valve (aortic stenosis). In the current era,
the use of TAVR has increased in patients suffering from uncomfortable and
potentially life-threatening symptoms of severe aortic stenosis who are at
increased risk for undergoing a surgical procedure to replace their
valves. However, accompanying valve diseases like mitral regurgitation
(mitral valve cannot close tightly), mitral stenosis (a narrowed mitral
valve) and tricuspid regurgitation (tricuspid valve cannot close tightly)
are highly common in these patients. Therefore in this paper we assessed
the effect of accompanying valvular disorders on the likelihood of death
following TAVR in this patient population. Our findings suggest that
accompanying moderate-to-severe mitral regurgitation and tricuspid
regurgitation leads to an increase in deaths post-TAVR. Likewise, severe
mitral stenosis also increased the risk of deaths after TAVR. Tweetable
abstract TAVR in patients with multivalvular disease. <br/>Copyright
&#xa9; 2022 Future Medicine Ltd.

<9>
Accession Number
2017056741
Title
Medical therapy versus percutaneous coronary intervention or coronary
artery bypass graft in stable coronary artery disease; a systematic review
and meta-analysis of randomized clinical trials.
Source
ARYA Atherosclerosis. 18(May) (no pagination), 2022. Article Number: 2288.
Date of Publication: May 2022.
Author
Davari M.; Sorato M.M.; Fatemi B.; Rezaei S.; Sanei H.
Institution
(Davari, Sorato, Fatemi, Rezaei) Department of Pharmacoeconomics and
Pharma Administration, School of Pharmacy, Tehran University of Medical
Sciences, Tehran, Iran, Islamic Republic of
(Sanei) Isfahan Cardiovascular Research Center, Cardiovascular Research
Institute, Isfahan University of Medical Sciences, Isfahan, Iran, Islamic
Republic of
Publisher
Isfahan University of Medical Sciences(IUMS)
Abstract
BACKGROUND: Ischemic heart disease (IHD) is the first cause of mortality
in the world. Stable coronary artery disease (CAD) is the most common IHD.
Medical therapy (MT), percutaneous coronary intervention (PCI), and
coronary artery bypass grafting (CABG) are three strategies for the
management of this disease. The main aim of this study was the comparison
of MT with PCI or CABG in terms of cardiovascular (CV) mortality,
myocardial infarction (MI), unplanned revascularization (UR), stroke, and
freedom from angina in managing stable CAD. <br/>METHOD(S): The Cochrane
Central Register of Controlled Trials, Embase, PubMed, and Scopus were
searched. Two reviewers independently appraised the titles and abstracted
data of the identified studies. After the Full-text reviewing phase,
eligible studies were analyzed through the random-effect meta-analysis
method. Finally, a sensitivity analysis was conducted for the robustness
of findings. <br/>RESULT(S): Nine randomized controlled trials (RCTs) were
included. The pooled RR of CV mortality associated with MT compared with
PCI and CABG was 1.22 and 1.385, respectively. Overall, The RR of MT
associated with MI, UR, stroke, and freedom from angina compared with PCI
was 1.001, 1.151, 0.799, and 0.801, respectively. <br/>CONCLUSION(S): Our
results revealed no statistically significant difference between MT and
PCI in terms of studied primary outcomes. The findings also highlighted
that there is no statistically significant difference between MT and CABG
in terms of CV mortality.<br/>Copyright &#xa9; 2022, Isfahan University of
Medical Sciences(IUMS). All rights reserved.

<10>
Accession Number
2018732423
Title
Red blood cell transfusion threshold after pediatric cardiac surgery.
Source
Medicine (United States). 98(11) (no pagination), 2019. Article Number:
e14884. Date of Publication: 01 Mar 2019.
Author
Deng X.; Wang Y.; Huang P.; Luo J.; Xiao Y.; Qiu J.; Yang G.
Institution
(Deng, Wang, Huang, Luo, Xiao, Yang) Heart Center, Hunan Children's
Hospital, Changsha, China
(Qiu) Department of Emergency Center, Hunan Children's Hospital, Changsha,
China
Publisher
Lippincott Williams and Wilkins
Abstract
Background: Restrictive red blood cell transfusion strategy is implemented
to minimize risk following allogeneic blood transfusion in adult cardiac
surgery. However, it is still unclear if it can be applied to pediatric
cardiac patients. The purpose of this systematic review and meta-analysis
was to determine the effect of postoperative restrictive transfusion
thresholds on clinical outcomes based on up-to-date results of randomized
controlled trials (RCTs) and observational studies in pediatric cardiac
surgery. <br/>Method(s):We searched for RCTs and observational studies in
the following databases: the Cochrane Central Register of Controlled
Trials, MEDLINE, EMBASE, and ClinicalTrials.gov from their inception to
October 26, 2017. We also searched reference lists of published
guidelines, reviews, and relevant articles, as well as conference
proceedings. No language restrictions were applied and no observational
study met the inclusion criteria. <br/>Result(s): Four RCTs on cardiac
surgery involving 454 patients were included. There were no differences in
the pooled fixed effects of intensive care unit (ICU) stay between the
liberal and restrictive transfusion thresholds (standardized mean
difference SMD, 0.007; 95% confidence interval CI, -0.18-0.19; P=.94).
There were also no differences in the length of hospital stay (SMD,
-0.062; 95% CI, -0.28-0.15; P=.57), ventilation duration (SMD, -0.015; 95%
CI, -0.25-0.22; P=.90), mean arterial lactate level (SMD, 0.071; 95% CI,
-0.22-0.36; P=.63), and mortality (risk ratio, 0.49; 95% CI, 0.13-1.94;
P=.31). There was no inter-trial heterogeneity for any pooled analysis.
Publication bias was tested using Egger, Begg, or the trim-and-fill test,
and the results indicated no significant publication bias.
<br/>Conclusion(s): Evidence from RCTs in pediatric cardiac surgery,
though limited, showed non-inferiority of restrictive thresholds over
liberal thresholds in length of ICU stay and other outcomes following red
blood cell transfusion. Further high-quality RCTs are necessary to confirm
the findings. <br/>Copyright &#xa9; 2019 the Author(s).

<11>
[Use Link to view the full text]
Accession Number
2018732348
Title
A randomized study on the effect of sequential acupoint stimulation on
pulmonary function of patients with spontaneous pneumothorax during VATS
perioperative period.
Source
Medicine (United States). 98(10) (no pagination), 2019. Article Number:
e14575. Date of Publication: 01 Mar 2019.
Author
Sui T.-Q.; Zhang F.-Y.; Jiang A.-L.; Zhang X.-Q.; Zhang Z.-W.; Yang Y.;
Sun L.-P.
Institution
(Sui, Zhang, Zhang, Yang) Department of Thoracic Surgery, Tianjin, China
(Zhang, Jiang) Department Nursing of Thoracic Surgery, Tianjin, China
(Sun) Department of Emergency Services, The 5th Central Hospital of
Tianjin, Tianjin, China
Publisher
Lippincott Williams and Wilkins
Abstract
This study aims to explore the effect of sequential acupoint stimulation
on the postoperative pulmonary function of patients with spontaneous
pneumothorax who underwent video-assisted thoracoscopic surgery (VATS).
Using a random number table, the patients were randomly divided into 2
groups: routine nursing group and sequential acupoint stimulation group.
Patients in the routine nursing group received standard nursing care of
thoracic surgery, while patients in the acupoint group received sequential
acupoint stimulation on Shenshu (BL23), Gaohuang (BL43), Feishu (BL13),
and Tiantu (CV22). Then, the maximal ventilatory volume (MVV), oxygen
saturation (SpO2), postoperative drainage volume, postoperative drainage
time, postoperative hospitalization days, and procalcitonin (PCT) were
observed on the first, third, fifth and 30th day after VATS operation. On
the fifth day after spontaneous pneumothorax was treated with VATS, MVV,
and SpO2 of the sequential acupoint stimulation group were significantly
higher than those of the routine nursing group (P<.05). On both the third
day and fifth day after VATS, PCT of the sequential acupoint stimulation
group was significantly lower than that of the routine nursing group
(P<.01). Furthermore, the difference in postoperative drainage volume
between the 2 groups was not statistically significant (P>.05), while
chest tube drainage time (P<.01) and postoperative hospitalization days
(P<.05) of the sequential acupoint stimulation group were significantly
lower than those of the routine nursing group. In spontaneous pneumothorax
patients who underwent VATS, sequential acupoint stimulation nursing was
significantly more effective than routine postoperative nursing in
promoting postoperative recovery of lung function, alleviating
inflammatory response and shortening hospitalization days.<br/>Copyright
&#xa9; 2019 the Author(s).

<12>
Accession Number
2018717958
Title
Antithrombotic strategies after transcatheter aortic valve implantation: A
systematic review and network meta-analysis of randomized controlled
trials.
Source
International Journal of Cardiology. (no pagination), 2022. Date of
Publication: 2022.
Author
Ke Y.; Wang J.; Wang W.; Guo S.; Dai M.; Wu L.; Bao Y.; Li B.; Ju J.; Xu
H.; Jin Y.
Institution
(Ke) Discipline of Pharmacy Administration, Anqing Medical Center
affiliated to Anhui Medical University(Anqing Municipal Hospital), Anhui,
Anqing, China
(Ke, Wu, Bao, Jin) School of Pharmacy, Anhui Medical University, Anhui,
Hefei, China
(Wang) Department of Pharmacy, The Friendship Hospital of ILY Kazak
Autonomous Prefecture, Xinjiang, Yili, China
(Wang) Department of Gastroenterology, Anqing Medical Center affiliated to
Anhui Medical University(Anqing Municipal Hospital), Anhui, Anqing, China
(Guo) Department of Pharmacy, The People's Hospital of Guangxi Zhuang
Autonomous Region, Guangxi, Nanning, China
(Dai) School of Pharmacy, China Pharmaceutical University, Jiangsu,
Nanjing 210000, China
(Li) School of Public Health, Anhui Medical University, Anhui, Hefei,
China
(Ju) Department of Equipment, Anqing Medical Center affiliated to Anhui
Medical University(Anqing Municipal Hospital), Anhui, Anqing, China
(Xu) Department of Pharmacy, Nanjing Drum Tower Hospital Affiliated to
Nanjing University Medical School, Jiangsu, Nanjing, China
Publisher
Elsevier Ireland Ltd
Abstract
Aims: Meta-analyses comparing different antithrombotic strategies were
conducted to determine the optimal therapeutic regimen post transcatheter
aortic valve implantation (TAVI). However, there were restricted
high-quality direct comparisons across the different antithrombotic
therapeutic regimens. We sought to explore the safety and efficacy of
different antithrombotic therapy strategies after TAVI using network
meta-analyses of randomized controlled trials (RCTs). <br/>Method(s): We
searched CENTRAL, PubMed, Embase and Medline through August 2021 for RCTs
that directly compared different antithrombotic schemes in adults who had
undergone TAVI. We conducted a pairwise and network meta-analysis
measuring all-cause mortality, stroke, myocardial infarction, all bleeding
and life-threatening or major bleeding events. The surface under the
cumulative ranking (SUCRA) curve was estimated to rank the therapies. We
evaluated the risk of bias and graded the quality of the evidence using
established methods. <br/>Result(s): Six RCTs of 2824 patients who
underwent TAVI were analysed. The risk of all bleeding [relative risk (RR)
1.88 (1.34-2.64)] and life-threatening or major bleeding [RR 2.03
(1.27-3.24)] was significantly higher for dual antiplatelet therapy (DAPT)
than single antiplatelet therapy (SAPT), whereas there was no significant
difference in the risk of all-cause mortality [RR 1.01 (0.61-1.68)]
between DAPT and SAPT. Oral anticoagulant (OAC) + SAPT (OACSAPT) had
significantly higher rates of all bleeding and life-threatening or major
bleeding events compared with SAPT ([RR 3.46 (2.23-5.36)], [RR 2.86
(1.50-5.45)]). The risk of all-cause mortality [RR 1.72 (1.14-2.59)] and
all bleeding [RR 1.84 (1.38-2.44)] were significantly higher for OACSAPT
than DAPT, whereas there was no significant difference in the risk of
life-threatening or major bleeding events [RR 1.41 (0.89-2.23)] between
DAPT and OACSAPT. There was no significant difference in stroke or
myocardial infarction among the different antithrombotic strategies (SAPT,
DAPT and OACSAPT). Additionally, patients receiving OACSAPT had the
highest risks for all-cause mortality (SUCRA 3.5%) and life-threatening or
major bleeding (SUCRA 2.3%). SAPT seemed to be superior to DAPT in terms
of all-cause mortality (SUCRA SAPT: 76.7%, DAPT: 69.8%) and stroke (SUCRA
69.6%, 59.7%). <br/>Conclusion(s): Except for OACSAPT having a higher
all-cause mortality than DAPT, patients who underwent TAVI had similar
all-cause mortality, stroke and myocardial infarction rates among
different antithrombotic regimens. Patients on SAPT had a significantly
lower bleeding risk than those on DAPT and OACSAPT. Our study indicates
that SAPT is the preferred therapeutic strategy when there is no
indication for OAC or DAPT. Furthermore, the application of OACSAPT was
ranked the worst among all antithrombotic regimens and should be averted
due to an increased risk of all-cause mortality and all
bleeding.<br/>Copyright &#xa9; 2022 Elsevier B.V.

<13>
Accession Number
2017877258
Title
Rivaroxaban After Transcatheter Aortic Valve Replacement: A Critical
Appraisal of the GALILEO Trial.
Source
Cardiovascular Drugs and Therapy. (no pagination), 2022. Date of
Publication: 2022.
Author
Sulzgruber P.; Hammer A.; Niessner A.
Institution
(Sulzgruber, Hammer, Niessner) Division of Cardiology, Department of
Internal Medicine II, Medical University of Vienna, Waehringer Guertel
18-20, Vienna 1090, Austria
Publisher
Springer
Abstract
Purpose: The anti-thrombotic approach in individuals undergoing
transcatheter aortic valve replacement (TAVR) mirrors a controversial
field in clinical practice. Methods/Results: The aim of this article was
to critically appraise the randomized controlled GALILEO trial, where two
different antithrombotic regimes (10 mg rivaroxaban + 3 months aspirin vs.
aspirin + 3 months clopidogrel) were compared in patients who underwent
TAVR as well as available evidence in literature in this field.
<br/>Conclusion(s): The GALILEO trial was prematurely terminated as a
consequence of increased risk of both death or thromboembolic
complications and a higher risk of bleeding in the anticoagulation arm,
compared to the antiplatelet-based strategy. Various concerns have been
raised that the negative results of the GALILEO trial need to be regarded
with caution. A routine use of oral anticoagulation (OAC) for the
prevention of atherothrombotic events and valve thrombosis after TAVR in
individuals who do not have an indication for oral anticoagulation, can
currently not be recommended when considering the evidence base of
available literature. However, the negative results of the GALILEO trial
need to be interpreted with caution - especially in terms of dose of
rivaroxaban - and should not discourage from performing further trials
investigating safety and efficacy of this therapeutic approach.
Additionally, further dose-finding trials for rivaroxaban should be
considered.<br/>Copyright &#xa9; 2022, The Author(s).

<14>
Accession Number
638215904
Title
Bioresorbable flow diverters for the treatment of intracranial aneurysms:
Review of current literature and future directions.
Source
Journal of NeuroInterventional Surgery. (no pagination), 2022. Article
Number: neurintsurg-2022-018941. Date of Publication: 2022.
Author
Oliver A.A.; Carlson K.D.; Bilgin C.; Arturo Larco J.L.; Kadirvel R.;
Guillory Ii R.J.; Dragomir Daescu D.; Kallmes D.F.
Institution
(Oliver, Dragomir Daescu, Kallmes) Biomedical Engineering and Physiology,
Mayo Clinic, Graduate School of Biomedical Sciences, Rochester, MN, United
States
(Oliver, Bilgin, Kadirvel, Kallmes) Radiology, Mayo Clinic, Rochester, MN,
United States
(Oliver, Carlson, Dragomir Daescu) Physiology and Biomedical Engineering,
Mayo Clinic, Rochester, MN, United States
(Arturo Larco) Neurosurgery, Mayo Clinic, Rochester, MN, United States
(Guillory Ii) Biomedical Engineering, Michigan Technological University,
Houghton, MI, United States
Publisher
BMJ Publishing Group
Abstract
The use of flow diverters is a rapidly growing endovascular approach for
the treatment of intracranial aneurysms. All FDA-approved flow diverters
are composed of nitinol or cobalt-chromium, which will remain in the
patient for the duration of their life. Bioresorbable flow diverters have
been proposed by several independent investigators as the next generation
of flow diverting devices. These devices aim to serve their transient
function of occluding and healing the aneurysm prior to being safely
resorbed by the body, eliminating complications associated with the
permanent presence of conventional flow diverters. Theoretical advantages
of bioresorbable flow diverters include (1) reduction in device-induced
thrombosis; (2) reduction in chronic inflammation and device-induced
stenosis; (3) reduction in side branch occlusion; (4) restoration of
physiological vasomotor function; (5) reduction in imaging artifacts; and
(6) use in pediatric applications. Advances made in the similar
bioresorbable coronary stenting field highlight some of these advantages
and demonstrate the feasibility and safety of bioresorbable endovascular
devices in the clinic. The current work aims to review the progress of
bioresorbable flow diverters, identify opportunities for further
investigation, and ultimately stimulate the advancement of this
technology. <br/>Copyright &#xa9; Author(s) (or their employer(s)) 2022.
No commercial re-use. See rights and permissions. Published by BMJ.

<15>
Accession Number
2016605122
Title
Peri-Operative Prophylaxis in Patients of Neonatal and Pediatric Age
Subjected to Cardiac and Thoracic Surgery: A RAND/UCLA Appropriateness
Method Consensus Study.
Source
Antibiotics. 11(5) (no pagination), 2022. Article Number: 554. Date of
Publication: May 2022.
Author
Bianchini S.; Nicoletti L.; Monaco S.; Rigotti E.; Corbelli A.; Colombari
A.; Auriti C.; Caminiti C.; Conti G.; De Luca M.; Dona D.; Galli L.;
Garazzino S.; Inserra A.; La Grutta S.; Lancella L.; Lima M.; Lo Vecchio
A.; Pelizzo G.; Petrosillo N.; Piacentini G.; Pietrasanta C.; Principi N.;
Puntoni M.; Simonini A.; Tesoro S.; Venturini E.; Staiano A.; Caramelli
F.; Gargiulo G.D.; Esposito S.
Institution
(Bianchini, Nicoletti, Monaco, Esposito) Pediatric Clinic, University
Hospital, Department of Medicine and Surgery, University of Parma, Parma
43126, Italy
(Rigotti, Corbelli, Colombari, Piacentini) Pediatric Clinic, Azienda
Ospedaliera Universitaria Integrata, Verona 37134, Italy
(Auriti) Neonatology and Neonatal Intensive Care Unit, IRCCS Bambino Gesu
Children's Hospital, Rome 00165, Italy
(Caminiti, Puntoni) Clinical and Epidemiological Research Unit, University
Hospital of Parma, Parma 43126, Italy
(Conti) Pediatric ICU and Trauma Center, Fondazione Policlinico
Universitario A. Gemelli IRCCS, Rome 00165, Italy
(De Luca, Lancella) Paediatric and Infectious Disease Unit, Academic
Department of Pediatrics, IRCCS Bambino Gesu Children's Hospital, Rome
00165, Italy
(Dona) Division of Paediatric Infectious Diseases, Department for Woman
and Child Health, University of Padua, Padua 35100, Italy
(Galli, Venturini) Infectious Diseases Unit, Meyer's Children Hospital,
Florence 50139, Italy
(Garazzino) Pediatric Infectious Diseases Unit, Regina Margherita
Children's Hospital, University of Turin, Turin 10122, Italy
(Inserra) General Surgery Department, IRCCS Bambino Gesu Children's
Hospital, Rome 00165, Italy
(La Grutta) Institute of Translational Pharmacology IFT, National Research
Council, Palermo 90146, Italy
(Lima) Pediatric Surgery, IRCCS Azienda Ospedaliera-Universitaria di
Bologna, Bologna 40138, Italy
(Lo Vecchio) Department of Translational Medical Science, Section of
Pediatrics, University of Naples "Federico II", Naples 80138, Italy
(Pelizzo, Staiano) Pediatric Surgery Department, "Vittore Buzzi"
Children's Hospital, Milano 20154, Italy
(Petrosillo) Infectious Disease and Infection Control Unit, Medicine
University Hospital, Campus Bio-Medico, Rome 00128, Italy
(Pietrasanta) NICU, Fondazione IRCCS Ca' Granda Ospedale Maggiore
Policlinico, Department of Mother, Child and Infant, Milan 20122, Italy
(Principi) Universita degli Studi di Milano, Milan 20122, Italy
(Simonini) Pediatric Anesthesia and Intensive Care Unit, Salesi Children's
Hospital, Ancona 60123, Italy
(Tesoro) Division of Anesthesia, Analgesia, and Intensive Care, Department
of Surgical and Biomedical Sciences, University of Perugia, Perugia 06129,
Italy
(Caramelli) Paediatric Intensive Care Unit, IRCCS Azienda
Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy
(Gargiulo) Department of Cardio-Thoracic and Vascular Medicine, Adult
Cardiac Surgery, IRCCS Azienda Ospedaliero-Universitaria di Bologna,
Bologna 40138, Italy
Publisher
MDPI
Abstract
Surgical site infections (SSIs) represent a potential complication of
surgical procedures, with a significant impact on mortality, morbidity,
and healthcare costs. Patients undergoing cardiac surgery and thoracic
surgery are often considered patients at high risk of developing SSIs.
This consensus document aims to provide information on the management of
peri-operative antibiotic prophylaxis for the pediatric and neonatal
population undergoing cardiac and non-cardiac thoracic surgery. The
following scenarios were considered: (1) cardiac surgery for the
correction of congenital heart disease and/or valve surgery; (2) cardiac
catheterization without the placement of prosthetic material; (3) cardiac
catheterization with the placement of prosthetic material; (4) implantable
cardiac defibrillator or epicardial pacemaker placement; (5) patients
undergoing ExtraCorporal Membrane Oxygenation; (6) cardiac tumors and
heart transplantation; (7) non-cardiac thoracic surgery with tho-racotomy;
(8) non-cardiac thoracic surgery using video-assisted thoracoscopy; (9)
elective chest drain placement in the pediatric patient; (10) elective
chest drain placement in the newborn; (11) thoracic drain placement in the
trauma setting. This consensus provides clear and shared indications,
repre-senting the most complete and up-to-date collection of practice
recommendations in pediatric cardiac and thoracic surgery, in order to
guide physicians in the management of the patient, standardizing
approaches and avoiding the abuse and misuse of antibiotics.<br/>Copyright
&#xa9; 2022 by the authors. Licensee MDPI, Basel, Switzerland.

<16>
Accession Number
2015643289
Title
High Dose Methylprednisolone versus Low Dose in Correction of Congenital
Acyanotic Heart Disease.
Source
Egyptian Journal of Anaesthesia. 38(1) (pp 220-228), 2022. Date of
Publication: 2022.
Author
El Derh M.S.; Abdelaziz N.M.; Abdel Twab S.M.
Institution
(El Derh, Abdelaziz, Abdel Twab) Ain Shams University, Cairo, Egypt
Publisher
Taylor and Francis Ltd.
Abstract
Background: A large number of pediatric patients undergoing congenital
heart disease corrective procedures receive peri-operative
corticosteroids, aiming to reduce post-operative inflammation and
capillary leak following cardiopulmonary bypass (CPB). This study aimed to
compare the effect of different doses of methylprednisolone on
inflammatory mediators' production and effect on myocardium.
<br/>Method(s): A trial was conducted on pediatric patients undergoing
surgical correction for congenital acyanotic lesion needing CPB machine.
Patients were divided into 3 groups: group A patients received 10 mg/kg
methylprednisolone (MP) after induction, group B received 30 mg/kg MP and
group C patients received placebo. <br/>Result(s): Serial measurement of
serum troponin, IL6 and random blood sugar showed no differences in the 3
studied groups at the first measurement, and random blood glucose at ICU
admission and hour-24 were highest in the high-dose group (IL6 was lowest)
with P value <0.001. Troponin showed no difference at ICU admission, while
at hour-24, it was lowest in the high-dose group with p value<0.001,
followed by the low-dose group and the highest in control. The ejection
fraction (EF) at hour-6 was highest in the high-dose group with p
value<0.001, followed by the low-dose group and lowest in control. The
vasoactive inotrope score was lowest in high-dose followed by low-dose
groups followed by control. As regards complications, there was no
different significance between groups. <br/>Conclusion(s): High-dose MP
(30 mg/kg) given to pediatric patients undergoing surgical correction of
congenital acyanotic heart disease showed better outcomes such as less
elevation of inflammatory mediators, lower level of troponin, vasoactive
score and higher ejection fraction, with no additional complications
recorded.<br/>Copyright &#xa9; 2022 The Author(s). Published by Informa UK
Limited, trading as Taylor & Francis Group.

<17>
Accession Number
2015613203
Title
The effect of calcium gluconate administration during cardiopulmonary
bypass on hemodynamic variables in infants undergoing open-heart surgery.
Source
Egyptian Heart Journal. 74(1) (no pagination), 2022. Article Number: 29.
Date of Publication: December 2022.
Author
Faritous S.Z.; Zaree S.R.; Morshedizad Z.; Jalali A.H.; Mahani S.M.;
Gholampour M.
Institution
(Faritous, Zaree, Morshedizad, Jalali, Mahani, Gholampour) Rajaie
Cardiovascular Medical and Research Center, Iran University of Medical
Sciences, Vali_e_Asr St., Tehran, Iran, Islamic Republic of
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: The incidence of complications after heart surgery is a
critical factor in disability, deaths, lengthening hospital stays, and
increasing treatment costs. The metabolic balance of certain hormones and
electrolytes is necessary for proper cardiac function. In children,
various biochemical conditions may cause calcium depletion during heart
surgery. The purpose of this study was to determine the effect of calcium
gluconate administration during cardiopulmonary bypass on hemodynamic
variables and clinical outcomes in infants undergoing open-heart surgery.
This study was conducted at Rajaie Cardiovascular Medical and Research
Center in 2021 using a controlled randomized clinical trial. A total of 60
patients with open-heart surgery weighing up to 10 kg were included in the
study. The first group received an intravenous injection of calcium
gluconate 20 min after opening the aortic clamp, and the second group was
monitored as a control group. Data collection tools included checklists
containing demographics, surgical information, and intensive care unit
measures. <br/>Result(s): The Chi-square test or Fisher's exact test
showed that the frequency distribution of gender, blood group, Rhesus
factor (RH), and clinical diagnosis in the two groups of intervention and
control was not statistically significant (p < 0.05). The mean and
standard deviation of Ejection Fraction (EF) changes (before and after)
were 13.27 +/- 9.16 in the intervention group and 8.31 +/- 9.80 in the
control group (p = 0.065). The results of two-way repeated measures ANOVA
showed that mean systolic blood pressure (p = 0.030), mean diastolic blood
pressure (p = 0.021), mean heart rate (p = 0.025), mean arterial pressure
(p = 0.020), mean pH (p < 0.001), and mean hemoglobin (p = 0.018) in the
intervention, and control groups were statistically significant.
<br/>Conclusion(s): In the present study, unlike systolic pressure, mean
diastolic blood pressure decreased, and mean arterial pressure increased
significantly. As a result, the slope of changes during the study period
was different in the intervention and control groups.<br/>Copyright &#xa9;
2022, The Author(s).

<18>
[Use Link to view the full text]
Accession Number
2017651760
Title
Ivabradine and Atrial Fibrillation: A Meta-Analysis of Randomized
Controlled Trials.
Source
Journal of Cardiovascular Pharmacology. 79(4) (pp 549-557), 2022. Date of
Publication: 03 Apr 2022.
Author
Wang Z.; Wang W.; Li H.; Zhang A.; Han Y.; Wang J.; Hou Y.
Institution
(Wang, Wang, Wang, Hou) Department of Cardiology, First Affiliated
Hospital of Shandong First Medical University and Shandong Provincial
Qianfoshan Hospital, Shandong Province, Jinan, China
(Li, Zhang) Cheeloo College of Medicine, Shandong University, Shandong
Province, Jinan, China
(Han) Department of Pharmacy, First Affiliated Hospital of Shandong First
Medical University and Shandong Provincial Qianfoshan Hospital, Shandong
Province, Jinan, China
Publisher
Lippincott Williams and Wilkins
Abstract
This was a meta-analysis of randomized control trials (RCTs) to evaluate
the effect of ivabradine on the risk of atrial fibrillation (AF) and its
effect on the ventricular rate in patients with AF. The PubMed, EMBASE,
Cochrane Controlled Trials Register, and other databases were searched for
RCTs on ivabradine. Thirteen trials with 37,533 patients met the inclusion
criteria. The incidence of AF was significantly higher in the ivabradine
treatment group than in the control group [odds ratio (OR), 1.23; 95%
confidence interval (CI), 1.08-1.41], although it was reduced after
cardiac surgery (OR, 0.70; 95% CI, 0.23-2.12). Regarding left ventricular
ejection fraction (LVEF), ivabradine increased the risk of AF in both LVEF
>40% (OR, 1.42; 95% CI, 1.24-1.63) and LVEF <=40% subgroups (OR, 1.16; 95%
CI, 0.98-1.37). The risk of AF was increased by both small and large
cumulative doses of ivabradine (small cumulative dose: OR, 3.00; 95% CI,
0.48-18.93; large cumulative dose: OR, 1.05; 95% CI, 0.83-1.34).
Furthermore, ivabradine may reduce the ventricular rate in patients with
AF. In conclusion, we found that both large and small cumulative doses of
ivabradine were associated with an increased incidence of AF, and the
effect was more marked in the LVEF >40% subgroup. Nevertheless, ivabradine
therapy is beneficial for the prevention of postoperative AF. Furthermore,
ivabradine may be effective in controlling the ventricular rate in
patients with AF, although more RCTs are needed to support this
conclusion.<br/>Copyright &#xa9; 2022 Lippincott Williams and Wilkins. All
rights reserved.

<19>
Accession Number
2016894956
Title
Surgical Timing in Patients With Infective Endocarditis and With
Intracranial Hemorrhage: A Systematic Review and Meta-Analysis.
Source
Journal of the American Heart Association. 11(10) (no pagination), 2022.
Article Number: e024401. Date of Publication: 17 May 2022.
Author
Musleh R.; Schlattmann P.; Caldonazo T.; Kirov H.; Witte O.W.; Doenst T.;
Gunther A.; Diab M.
Institution
(Musleh, Witte, Gunther) Department of Neurology, Jena University
Hospital, Friedrich-Schiller-University Jena, Am Klinikum 1, Jena 07747,
Germany
(Schlattmann) Department of Medical Statistics, Computer Science and Data
Science, Jena University Hospital, Friedrich-Schiller-University Jena,
Jena, Germany
(Caldonazo, Kirov, Doenst, Diab) Department of Cardiothoracic Surgery,
Jena University Hospital, Friedrich-Schiller-University Jena, Jena,
Germany
Publisher
American Heart Association Inc.
Abstract
BACKGROUND: Intracranial hemorrhage (ICH) is one of the main causes for
lack of surgery in patients with infective endocarditis (IE), despite the
presence of surgical indications. We aimed to evaluate the impact of early
surgery in patients with IE and with ICH on postoperative neurological
deterioration and all-cause mortality and to elucidate the risk of 30-day
mortality in patients who were denied surgery. METHODS AND RESULTS: Three
libraries (MEDLINE, EMBASE, and Cochrane Library) were assessed. The
primary outcome was all-cause mortality, and the secondary outcome was
neurological deterioration. Inverse variance method and random model were
performed. We identified 16 studies including 355 patients. Nine studies
examined the impact of surgical timing (early versus late) and were
included in the meta-analysis. Only one study examined the fate of
patients with IE and with ICH who were treated conservatively despite
having an indication for cardiac surgery, showing higher mortality rates
than those who underwent surgery (11.8% versus 2.5%). We found no
significant association between early surgery, regardless of its
definition, and a higher mortality (odds ratio [OR], 1.69; 95% CI, 0.95-
3.02). Early surgery was associated with higher risk for neurological
deterioration (OR, 2.00; 95% CI, 1.10- 3.65). <br/>CONCLUSION(S): Cardiac
surgery for IE within 30 days of ICH was not associated with higher
mortality, but with an increased rate of neurological deterioration. The
30-day mortality in patients with IE and with ICH who were denied surgery
has not yet been sufficiently investigated. This patient group should be
analyzed in future studies in more detail.<br/>Copyright &#xa9; 2022 The
Authors. Published on behalf of the American Heart Association, Inc., by
Wiley.

<20>
Accession Number
2016810114
Title
Use of a Neurometabolism-Targeting Drug in Prevention of Postoperative
Cognitive Dysfunction.
Source
Obshchaya Reanimatologiya. 18(2) (pp 12-21), 2022. Date of Publication:
2022.
Author
Kovalenko A.L.; Nagibovich O.A.; Vishnevsky A.Yu.; Belekhov G.A.;
Gubaidullin R.R.; Popov D.V.; Agafiina A.S.
Institution
(Kovalenko) S. N. Golikov Scientific Consulting Center for Toxicology,
Federal Medico-Biological Agency of Russia, 1 Bechtereva Str.,
Saint-Petersburg 192242, Russian Federation
(Nagibovich) S. M. Kirov Military Medical Academy, 6 Academician Lebedev
Str., St. Petersburg 194044, Russian Federation
(Vishnevsky) Pokrovsky City Hospital, 85 Bolshoy Prospekt V. O., St.
Petersburg 199106, Russian Federation
(Belekhov) Saint Petersburg Hospital for War Veterans, 21 Narodnaya Str.,
Bld. 2, St. Petersburg 193079, Russian Federation
(Gubaidullin) Central Clinical Hospital with Outpatient Department of the
Russian Presidential Administration, 15 Marshala Timoshenko Str., Moscow
121359, Russian Federation
(Popov) Regional Clinical Hospital No. 3, 287 Pobedy Ave., Chelyabinsk
454021, Russian Federation
(Agafiina) City Hospital No. 40, Kurortny District, 9B Borisova Str.,
Sestroretsk 197706, Russian Federation
Publisher
V.A. Negovsky Research Institute of General Reanimatology
Abstract
Aim of the study: to evaluate the feasibility of preventing cognitive
dysfunction after long-term surgery in elderly patients using an original
neurometabolic succinate-containing drug. Material and methods. A
multicenter, double-blind, placebo-controlled randomized trial enrolled
200 patients aged 60-80 years who underwent elective cardiac or orthopedic
surgery. The patients received either the study drug (inosine +
nicotinamide + riboflavin + succinate) (treatment group, n=101) or a
placebo (con-trol group, n=99) intravenously for 7 days then orally for 25
days. Efficacy was assessed by the change in the Montreal Cognitive
Assessment Scale (MoCA) score at the end of the treatment course compared
with the preoperative level. Results. Before surgery, the total MoCA score
values did not differ between the groups. By the end of the treatment
course (31 days after surgery), the MoCA total score was 26.4+/-1.96 in
the main group and 25.0+/-2.83 in the control group (P<0.001). The
intergroup difference in the mean change in the MoCA total score on day 31
was 1.56 points (95% CI 1.015; 2.113; P<0.0001) favoring the study drug in
all randomized population. The lower limit of CI (1.015) exceeded the
limit of superiority set by the protocol (0.97 points), which allowed
acceptance of the hypothesis of superiority of the study drug over placebo
with respect to the primary efficacy criterion. No significant differences
in the frequency of adverse events were found between the groups.
Conclusion. The succinate-containing study drug demonstrated an acceptable
safety profile and helped to reduce the severity of postoperative
cognitive dysfunction in elderly patients who underwent a major surgery,
which allows recommending the drug for prevention of postoperative
cognitive impairment in high-risk patients.<br/>Copyright &#xa9; 2022,
V.A. Negovsky Research Institute of General Reanimatology. All rights
reserved.

<21>
Accession Number
2016767860
Title
Effects of Iron Sucrose and Erythropoietin on Transfusion Requirements
inPatientswithPreoperative IronDeficiency Anemia Undergoing on-Pump
Coronary Artery Bypass Graft.
Source
Journal of Tehran University Heart Center. 17(1) (pp 7-14), 2022. Date of
Publication: 2022.
Author
Jafari S.; Talasaz A.H.; Salehiomran A.; Ariannejad H.; Jalali A.
Institution
(Jafari) Cardiovascular Diseases Research Center, Birjand University of
Medical Sciences, Birjand, Iran, Islamic Republic of
(Jafari) Department of Clinical Pharmacy, School of Pharmacy, Birjand
University of Medical Sciences, Birjand, Iran, Islamic Republic of
(Talasaz) Department of Clinical Pharmacy, School of Pharmacy, Tehran
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Talasaz, Salehiomran, Ariannejad, Jalali) Tehran Heart Center, Tehran
University of Medical Sciences, Tehran, Iran, Islamic Republic of
Publisher
Tehran Heart Center
Abstract
Background: Preoperative anemia is an independent risk factor for higher
rates of blood transfusion in cardiac surgery. This study aimed to
evaluate the effects of intravenous iron sucrose and erythropoietin on
transfusion requirements in patients with preoperative iron deficiency
anemia (IDA) undergoing on-pump coronary artery bypass graft (CABG)
surgery. <br/>Method(s): In this open-label, randomized clinical trial,
patients with preoperative IDA who were candidates for on-pump CABG were
randomized into intervention (iron plus erythropoietin) or control groups.
Iron sucrose was administered as a 200 mg intravenous dose and
erythropoietin as a 100 IU/kg bolus 1 to 2 days before surgery. The
primary outcome was the amount of blood transfusion during the first 4
postoperative days. <br/>Result(s): The study population consisted of 114
patients. The mean age was 64.11+/-8.18 years in the intervention group
and 63.35+/-8.70 years in the control group. Twenty-seven patients (47.4%)
in the intervention group and 25 (43.9%) in the control group were males.
The number of red blood cell units transfused per patient exhibited a
significant fall in the intervention group compared with the control group
(P0.001). The ferritin level showed a significant rise in the intervention
group on postoperative day 7 (P=0.027). The length of stay in the
intensive care unit and the hospital was significantly lower in the
intervention arm (P=0.041 and P=0.006, respectively). No adverse events
were reported in both groups. <br/>Conclusion(s): The use of
erythropoietin and iron sucrose 1 to 2 days before surgery significantly
decreased the need for blood transfusion in patients with IDA undergoing
CABG without any significant adverse events.<br/>Copyright &#xa9; 2022
Tehran University of Medical Sciences. Published by Tehran University of
Medical Sciences.

<22>
Accession Number
2015408718
Title
Postoperative outcomes in surgical patients with obstructive sleep apnoea
diagnosed by sleep studies: a meta-analysis and trial sequential analysis.
Source
Anaesthesia. 77(7) (pp 818-828), 2022. Date of Publication: July 2022.
Author
Pivetta B.; Sun Y.; Nagappa M.; Chan M.; Englesakis M.; Chung F.
Institution
(Pivetta, Sun) Department of Anaesthesia and Pain Medicine, University of
Toronto, Toronto, ON, Canada
(Nagappa) Department of Anaesthesia and Peri-Operative Medicine, London
Health Sciences Centre and St. Joseph Health Care, Schulich School of
Medicine and Dentistry, Western University, London, ON, Canada
(Chan) Department of Anaesthesia and Intensive Care, Chinese University of
Hong Kong, Hong Kong
(Englesakis) Library and Information Services, University Health Network,
Toronto, ON, Canada
(Chung) University Health Network, University of Toronto, Toronto, ON,
Canada
Publisher
John Wiley and Sons Inc
Abstract
Identifying surgical patients with obstructive sleep apnoea may assist
with anaesthetic management to minimise postoperative complications. Using
trial sequential analysis, we evaluated the impact of obstructive sleep
apnoea diagnosed by polysomnography or home sleep apnoea testing on
postoperative outcomes in surgical patients. Multiple databases were
systematically searched. Outcomes included: total postoperative
complications, systemic complications (cardiovascular, respiratory,
neurological, renal, infectious) and specific complications (atrial
fibrillation, myocardial infarction, combined hospital and intensive care
unit re-admission, mortality). The pooled odds ratios of postoperative
complications were evaluated by the Mantel-Haenszel method random-effects
model. Meta-analysis and meta-regression were conducted, and the GRADE
approach was used to evaluate the certainty of evidence. Twenty
prospective cohort studies with 3756 patients (2127 obstructive sleep
apnoea and 1629 non-obstructive sleep apnoea) were included (9 in
non-cardiac surgery and 11 in cardiac surgery). Postoperative
complications were almost two-fold higher with obstructive sleep apnoea,
OR (95%CI) 1.92 (1.52-2.42), p < 0.001; certainty of evidence, moderate.
Obstructive sleep apnoea was associated with a 1.5 times increased risk of
postoperative cardiovascular complications, OR (95%CI) 1.56 (1.20-2.02), p
= 0.001; certainty of evidence, moderate; an almost two-fold increase in
respiratory complications, OR (95%CI) 1.91 (1.39-2.62), p < 0.001;
certainty of evidence, moderate; and hospital and ICU re-admission, OR
(95%CI) 2.25 (1.21-4.19), p = 0.01; certainty of evidence, low. Trial
sequential analysis showed adequate information size for postoperative
complications. Baseline confounding factors were adjusted by
meta-regression, and the sub-group analysis did not materially change our
results. This increased risk occurred especially in patients in whom
obstructive sleep apnoea had been newly diagnosed, emphasising the
importance of pre-operative screening.<br/>Copyright &#xa9; 2022
Association of Anaesthetists.

<23>
Accession Number
2018651945
Title
Comparative study of costs and resource utilization of rotational
atherectomy versus intravascular lithotripsy for percutaneous coronary
intervention.
Source
Minerva Cardiology and Angiology. 70(3) (pp 332-340), 2022. Date of
Publication: June 2022.
Author
Rishad S.; McEntegart M.; Ford T.J.; Di Mario C.; Fajadet J.; Lindsay M.;
Watkins S.; Eteiba H.; Brogan R.; Good R.; Oldroyd K.G.
Institution
(Rishad, Oldroyd) University of Glasgow, Glasgow, United Kingdom
(Rishad, McEntegart, Ford, Lindsay, Watkins, Eteiba, Brogan, Good,
Oldroyd) West of Scotland Heart and Lung Center, Golden Jubilee National
Hospital, Clydebank, United Kingdom
(Ford) Faculty of Medicine, University of Newcastle NSW, Newcastle,
Australia
(Di Mario) Careggi University Hospital, Florence, Italy
(Fajadet) Clinique Pasteur, Toulouse, France
Publisher
Edizioni Minerva Medica
Abstract
BACKGROUND: Intravascular lithotripsy (IVL) is a novel alternative to
rotational atherectomy (RA) for the modification of heavily calcified
coronary stenoses prior to percutaneous coronary intervention (PCI). We
compare the real-world resource utilization and associated costs of PCI
with adjunctive RA and IVL. <br/>METHOD(S): We compared the resource
utilization, in-lab consumable costs and procedural data of 120 patients
who underwent PCI with IVL from the Disrupt-CAD II study (NCT03328949) to
60 patients who underwent PCI with RA at the Golden Jubilee National
Hospital, Glasgow, UK. The RA patients were consecutive and selected on
the basis of being deemed suitable for IVL by an independent
interventional cardiologist experienced in the use of both techniques.
<br/>RESULT(S): PCI with IVL was associated with significantly lower costs
than PCI with RA (mean difference A 398 [95% CI: A 181-615]; P<0.001).
Considering between-group differences, the IVL group used 4.02 fewer
balloons (P<0.001), 3.03 fewer guidewires (P<0.001), 0.52 fewer guide
catheters (P=0.001), 0.22 fewer guide extensions (P=0.004) and 1.03 fewer
drug eluting stents (DES) (P<0.001) per case than the RA group. The IVL
group had shorter procedural duration (mean difference 13.3 min [95% CI:
3.6-23.0]; P=0.008) but longer fluoroscopy times (mean difference 4.4 min
[95% CI: 1.7-7.1]; P=0.002). <br/>CONCLUSION(S): In this indirect
comparison, we found that the higher initial device costs of IVL may be
offset by a lower overall resource utilization. Further research is
required to confirm this, and future randomized trials should include a
formal health economic analysis.<br/>Copyright &#xa9; 2021 EDIZIONI
MINERVA MEDICA

<24>
Accession Number
638085401
Title
Thromboembolic events in left ventricular non-compaction: Comparison
between children and adults - A systematic review and meta-analysis.
Source
Open Heart. 9(1) (no pagination), 2022. Article Number: e001908. Date of
Publication: 25 May 2022.
Author
Hirono K.; Takarada S.; Miyao N.; Nakaoka H.; Ibuki K.; Ozawa S.; Origasa
H.; Ichida F.
Institution
(Hirono, Takarada, Miyao, Nakaoka, Ibuki, Ozawa, Origasa) Department of
Pediatrics and Biostatistics and Clinical Epidemiology, University of
Toyama, Toyama, Japan
(Ichida) Department of Pediatrics, International University of Health and
Welfare, Otawara, Japan
Publisher
BMJ Publishing Group
Abstract
Objective Left ventricular non-compaction (LVNC) is morphologically
characterised by excessive trabeculations and deep recesses in the
ventricular wall. The risk of thromboembolic disease in the paediatric
patients with LVNC has not been clearly established. We conducted this
systematic review to evaluate the prevalence and incidence of
thromboembolism (TE) in paediatric and adult patients with LVNC and
searched for risk factors for TE to explore management strategies. Methods
The primary outcome was the prevalence and incidence of TE in the patients
with LVNC. The secondary outcome was the TE and mortality and heart
transplantation rates between paediatric and adult patients with LVNC. We
searched for studies published in MEDLINE, Embase and Cochrane Central
Register of Controlled Trials between January 1950 and December 2020. A
systematic search of keywords related to LVNC,
anticoagulants/antiplatelets and TE was conducted. Studies that did not
present original research, non-human studies, duplicated studies were
excluded. Results Fifty-seven studies met the inclusion criteria. A total
of 726 paediatric and 3862 adult patients were included. The mean
prevalence rates of TE in the paediatric and adult patients with LVNC were
2.6% and 6.2% (I 2 =0%; p<0.450 and I 2 =73.7%; p<0.001), respectively.
The mean annual incidences of TE in paediatric and adult patients with
LVNC were 1.4% and 2.9% (I 2 =99.4%; p<0.001 and I 2 =99.5%; p<0.001),
respectively. Multivariate logistic regression analysis showed that TE was
associated with left ventricular ejection fraction in <40% of paediatric
patients (OR, 9.47; 95% CI, 1.35 to 188.23; p=0.0225). Conclusions The
prevalence and incidence rates in paediatric patients were lower than
those in adult patients. TE was associated with a reduced systolic
function in paediatric patients with LVNC.<br/>Copyright &#xa9;

<25>
Accession Number
2017814554
Title
Mycophenolate and SARS-CoV-2 vaccination: Mixing oil and water.
Source
Liver International. 42(6) (pp 1218-1221), 2022. Date of Publication: June
2022.
Author
Arenas-De Larriva M.; Rodriguez-Peralvarez M.L.
Institution
(Arenas-De Larriva) Department of Interventional Pulmonology, Hospital
Universitario Reina Sofia, IMIBIC, Cordoba, Spain
(Rodriguez-Peralvarez) Department of Hepatology and Liver Transplantation,
Hospital Universitario Reina Sofia, Universidad de Cordoba, IMIBIC,
Cordoba, Spain
(Rodriguez-Peralvarez) CIBER de enfermedades hepaticas y digestivas,
Madrid, Spain
Publisher
John Wiley and Sons Inc

<26>
Accession Number
2018058225
Title
Selected 2021 Highlights in Congenital Cardiac Anesthesia.
Source
Journal of Cardiothoracic and Vascular Anesthesia. Part A. 36(8) (pp
2265-2270), 2022. Date of Publication: August 2022.
Author
Motta P.; Kreeger R.; Resheidat A.M.; Faraoni D.; Nasr V.G.; Mossad E.B.;
Mittnacht A.J.C.
Institution
(Motta, Resheidat, Faraoni, Mossad, Mittnacht) Division of Pediatric
Cardiovascular Anesthesia, Baylor College of Medicine, Texas Children's
Hospital, Houston, TX
(Kreeger) Department of Anesthesia, Cincinnati Children's Hospital,
University of Cincinnati, Cincinnati, OH
(Nasr) Department of Anesthesiology, Critical Care and Pain Medicine,
Boston Children's Hospital, Boston, MA
(Mittnacht) Department of Anesthesiology, Westchester Medical Center, New
York Medical College, Valhalla, NY
Publisher
W.B. Saunders
Abstract
This article is a review of the highlights of pertinent literature of
interest to the congenital cardiac anesthesiologist and was published in
2021. After a search of the United States National Library of Medicine
PubMed database, several topics emerged where significant contributions
were made in 2021. The authors of this manuscript considered the following
topics noteworthy to be included in this review: risk stratification in
adult congenital heart disease surgery, physician burnout in pediatric
cardiac anesthesia, transfusion practice in pediatric congenital heart
surgery, and racial disparity and outcomes in pediatric patients with
congenital heart disease.<br/>Copyright &#xa9; 2022 Elsevier Inc.

<27>
Accession Number
2017869489
Title
Heparin versus normal saline locking for prevention of occlusion,
catheter-related infections and thrombosis in central venous catheter in
adults: Overview of systematic reviews.
Source
Journal of Vascular Access. (no pagination), 2022. Date of Publication:
2022.
Author
Santomauro I.; Campani D.; Tiozzo V.; Barletta B.; Scotti L.; Barisone M.;
Dal Molin A.
Institution
(Santomauro, Campani, Tiozzo, Barletta, Scotti, Barisone, Dal Molin)
Department of Translational Medicine, Universita del Piemonte Orientale,
Italy
(Dal Molin) Health Professions' Direction, Maggiore della Carita Hospital,
Novara, Italy
Publisher
SAGE Publications Ltd
Abstract
Venous access devices are used in health care. To prevent occlusions the
evidence confirmed the need for routine catheter flushing before and after
infusion as well as at the end of use. To date, the efficacy of heparin
has not been demonstrated. The aim of this study was to evaluate the
effectiveness of the locking of central venous catheters with heparin
versus normal saline in adults to prevent occlusion, catheter-related
infections and thrombosis in adults. A literature search using Medline,
Embase, Cochrane Library and Cinahl was performed to identify all
meta-analyses addressing the effectiveness of heparin versus normal saline
in locking central venous catheters in adults. Four reviewers
independently selected publications assessed quality and extracted data.
Parameter estimates regarding occlusion, catheter- related infections and
thrombosis were pooled using an umbrella review. We identified 6356
references. Seven systematic reviews were included in the study. Most of
the studies included in the systematic reviews were conducted in
oncohaematology departments, intensive care and cardiac surgery units
among patients with multiple diseases and chronicity. Most studies report
a heparin concentration of 10 to 5000 IU/ml versus normal saline and other
solutions. There was no evidence that heparin was more effective than
normal saline in reducing complications such as occlusion,
catheter-related infections and thrombosis. No statistically significant
difference was found between heparin and normal saline in reducing
catheter occlusion. Heparin is not superior compared to normal
saline.<br/>Copyright &#xa9; The Author(s) 2022.

<28>
Accession Number
2017868182
Title
PCSK9 inhibitors safely and effectively lower LDL after heart
transplantation: a systematic review and meta-analysis.
Source
Heart Failure Reviews. (no pagination), 2022. Date of Publication: 2022.
Author
Jennings D.L.; Sultan L.; Mingov J.; Choe J.; Latif F.; Restaino S.;
Clerkin K.; Habal M.V.; Colombo P.C.; Yuzefpulskaya M.; Sayer G.; Uriel
N.; Baker W.L.
Institution
(Jennings, Sultan, Mingov) Department of Pharmacy Practice, Long Island
University College of Pharmacy, New York, NY, United States
(Jennings, Choe) Department of Pharmacy, New York-Presbyterian Hospital,
Columbia University Medical Center, 622 W. 168th Street, New York, NY,
United States
(Latif, Restaino, Clerkin, Habal, Colombo, Yuzefpulskaya, Sayer, Uriel)
Division of Cardiology, Department of Medicine, New York-Presbyterian
Hospital, Columbia University, New York, NY, United States
(Baker) Department of Pharmacy Practice, University of Connecticut School
of Pharmacy, Storrs, CT, United States
Publisher
Springer
Abstract
Coronary allograft vasculopathy (CAV) continues to afflict a high number
of heart transplant (HT) recipients, and elevated LDL is a key risk
factor. Many patients cannot tolerate statin medications after HT;
however, data for alternative agents remains scarce. To address this key
evidence gap, we evaluated the safety and efficacy of the PCSK9i after HT
through systematic review and meta-analysis. We searched Medline, Cochrane
Central, and Scopus from the earliest date through July 15th, 2021.
Citations were included if they were a report of PCSK9i use in adults
after HT and reported an outcome of interest. Outcomes included change in
LDL cholesterol from baseline, incidence of adverse events, and evidence
of CAV. Changes from baseline and outcome incidences were pooled using
contemporary random-effects model methodologies. A total of six studies
including 97 patients were included. Over a mean follow-up of 13 months
(range 3-21), PCSK9i use lowered LDL by 82.61 mg/dL (95% CI - 119.15 to -
46.07; I² = 82%) from baseline. Serious adverse drug reactions
were rarely reported, and none was attributable to the PCSK9i therapy.
Four studies reported stable calcineurin inhibitor levels during PCSK9i
initiation. One study reported outcomes in 33 patients with serial
coronary angiography and intravascular ultrasound, and PCSK9i were
associated with stable coronary plaque thickness and lumen area. One study
reported on immunologic safety, showing no DSA development within 1 month
of therapy. Preliminary data suggest that long-term PCSK9i therapy is
safe, significantly lowers LDL, and may attenuate CAV after HT. Additional
study on larger cohorts is warranted to confirm these
findings.<br/>Copyright &#xa9; 2022, The Author(s), under exclusive
licence to Springer Science+Business Media, LLC, part of Springer Nature.

<29>
Accession Number
2016884193
Title
Effect of Volatile Anesthetics on Myocardial Infarction After Coronary
Artery Surgery: A Post Hoc Analysis of a Randomized Trial.
Source
Journal of Cardiothoracic and Vascular Anesthesia. Part A. 36(8) (pp
2454-2462), 2022. Date of Publication: August 2022.
Author
Zangrillo A.; Lomivorotov V.V.; Pasyuga V.V.; Belletti A.; Gazivoda G.;
Monaco F.; Nigro Neto C.; Likhvantsev V.V.; Bradic N.; Lozovskiy A.; Lei
C.; Bukamal N.A.R.; Silva F.S.; Bautin A.E.; Ma J.; Yong C.Y.; Carollo C.;
Kunstyr J.; Wang C.Y.; Grigoryev E.V.; Riha H.; Wang C.; El-Tahan M.R.;
Scandroglio A.M.; Mansor M.; Lembo R.; Ponomarev D.N.; Bezerra F.J.L.;
Ruggeri L.; Chernyavskiy A.M.; Xu J.; Tarasov D.G.; Navalesi P.;
Yavorovskiy A.; Bove T.; Kuzovlev A.; Hajjar L.A.; Landoni G.
Institution
(Zangrillo, Belletti, Monaco, Scandroglio, Lembo, Ruggeri, Landoni)
Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific
Institute, Milan, Italy
(Zangrillo, Landoni) School of Medicine, Vita-Salute San Raffaele
University, Milan, Italy
(Lomivorotov, Ponomarev, Chernyavskiy) Department of Anesthesiology and
Intensive Care, E. Meshalkin National Medical Research Center,
Novosibirsk, Russian Federation
(Lomivorotov) Department of Anesthesiology and Intensive Care, Novosibirsk
State University, Novosibirsk, Russian Federation
(Pasyuga) Department of Anesthesiology and Intensive Care, Federal Center
for Cardiovascular Surgery Astrakhan, Astrakhan, Russian Federation
(Gazivoda) Department of Anaesthesia and Intensive Care, Cardiovascular
Institute Dedinje, Belgrade, Serbia
(Nigro Neto, Bezerra) Anesthesia Section, Department of Cardiovascular
Surgery, Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil
(Likhvantsev) Department of Anesthesiology and Intensive Care, First
Moscow State Medical University, Moscow, Russian Federation
(Likhvantsev, Kuzovlev) V. Negovsky Reanimatology Research Institute,
Moscow, Russian Federation
(Bradic) Department of Cardiovascular Anesthesiology and Intensive Care
Medicine, Clinical Department of Anesthesiology, Resuscitation and
Intensive Care Medicine, University Hospital Dubrava, Zagreb, Croatia
(Bradic) Department of Biomedical Sciences, University North, Varazdin,
Croatia
(Lozovskiy) Department of Anesthesia and Intensive Care, Ural Institute of
Cardiology, Ekaterinburg, Russian Federation
(Lei) Department of Anesthesiology and Perioperative Medicine, Xijing
Hospital, Shaanxi, Xi'an, China
(Bukamal) Cardiothoracic ICU and Anesthesia Department, Mohammed Bin
Khalifa Cardiac Center, Riffa, Bahrain
(Silva) Department of Anaesthesiology, Hospital de Santa Maria, Lisboa,
Portugal
(Bautin) Laboratory for Anesthesiology and Intensive Care, Almazov
National Medical Research Center, Saint Petersburg, Russian Federation
(Ma, Wang) Center for Anesthesiology, Beijing Anzhen Hospital, Capital
Medical University, Beijing, China
(Yong) Department of Anaesthesiology and Intensive Care, Hospital Pulau
Pinang, Pulau Pinang, Malaysia
(Carollo, Navalesi) Institute of Anesthesia and Intensive Care, Padua
University Hospital, Padua, Italy
(Kunstyr) Department of Anesthesiology and Intensive Care, First Faculty
of Medicine Charles University and General University Hospital, Prague,
Czechia
(Wang, Mansor) Department of Anaesthesiology, Faculty of Medicine,
University of Malaya, Kuala Lumpur, Malaysia
(Grigoryev) Intensive Care Unit, Scientific Research Institute for Complex
Issues of Cardiovascular Diseases, Kemerovo, Russian Federation
(Riha) Cardiothoracic Anesthesiology and Intensive Care Medicine,
Department of Anesthesiology and Intensive Care Medicine, Institute for
Clinical and Experimental Medicine, Prague, Czechia
(El-Tahan) Department of Anesthesiology, Imam Abdulrahman Bin Faisal
University, Dammam, Saudi Arabia
(Xu) Department of Anesthesiology, The Second Xiangya Hospital of Central
South University, Changsha, China
(Tarasov) Department of Cardiac Surgery, Federal Center for Cardiovascular
Surgery Astrakhan, Astrakhan, Russian Federation
(Navalesi) Department of Medicine, University of Padua, Padua, Italy
(Yavorovskiy) Federal Research and Clinical Center of Resuscitation and
Rehabilitation, Moscow, Russian Federation
(Bove) Department of Medicine (DAME), University of Udine, Udine, Italy
(Bove) Department of Anesthesia and Intensive Care Medicine, ASUFC
University-Hospital of Central Friuli, Udine, Italy
(Hajjar) Department of Cardiopneumology, Instituto do Coracao,
Universidade de Sao Paulo, Sao Paulo, Brazil
(Hajjar) Intensive Care Unit, Hospital SirioLibanes, Sao Paulo, Brazil
Publisher
W.B. Saunders
Abstract
Objective: To investigate the effect of volatile anesthetics on the rates
of postoperative myocardial infarction (MI) and cardiac death after
coronary artery bypass graft (CABG). <br/>Design(s): A post hoc analysis
of a randomized trial. <br/>Setting(s): Cardiac surgical operating rooms.
<br/>Participant(s): Patients undergoing elective, isolated CABG.
<br/>Intervention(s): Patients were randomized to receive a volatile
anesthetic (desflurane, isoflurane, or sevoflurane) or total intravenous
anesthesia (TIVA). The primary outcome was hemodynamically relevant MI (MI
requiring high-dose inotropic support or prolonged intensive care unit
stay) occurring within 48 hours from surgery. The secondary outcome was
1-year death due to cardiac causes. <br/>Measurements and Main Results: A
total of 5,400 patients were enrolled between April 2014 and September
2017 (2,709 patients randomized to the volatile anesthetics group and
2,691 to TIVA). The mean age was 62 +/- 8.4 years, and the median baseline
ejection fraction was 57% (50-67), without differences between the 2
groups. Patients in the volatile group had a lower incidence of MI with
hemodynamic complications both in the per-protocol (14 of 2,530 [0.6%] v
27 of 2,501 [1.1%] in the TIVA group; p = 0.038) and as-treated analyses
(16 of 2,708 [0.6%] v 29 of 2,617 [1.1%] in the TIVA group; p = 0.039),
but not in the intention-to-treat analysis (17 of 2,663 [0.6%] v 28 of
2,667 [1.0%] in the TIVA group; p = 0.10). Overall, deaths due to cardiac
causes were lower in the volatile group (23 of 2,685 [0.9%] v 40 of 2,668
[1.5%] than in the TIVA group; p = 0.03). <br/>Conclusion(s): An
anesthetic regimen, including volatile agents, may be associated with a
lower rate of postoperative MI with hemodynamic complication in patients
undergoing CABG. Furthermore, it may reduce long-term cardiac
mortality.<br/>Copyright &#xa9; 2022 Elsevier Inc.

<30>
Accession Number
2015508193
Title
Impact of High-Frequency Oscillatory Ventilation Combined With Volume
Guarantee on Lung Inflammatory Response in Infants With Acute Respiratory
Distress Syndrome After Congenital Heart Surgery: A Randomized Controlled
Trial.
Source
Journal of Cardiothoracic and Vascular Anesthesia. Part A. 36(8) (pp
2368-2375), 2022. Date of Publication: August 2022.
Author
Zheng Y.-R.; Xie W.-P.; Liu J.-F.; Wu H.-L.; Xu N.; Huang S.-T.; Cao H.;
Chen Q.
Institution
(Zheng, Xie, Liu, Wu, Xu, Huang, Cao, Chen) Department of Cardiac Surgery,
Fujian branch of Shanghai Children's Medical Center, Fuzhou, China
(Zheng, Xie, Liu, Wu, Xu, Huang, Cao, Chen) Fujian Children's Hospital,
Fuzhou, China
(Zheng, Xie, Liu, Wu, Xu, Huang, Cao, Chen) Fujian Maternity and Child
Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou,
China
(Zheng, Xie, Liu, Wu, Xu, Huang, Cao, Chen) Fujian Key Laboratory of Women
and Children's Critical Diseases Research, Fujian Maternity and Child
Health Hospital, Fuzhou, China
Publisher
W.B. Saunders
Abstract
Objectives: Congenital heart disease (CHD) after cardiopulmonary bypass
can cause systemic inflammation, and its degree is closely related to the
incidence of acute respiratory distress syndrome (ARDS). The purpose of
this study was to determine the effectiveness of high-frequency
oscillatory ventilation (HFOV) combined with volume guarantee (VG) in
reducing systemic inflammation in infants with ARDS after cardiopulmonary
bypass for congenital heart surgery. <br/>Design(s): A randomized
controlled trial. <br/>Setting(s): Single-center study in a tertiary
teaching hospital. <br/>Participant(s): A total of 58 infants with ARDS
after congenital heart surgery were eligible and were randomized to the
HFOV (n = 29) or the HFOV-VG (n = 29) between January 2020 and January
2021. <br/>Intervention(s): Tracheal aspirate samples for the measurement
of interleukin (IL)-6, IL-8, and tumor necrosis factor-alpha (TNF-alpha)
were obtained on days one, two, and three of HFOV or HFOV-VG ventilation.
<br/>Measurements and Main Results: The authors found a significantly
increasing trend in the HFOV group mean values of IL-6, IL-8, and
TNF-alpha (p < 0.05 on days two and three v day one), and IL-6, IL-8, and
TNF-alpha levels were significantly higher on day three in the HFOV group
versus the HFOV+VG group (p < 0.05). In addition, the incidences of
hypocapnia and hypercapnia in infants supported with HFOV-VG were
significantly lower (p < 0.05). Furthermore, the postoperative mechanical
ventilation duration in the HFOV-VG group also was shorter than that in
the HFOV group (p < 0.05). <br/>Conclusion(s): Compared with HFOV alone,
HFOV-VG reduced proinflammatory systemic reactions after congenital
cardiac surgery, decreased the incidences of hypercapnia and hypocapnia,
and shortened the postoperative mechanical ventilation
duration.<br/>Copyright &#xa9; 2021 Elsevier Inc.

<31>
Accession Number
2015266762
Title
Comparison of Ultrasound-Guided Pecto-intercostal Fascial Block and
Transversus Thoracic Muscle Plane Block for Acute Poststernotomy Pain
Management After Cardiac Surgery: A Prospective, Randomized, Double-Blind
Pilot Study.
Source
Journal of Cardiothoracic and Vascular Anesthesia. Part A. 36(8) (pp
2313-2321), 2022. Date of Publication: August 2022.
Author
Kaya C.; Dost B.; Dokmeci O.; Yucel S.M.; Karakaya D.
Institution
(Kaya, Dost, Dokmeci, Karakaya) Department of Anaesthesiology and
Reanimation, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey
(Yucel) Department of Cardiovascular Surgery, Ondokuz Mayis University
Faculty of Medicine, Samsun, Turkey
Publisher
W.B. Saunders
Abstract
Objective: The objective of the present study was to evaluate morphine
consumption and pain scores 24 hours postoperatively to compare the
effects of a bilateral pectointercostal fascial block (PIFB) with those of
a transversus thoracic muscle plane block (TTMPB) on acute poststernotomy
pain in cardiac surgery patients who have undergone median sternotomy.
<br/>Design(s): Prospective, randomized, double-blinded. <br/>Setting(s):
The operating room, intensive care unit, and patient ward at a university
hospital. <br/>Participant(s): Thirty-nine American Society of
Anesthesiologists II-to-III patients aged 18- to-80 years, scheduled for
elective cardiac surgery via median sternotomy. <br/>Intervention(s):
Patients randomly were allocated to groups scheduled to receive bilateral
ultrasound-guided PIFB or TTMPB. <br/>Measurements and Main Results: The
primary outcome was postoperative morphine use within the first 24 hours.
Secondary outcomes were the numerical pain rating scale (NRS) scores at
rest and during coughing, time of first analgesic demand from the
patient-controlled analgesia (PCA) device, and rescue analgesia use. The
nausea/vomiting scores, time to extubation, length of stays in intensive
care and the hospital, patient satisfaction scores, and complications were
also recorded. The first 24-hour morphine use did not significantly differ
between the PIFB and TTMPB groups (mean +/- standard deviation [95% CI],
13.89 +/- 6.80 [10.83-16.95] mg/24 h and 15.08 +/- 7.42 [11.83-18.33]
mg/24 h, respectively, p = 0.608). No significant difference between the
two groups in the NRS scores at rest and during coughing was observed; the
groups had similar requirements for rescue analgesia in the first 24 hours
(n [%], three [15.8] and seven [35], p = 0.273, respectively). The time
from PCA to the first analgesia request was longer in the PIFB than in the
TTMPB group (median [interquartile range], 660 [540-900] minutes, and 240
[161-525] minutes, respectively, p = 0.002). <br/>Conclusion(s): PIFB and
TTMPB showed similar effectiveness for morphine consumption within 24
hours postoperatively and in pain scores in cardiac surgery
patients.<br/>Copyright &#xa9; 2021 Elsevier Inc.

<32>
Accession Number
2014888595
Title
Serratus Anterior Plane Block in Pediatric Patients Undergoing Thoracic
Surgeries: A Randomized Controlled Trial.
Source
Journal of Cardiothoracic and Vascular Anesthesia. Part A. 36(8) (pp
2271-2277), 2022. Date of Publication: August 2022.
Author
Gado A.A.; Abdalwahab A.; Ali H.; Alsadek W.M.; Ismail A.A.
Institution
(Gado, Abdalwahab, Ali, Alsadek, Ismail) Anesthesia and Pain Management,
Department of Anesthesia, Kasr Alainy Faculty of Medicine, Cairo
University, Egypt
Publisher
W.B. Saunders
Abstract
Objective(s): This study was designed to evaluate the efficacy and safety
of serratus anterior plane block (SAPB) as an analgesic technique for
thoracotomies in pediatric patients. <br/>Design(s): Double-blinded
randomized controlled trial. <br/>Setting(s): A single-center study at
Aboelrish Pediatric Hospital, one tertiary hospital of Cairo University
Hospitals. <br/>Participant(s): Seventy pediatric patients aged six
months-to-three years scheduled for thoracotomies. <br/>Intervention(s):
Patients were randomized into two groups, group SF and group F. Group SF
received an ultrasound-guided SAPB (n = 35), whereas group F (n = 35) did
not. All groups received an intraoperative fentanyl infusion (at 0.5
mug/kg /h). Measurements: The primary outcome was the total dose of
postoperatively administrated fentanyl in the first 24 hours. The
secondary outcomes included the total dose of intraoperative additional
fentanyl boluses; time of the first postoperative rescue analgesia; and
postoperative Face, Legs, Activity, Cry, Consolability scale (FLACC) score
values. <br/>Main Result(s): The main results of this study showed that
the administrated fentanyl in the 24 hours postoperatively was
significantly lower in SF group than in F group (p value < 0.001). In
addition, significant decreases of the postoperative FLACC pain score (p
value < 0.001), reduction of intraoperative fentanyl consumption (p value
< 0.001), and delay of the first rescue analgesia (p value < 0.001) were
recorded in SF group in relation to F group without significant
complications in both groups. <br/>Conclusion(s): Serratus anterior plane
block can provide a safe, effective, and easy-to-perform regional
technique for children undergoing thoracotomies.<br/>Copyright &#xa9; 2021
Elsevier Inc.

<33>
Accession Number
638213977
Title
Influence on Depression, Anxiety, and Satisfaction of the Relatives' Visit
to Intensive Care Units prior to Hospital Admission for Elective Cardiac
Surgery: A Randomized Clinical Trial.
Source
International journal of clinical practice. 2022 (pp 1746782), 2022. Date
of Publication: 2022.
Author
Gonzalez-Martin S.; Becerro-de-Bengoa-Vallejo R.; Rodriguez-Garcia M.;
Losa-Iglesias M.E.; Mazoteras-Pardo V.; Palomo-Lopez P.; Rodriguez-Sanz
D.; Calvo-Lobo C.; Lopez-Lopez D.
Institution
(Gonzalez-Martin, Becerro-de-Bengoa-Vallejo, Rodriguez-Garcia,
Rodriguez-Sanz, Calvo-Lobo) Faculty of Nursing, Physiotherapy and
Podiatry, Universidad Complutense de Madrid, Madrid, Spain
(Losa-Iglesias) Faculty of Health Sciences, Universidad Rey Juan Carlos,
Mostoles, Spain
(Mazoteras-Pardo) Department of Nursing, Physiotherapy and Occupational
Therapy, School of Physiotherapy and Nursing, University of Castilla-La
Mancha, Toledo, Spain
(Palomo-Lopez) University Center of Plasencia, Universidad de Extremadura,
Plasencia, Spain
(Lopez-Lopez) Research, Health and Podiatry Group, Department of Health
Sciences, Faculty of Nursing and Podiatry, Universidade da Coruna,
Industrial Campus of Ferrol, A Coruna, Spain
Publisher
NLM (Medline)
Abstract
Background: Intensive care units (ICUs) may produce stress on the
relatives of patients that have long-term physiological and psychological
implications. <br/>Objective(s): This study aimed to evaluate the effects
of the relatives' visit prior to hospital admission(s) on the patient's
scheduled cardiac surgery regarding depression, anxiety, and satisfaction
of the patient's family in an ICU. <br/>Method(s): A randomized clinical
trial [NCT03605420] was carried out according to the CONSORT criteria.
Thirty-eight relatives of ICU patients were recruited at an ICU and
randomized into study groups. Experimental group participants (n=19)
consisted of relatives who received 1 ICU visit prior to the patient's
admission. Control group participants (n=19) consisted of patients'
relatives who received standard care alone. A self-report test battery,
including the Impact of Event Scale-Revised (IES-R) and the Hospital
Anxiety and Depression Scale (HADS), was completed by the patient's
relative prior to the patient's ICU admission and again three and 90days
after ICU discharge. Furthermore, the Family Satisfaction with Care in the
Intensive Care Unit (FS-ICU) and Critical Care Family Needs Inventory
(CCFNI) were administered to help determine the respondents' satisfaction
three days after the patient's ICU discharge. <br/>Result(s):
Statistically significant differences in FS-ICU results were found between
control and experimental groups; no statistically significant differences
were found in IES-R, HADS, and CCFNI results. Thus, members in the control
group were more satisfied with the time elapsed to raise their concerns
(p=0.005), emotional support provided (p=0.020), quality of care
(p=0.035), opportunities to express concerns and ask questions (p=0.005),
and general satisfaction with the ICU's decision-making (p=0.003).
<br/>Conclusion(s): Relatives' satisfaction during patients' ICU admission
may be impaired after their prior visit to the hospital admission.
Relative's anxiety and depression scores did not seem to be significantly
affected. Relatives' visit prior to elective cardiac surgery hospital
admission impaired their satisfaction in an ICU and may not be advisable
for healthcare practice.<br/>Copyright &#xa9; 2022 Sara Gonzalez-Martin et
al.

<34>
Accession Number
2017570384
Title
Does Tranexamic Acid Reduce the Blood Loss in Various Surgeries? An
Umbrella Review of State-of-the-Art Meta-Analysis.
Source
Frontiers in Pharmacology. 13 (no pagination), 2022. Article Number:
887386. Date of Publication: 19 May 2022.
Author
Hong P.; Liu R.; Rai S.; Liu J.; Ding Y.; Li J.
Institution
(Hong, Li) Department of Orthopaedic Surgery, Union Hospital, Tongji
Medical College, Huazhong University of Science and Technology, Wuhan,
China
(Liu) Department of Endocrinology, Union Hospital, Tongji Medical College,
Huazhong University of Science and Technology, Wuhan, China
(Rai) Department of Orthopaedics and Trauma Surgery, Blue Cross Hospital,
Kathmandu, Nepal
(Liu, Ding) First Clinical School, Tongji Medical College, Huazhong
University of Science and Technology, Wuhan, China
(Ding) Basic Medical School, Tongji Medical College, Huazhong University
of Science and Technology, Wuhan, China
Publisher
Frontiers Media S.A.
Abstract
Background: Tranexamic acid (TXA) has been applied in various types of
surgery for hemostasis purposes. The efficacy and safety of TXA are still
controversial in different surgeries. Guidelines for clinical application
of TXA are needed. <br/>Material(s) and Method(s): We systematically
searched multiple medical databases for meta-analyses examining the
efficacy and safety of TXA. Types of surgery included joint replacement
surgery, other orthopedic surgeries, cardiac surgery, cerebral surgery,
etc. Outcomes were blood loss, blood transfusion, adverse events,
re-operation rate, operative time and length of hospital stay, hemoglobin
(Hb) level, and coagulation function. Assessing the methodological quality
of systematic reviews 2 (AMSTAR 2) and Grading of Recommendations,
Assessment, Development and Evaluation (GRADE) were used for quality
assessment of the included meta-analyses. Overlapping reviews were
evaluated by calculating the corrected covered area (CCA). <br/>Result(s):
In all, we identified 47 meta-analyses, of which 44 of them were of "high"
quality. A total of 319 outcomes were evaluated, in which 58 outcomes were
assessed as "high" quality. TXA demonstrates significant hemostatic
effects in various surgeries, with lower rates of blood transfusion and
re-operation, shorter operative time and length of stay, and higher Hb
levels. Besides, TXA does not increase the risk of death and vascular
adverse events, but it is a risk factor for seizure (a neurological event)
in cardiac surgery. <br/>Conclusion(s): Our study demonstrates that TXA
has a general hemostatic effect with very few adverse events, which
indicates TXA is the recommended medication to prevent excessive bleeding
and reduce the blood transfusion rate. We also recommend different dosages
of TXA for different types of adult surgery. However, we could not
recommend a unified dosage for different surgeries due to the
heterogeneity of the experimental design. Systematic Review Registration:
clinicaltrials.gov/, identifier CRD42021240303.<br/>Copyright &#xa9; 2022
Hong, Liu, Rai, Liu, Ding and Li.

<35>
[Use Link to view the full text]
Accession Number
2018732519
Title
A novel method of Uniblocker placement: Extraluminal technique supported
by trachea length measurement: A CONSORT-compliant article.
Source
Medicine (United States). 98(14) (no pagination), 2019. Article Number:
e15116. Date of Publication: 01 Apr 2019.
Author
Liu Z.; Zhao L.; He W.; Zhu Y.; Bao L.; Jia Q.; Yang X.; Liang S.
Institution
(Liu, He, Zhu, Bao, Jia, Yang, Liang) Department of Anesthesiology, First
Hospital of Qinhuangdao, Qinhuangdao, China
(Zhao) Department of Thoracic Surgery, First Hospital of Qinhuangdao,
Hebei, Qinhuangdao, China
Publisher
Lippincott Williams and Wilkins
Abstract
Background: The use of bronchial blockers has been increased for one-lung
ventilation; however, the placement of bronchial blockers is time
consuming. The objective of this study was to compare the novel
extraluminal technique of Uniblocker placement supported by trachea length
measurement on computerized tomography images with conventional
intraluminal Uniblocker placement method. <br/>Method(s): Seventy adult
patients undergoing left side thoracic surgery were included in the study.
All the patients were randomly assigned to one of two groups: conventional
intraluminal intubation group (CV-IN group, n=35) or extraluminal CT
guided group (CTEX group, n=35). The primary endpoints were the optimal
positions of Uniblocker and the injuries of bronchi and carina. The
secondary outcomes included the time of Uniblocker placement, the adequacy
of lung collapse, the incidences of Uniblocker displacement, sore throat,
and hoarseness postoperative. <br/>Result(s): In the CV-IN group, 19 of 35
Uniblockers went to the left main-stem bronchus on the initial blind
insertion and 15 of 35 Uniblockers were considered as in optimal depth,
whereas in the CT-EX group, 32 of 35 Uniblockers went to the left
main-stem bronchus on the initial blind insertion and 31 of 35 Uniblockers
were considered as in optimal depth (P<.01). The incidence of bronchi and
carina injuries was obviously lower in the CT-EX group (occurred in 1 of
35 cases) than that in the CV-IN group (occurred in 8 of 35 cases)
(P<.05). The time of Uniblocker placement took 145.4 s in the CV-IN group
and 85.4 s in the CT-EX group (P<.01). The malpositions of Uniblocker, the
degree of pulmonary collapse and the adverse events postoperative such as
sore throat and hoarseness were not significantly different between the
two groups (P>.05). <br/>Conclusion(s): The novel extraluminal technique
of Uniblocker placement supported by trachea length measurement on
computerized tomography images was proved to be more rapid, more accurate
and less complications than conventional intraluminal Uniblocker placement
method.<br/>Copyright &#xa9; 2019 Lippincott Williams and Wilkins. All
rights reserved.

<36>
[Use Link to view the full text]
Accession Number
2018732169
Title
Application of intrapulmonary wire combined with intrapleural fibrin glue
in preoperative localization of small pulmonary nodules.
Source
Medicine (United States). 98(4) (no pagination), 2019. Article Number:
e14029. Date of Publication: 01 Jan 2019.
Author
Zhang W.-H.; Bai Y.-Y.; Guo W.; Li M.; Chang G.-X.; Liu W.; Mao Y.
Institution
(Zhang, Guo, Li, Chang, Liu, Mao) Department of Thoracic Surgery, The
First Hospital of Hohhot, Inner Mongolia, China
(Bai) Department of Anesthesiology, The First Hospital of Hohhot, Inner
Mongolia, China
Publisher
Lippincott Williams and Wilkins
Abstract
Objective: This study aims to investigate the accuracy of the preoperative
localization of small nodules by computerized tomography (CT)-guided
placing wire and intrapleural fibrin glue near the nodules at 3 days
before the operation. <br/>Method(s): From October 2015 to December 2017,
a total of 79 patients, who received preoperative localization of small
pulmonary nodules and surgical treatment in the Department of Thoracic
Surgery of Hohhot First Hospital, were enrolled into this study. These
patients were randomly divided into 2 groups: methylene blue localization
group (n = 47), and modified localization group (n = 32), where the
patients received preoperative localization of the small nodules by
CT-guided placing wire and intrapleural fibrin glue near the nodule at 3
days before the operation. Localization accuracy, operation time and
difficulty in postoperative seeking for pathological specimens were
compared between these 2 groups. <br/>Result(s): In the methylene blue
localization group, 3 patients had localization failure due to the
intrathoracic diffusion of methylene blue, and the success rate was
93.61%. In the modified localization group, all 32 patients succeeded in
the localization, and the success rate was 100%. Operation time and
difficulty of finding the specimen was significantly lower in the modified
localization group than in the methylene blue localization group (P <
.05). <br/>Conclusion(s): The application of preoperative localization of
small nodules by placing wire and intrapleural fibrin glue improves the
success rate of resection, reduces operation time and the risk of the
operation, and lowers the difficulty of finding pathological specimens
after the operation. Hence this operative procedure is worthy of
popularization.<br/>Copyright &#xa9; 2019 the Author(s).

<37>
Accession Number
2017872048
Title
The management of paravalvular leaks post aortic valve replacement.
Source
Journal of Cardiac Surgery. (no pagination), 2022. Date of Publication:
2022.
Author
Kananathan S.; Perera L.A.; Mohanarajan M.; Sherif M.; Harky A.
Institution
(Kananathan, Perera, Mohanarajan) Dnipro Medical Institute of Traditional
and Non-Traditional Medicine, Dnipro, Ukraine
(Sherif) Department of Cardiothoracic Surgery, Northern General Hospital,
Sheffield, United Kingdom
(Harky) Department of Cardiothoracic Surgery, Liverpool Heart and Chest
Hospital, Liverpool, United Kingdom
Publisher
John Wiley and Sons Inc
Abstract
Background: Paravalvular leak (PVL) is uncommon but can lead to severe
complications after surgical or transcatheter aortic valve implantation.
Conditions associated with PVLs such as heart failure, hemolysis, and
infective endocarditis can lead to catastrophic results if not treated
promptly; the therapeutic goals differ according to the presentation. It
is vital that PVLs are diagnosed early using various imaging modalities.
Different approaches have been studied in managing PVLs; there is an
increased interest in the transcatheter aortic valve closure procedure as
it is minimally invasive and decreases the occurrence of further
reinterventions. <br/>Aim(s): To discuss the classification of PVLs,
diagnostic approaches, and available management options. <br/>Method(s): A
literature review was performed using 28 studies. <br/>Result(s): This
review evaluated the relationship between the time of diagnosis,
management of PVL and the resulting outcomes. <br/>Discussion(s): Patients
with PVL should be assessed through a multidisciplinary team approach and
a patient-selective plan should be in place. <br/>Conclusion(s): Open
surgical intervention is reserved for complex cases where minimally
invasive techniques cannot be utilized.<br/>Copyright &#xa9; 2022 Wiley
Periodicals LLC.

<38>
Accession Number
2017872047
Title
Implantable cardioverter defibrillators in patients with orthotopic heart
transplant: A multicenter case series.
Source
Journal of Cardiovascular Electrophysiology. (no pagination), 2022. Date
of Publication: 2022.
Author
Maskoun W.; Raad M.; Cha Y.-M.; Houmsse M.; Abualsuod A.; Ezzeddine F.;
Pieper J.; Jamoor K.; Tita C.; Miller J.
Institution
(Maskoun, Raad, Jamoor) Division of Electrophysiology, Department of
Cardiovascular Diseases, Henry Ford Health System, Detroit, MI, United
States
(Cha, Ezzeddine) Division of Electrophysiology, Department of
Cardiovascular Diseases, Mayo Clinic, Rochester, MN, United States
(Houmsse, Pieper) Division of Electrophysiology, Department of
Cardiovascular Diseases, Ohio State University, Columbus, OH, United
States
(Abualsuod, Miller) Division of Cardiology, Department of Medicine,
Indiana University School of Medicine, Indianapolis, IN, United States
(Tita) Division of Advanced Heart Failure and Transplant Cardiology,
Department of Cardiovascular Diseases, Henry Ford Health System, Detroit,
MI, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Sudden cardiac death (SCD) is common after orthotopic heart
transplant (OHT). No clear guidelines for implantable cardioverter
defibrillator (ICD) implantation in OHT patients at high risk for SCD
currently exist. <br/>Objective(s): To assess the safety, efficacy, and
benefit of ICDs and resynchronization therapy post-OHT. We also provide a
systematic review of previous reports. <br/>Method(s): A retrospective
multicenter cohort study within the United States. Patients with ICD
post-OHT between 2000 and 2020 were identified. <br/>Result(s): We
analyzed 16 patients from 4 centers. The mean standard-deviation (SD) age
was 43 (18) years at OHT and 51 (20) years at ICD implantation. The mean
(SD) duration from OHT to ICD implantation was 9 (5) years. The mean (SD)
left ventricular ejection fraction (LVEF) was 35% (17%). There were 2
(13%) postprocedural complications: 1 hematoma and 1 death. Mean (SD)
follow-up was 24 (23) months. Survival rate was 63% (10/16) at 1 year and
56% (9/16) at 2 years, with 6/7 of those who died having LVEF < 35% at the
time of the ICD implantation. Patients were more likely to receive
appropriate therapy if their ICD was implanted for secondary (5/8) rather
than primary (0/8) prevention (p =.007). Of those who did, 4 patients
survived to 30 days post-ICD therapy. Severe CAV was not associated with
the rate of appropriate therapy. <br/>Conclusion(s): Beneficial outcomes
were observed when ICDs were implanted for secondary prevention only, and
in patients with higher baseline LVEF. We also observed benefits with
resynchronization therapy.<br/>Copyright &#xa9; 2022 Wiley Periodicals
LLC.

<39>
Accession Number
372415724
Title
Acute coronary syndrome in pre- and post-partum women - a review.
Source
Interventional Cardiology: Reviews, Research, Resources. 8(1) (pp 8-13),
2013. Date of Publication: March 2013.
Author
Aprigliano G.; Palloshi A.; Morici N.; Ferraresi R.; Bianchi M.; Anzuini
A.
Institution
(Aprigliano, Palloshi, Ferraresi, Bianchi) Interventional Cardiovascular
Unit, Cardiology Department, Istituto Clinico Citta Studi, Milan, Italy
(Morici) Cardiologia 1, Azienda Ospedaliera Ospedale Niguarda Ca' Granda,
Milan, Italy
(Anzuini) Cardiology Department, Istituto Clinico Mater Domini,
Castellanza, Italy
Publisher
Radcliffe Cardiology
Abstract
Acute coronary syndrome (ACS) during pregnancy and the post-partum period
are weighed by a high mortality rate for the mother and foetus. They
should be considered as multifactorial diseases with a special role for
sexual hormones. In this setting, ACS is mostly related to an early
atherosclerotic disease, even if other conditions are responsible. Indeed,
an important part is due to spontaneous coronary artery dissection, more
common during delivery and the post-partum period. In the remaining
situation, an isolated intracoronary thrombus or a normal angiographic
pattern can be found at angiography. Pathophysiology is still uncertain
with different hypothetical mechanisms. Prompt diagnosis of ACS and
aetiology are essential for an optimal therapeutic strategy. Difficulties
in treatment management is a matter for debate, especially in pre-partum
women. In the last two decades improvements of diagnostic tools, coronary
angiography and subsequent percutaneous treatment have changed the natural
history of this rare condition. &#xa9; RADCLIFFE 2013.

<40>
Accession Number
2017664727
Title
Effects of Antihypertensive Deprescribing Strategies on Blood Pressure,
Adverse Events, and Orthostatic Symptoms in Older Adults: Results From
TONE.
Source
American Journal of Hypertension. 35(4) (pp 337-346), 2022. Date of
Publication: 01 Apr 2022.
Author
Juraschek S.P.; Cluett J.L.; Belanger M.J.; Anderson T.S.; Ishak A.; Sahni
S.; Millar C.; Appel L.J.; Miller E.R.; Lipsitz L.A.; Mukamal K.J.
Institution
(Juraschek, Cluett, Belanger, Anderson, Ishak, Sahni, Millar, Lipsitz,
Mukamal) Department of Medicine, Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, MA, United States
(Sahni, Lipsitz) Hinda and Arthur Marcus Institute for Aging Research,
Hebrew SeniorLife, Roslindale, MA, United States
(Appel, Miller) Department of Medicine, The Johns Hopkins University
School of Medicine, The Johns Hopkins Bloomberg School of Public Health,
The Welch Center for Prevention, Epidemiology and Clinical Research,
Baltimore, MD, United States
Publisher
Oxford University Press
Abstract
Background: The Trial of Nonpharmacologic Interventions in the Elderly
(TONE) demonstrated the efficacy of weight loss and sodium reduction to
reduce hypertension medication use in older adults. However, the
longer-term effects of drug withdrawal (DW) on blood pressure (BP),
adverse events, and orthostatic symptoms were not reported.
<br/>Method(s): TONE enrolled adults, ages 60-80 years, receiving
treatment with a single antihypertensive and systolic BP (SBP)/diastolic
BP <145/<85 mm Hg. Participants were randomized to weight loss, sodium
reduction, both, or neither (usual care) and followed up to 36 months; ~3
months postrandomization, the antihypertensive was withdrawn and only
restored if needed for uncontrolled hypertension. BP and orthostatic
symptoms (lightheadedness, feeling faint, imbalance) were assessed at
randomization and throughout the study. Two physicians independently
adjudicated adverse events, masked to intervention, classifying
symptomatic (lightheadedness, dizziness, vertigo), or clinical events
(fall, fracture, syncope). <br/>Result(s): Among the 975 participants
(mean age 66 years, 48% women, 24% black), mean (+/-SD) BP was 128 +/-
9/71 +/- 7 mm Hg. Independent of assignment, DW increased SBP by 4.59 mm
Hg (95% confidence interval [CI]: 3.89, 5.28) compared with baseline.
There were 113 adverse events (84 symptomatic, 29 clinical), primarily
during DW. Compared with usual care, combined weight loss and sodium
reduction mitigated the effects of DW on BP (beta = -4.33 mm Hg; 95% CI:
-6.48, -2.17) and reduced orthostatic symptoms long term (odds ratio =
0.62; 95% CI: 0.41, 0.92), without affecting adverse events (hazard ratio
= 1.81; 95% CI: 0.90, 3.65). In contrast, sodium reduction alone increased
risk of adverse events (hazard ratio = 1.75; 95% CI: 1.04, 2.95), mainly
during DW. <br/>Conclusion(s): In older adults, antihypertensive DW may
increase risk of symptomatic adverse events, highlighting the need for
caution in withdrawing their antihypertensive medications. Clinical trials
registration: Trial Number NCT00000535.<br/>Copyright &#xa9; 2021 American
Journal of Hypertension, Ltd 2021. All rights reserved.

<41>
Accession Number
2018358708
Title
Postoperative outcomes in older surgical patients with preoperative
cognitive impairment: A systematic review and meta-analysis.
Source
Journal of Clinical Anesthesia. 80 (no pagination), 2022. Article Number:
110883. Date of Publication: September 2022.
Author
Chen L.; Au E.; Saripella A.; Kapoor P.; Yan E.; Wong J.; Tang-Wai D.F.;
Gold D.; Riazi S.; Suen C.; He D.; Englesakis M.; Nagappa M.; Chung F.
Institution
(Chen, Au, Saripella, Kapoor, Yan, Wong, Riazi, Suen, Chung) Department of
Anesthesia and Pain Management, Toronto Western Hospital, University
Health Network, University of Toronto, Toronto, ON, Canada
(Wong) Department of Anesthesiology and Pain Medicine, Women's College
Hospital, Toronto, ON, Canada
(Tang-Wai) Division of Neurology, Department of Medicine, University of
Toronto, Toronto, ON, Canada
(Gold) Department of Psychiatry, Krembil Brain Institute, University of
Toronto, Toronto, ON, Canada
(He) Department of Anesthesiology and Pain Medicine, Mount Sinai Hospital,
University of Toronto, Toronto, ON, Canada
(Englesakis) Library & Information Services, University Health Network,
Toronto, ON, Canada
(Nagappa) Department of Anesthesia & Perioperative Medicine, Schulich
School of Medicine and Dentistry, Western University, London, ON, Canada
Publisher
Elsevier Inc.
Abstract
Study objective: To determine the effect of cognitive impairment (CI) and
dementia on adverse outcomes in older surgical patients. <br/>Design(s): A
systematic review and meta-analysis of observational studies and
randomized controlled trials (RCTs). Various databases were searched from
their inception dates to March 8, 2021. <br/>Setting(s): Preoperative
assessment. <br/>Patient(s): Older patients (>= 60 years) undergoing
non-cardiac surgery. Measurements: Outcomes included postoperative
delirium, mortality, discharge to assisted care, 30-day readmissions,
postoperative complications, and length of hospital stay. Effect sizes
were calculated as Odds Ratio (OR) and Mean Difference (MD) based on
random effect model analysis. The quality of included studies was assessed
using the Cochrane Risk Bias Tool for RCTs and Newcastle-Ottawa Scale for
observational cohort studies. <br/>Result(s): Fifty-three studies (196,491
patients) were included. Preoperative CI was associated with a significant
risk of delirium in older patients after non-cardiac surgery (25.1% vs.
10.3%; OR: 3.84; 95%CI: 2.35, 6.26; I²: 76%; p < 0.00001).
Cognitive impairment (26.2% vs. 13.2%; OR: 2.28; 95%CI: 1.39, 3.74;
I²: 73%; p = 0.001) and dementia (41.6% vs. 25.5%; OR: 1.96;
95%CI: 1.34, 2.88; I²: 99%; p = 0.0006) significantly increased
risk for 1-year mortality. In patients with CI, there was an increased
risk of discharge to assisted care (44.7% vs. 38.3%; OR 1.74; 95%CI: 1.05,
2.89, p = 0.03), 30-day readmissions (14.3% vs. 10.8%; OR: 1.36; 95%CI:
1.00, 1.84, p = 0.05), and postoperative complications (40.7% vs. 18.8%;
OR: 1.85; 95%CI: 1.37, 2.49; p < 0.0001). <br/>Conclusion(s): Preoperative
CI in older surgical patients significantly increases risk of delirium,
1-year mortality, discharge to assisted care, 30-day readmission, and
postoperative complications. Dementia increases the risk of 1-year
mortality. Cognitive screening in the preoperative assessment for older
surgical patients may be helpful for risk stratification so that
appropriate management can be implemented to mitigate adverse
postoperative outcomes.<br/>Copyright &#xa9; 2022 Elsevier Inc.

<42>
Accession Number
638198153
Title
Comparison of hybrid coronary revascularization versus coronary artery
bypass grafting in patients with multivessel coronary artery disease: a
meta-analysis.
Source
Journal of cardiothoracic surgery. 17(1) (pp 147), 2022. Date of
Publication: 07 Jun 2022.
Author
Yu L.; Zhu K.; Du N.; Si Y.; Liang J.; Shen R.; Chen B.
Institution
(Yu) Department of Cardiology, Ningbo Yinzhou No. 2 Hospital, Ningbo,
Zhejiang, China
(Zhu, Du, Shen) Clinical Medicine Science, Second Clinical Medical
College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
(Si) Biochemistry Laboratory, School of Basic Medical Sciences, Zhejiang
Chinese Medical University, Hangzhou, Zhejiang, China
(Liang) Clinical Medicine Science, First Clinical Medical College,
Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
(Chen) Emergency Medical Center, Ningbo Yinzhou No. 2 Hospital, Yinzhou
District, 998 North Qianhe Road, Ningbo, Zhejiang 315100, China
Publisher
NLM (Medline)
Abstract
BACKGROUND: Percutaneous coronary intervention (PCI) and coronary artery
bypass grafting (CABG) are widely used in the treatment of coronary heart
disease, but the best revascularization method for multivessel coronary
artery disease (MVD) patients is still controversial. Hybrid coronary
revascularization (HCR), together with CABG and PCI, have been proved to
be feasible methods, but the long-term effect of HCR is not as clear as
CABG. <br/>METHOD(S): By October 2020, we retrieved articles from PubMed,
Web of science, EMBASE and Cochrane library databases. The main results
are based on major adverse cardiovascular and cerebral events (MACCE).
<br/>RESULT(S): A total of 18 articles (3 randomized controlled trials
(RCTs) and 15 observational studies) were included in this meta-analysis.
The outcomes of MACCE in the HCR group at perioperative, short-term (30
days to 1 year), medium-term (1 year to 5 years) and long-term (5 years
and above) follow-up period were similar to those in the CABG group. The
mortality rates of patients in perioperative, short-term and medium-term
follow-up were similar to those in the CABG group, but lower than that in
the CABG group at long-term follow-up (OR=0.35, 95% CI 0.18-0.69,
p=0.002). The revascularization rate was higher in the HCR group during
the perioperative period (OR=3.50, 95% CI 2.07-5.94, p<0.001), short-term
(OR=3.28, 95% CI 1.62-6.64, p<0.001) and mid-term follow-up (OR=2.84, 95%
CI 1.64-4.92, p<0.001). <br/>CONCLUSION(S): Our results reveal that HCR is
a safe and therapeutically effective alternative in treatments for MVD
patients. It has not only less short-term adverse effect, but also better
long-term effect, especially in death.<br/>Copyright &#xa9; 2022. The
Author(s).

<43>
[Use Link to view the full text]
Accession Number
637040081
Title
Effect of ulinastatin on the inflammatory response after video-assisted
thoracic lobectomy in patients with lung cancer: a randomized controlled
study.
Source
Chinese medical journal. 135(7) (pp 806-812), 2022. Date of Publication:
05 Apr 2022.
Author
Hwang W.J.; Joo M.A.; Joo J.
Institution
(Hwang) Department of Anesthesiology and Pain Medicine, Seoul St. Mary's
Hospital, College of Medicine, Catholic University of Korea, Seoul, South
Korea
Publisher
NLM (Medline)
Abstract
BACKGROUND: The first-line treatment for lung cancer is surgical
resection, and one-lung ventilation (OLV) is the most basic anesthetic
management method in lung surgery. During OLV, inflammatory cytokines are
released in response to the lung tissue damage and promote local and
contralateral lung damage through the systemic circulation. We designed a
randomized, prospective study to evaluate the effect of the urinary
trypsin inhibitor (UTI) ulinastatin on the inflammatory response after
video-assisted thoracic lobectomy in patients with lung cancer.
<br/>METHOD(S): Adult patients aged 19 to 70 years, who were scheduled for
video-assisted thoracic lobectomy surgery to treat lung cancer between May
2020 and August 2020, were enrolled in this randomized, prospective study.
UTI (300,000 units) mixed with 100 mL of normal saline in the ulinastatin
group and 100 mL of normal saline in the control group was administered
over 1 h after inducing anesthesia. <br/>RESULT(S): The baseline (T0)
interferon-gamma (IFN-gamma)/interleukin-4 (IL-4) ratio was not different
between the groups (6941.3 +/- 2778.7 vs. 6954.3 +/- 2752.4 pg/mL,
respectively; P > 0.05). The IFN-gamma/IL-4 ratio was significantly
higher in ulinastatin group at 30 min after entering the recovery room
than control group (20,148.2 +/- 5054.3 vs. 6674.0 +/- 2963.6,
respectively; adjusted P < 0.017). <br/>CONCLUSION(S): Administering UTI
attenuated the anti-inflammatory response, in terms of INF-gamma
expression and the IFN-gamma/IL-4 ratio, after video-assisted thoracic
surgery in lung cancer patients. TRIAL REGISTRATION: Clinical Research
Information Service of Korea National Institute of Health (CRIS),
KCT0005533.<br/>Copyright &#xa9; 2022 The Chinese Medical Association,
produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

<44>
Accession Number
2017828372
Title
Intraoperative hyperoxygenation may negatively affect postoperative
cognitive functions in coronary artery bypass graft operations: A
randomized controlled study.
Source
Journal of Cardiac Surgery. (no pagination), 2022. Date of Publication:
2022.
Author
Onur T.; Karaca U.; Ata F.; Sayan H.E.; Onur A.; Yilmaz C.; Balkaya A.N.;
Eris C.
Institution
(Onur, Karaca, Ata, Sayan, Onur, Yilmaz, Balkaya) Departmant of
Anesthesiology and Reanimation, University of Health Sciences Bursa Yuksek
Ihtisas Training and Research Hospital, Bursa, Turkey
(Eris) Departmant of Cardiovascular Surgery, University of Health Sciences
Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
Publisher
John Wiley and Sons Inc
Abstract
Objective: In this study, it was aimed to compare various parameters
during surgery and postoperative cognitive functions in patients
undergoing coronary artery bypass graft (CABG) surgery using different
levels of perioperative oxygen. <br/>Method(s): One hundred patients
scheduled for elective CABG surgery were included in the study. The
patients were divided into two groups according to arterial oxygen levels
during surgery. In the normoxia group (NG) (n = 50), partial arterial
oxygen pressure (PaO<inf>2</inf>) was between >=100 and <180 mmHg with at
least 40% fraction of inspired oxygen (FiO<inf>2</inf>) mechanical
ventilation (MV), and in the hyperoxia group (HG) (n = 50),
PaO<inf>2</inf> was >=180 mmHg with 100% FiO<inf>2</inf> MV. Hemodynamic
parameters, peripheral oxygen saturation (SpO<inf>2</inf>), regional
cerebral oxygen saturation (rSO<inf>2</inf>) measured from bilateral
sensors, and blood gas values were recorded at the planned measurement
times. Postoperative features (mortality and infection rates, length of
stay in the hospital, and intensive care unit) and complications of the
patients have been recorded (low cardiac output syndrome, renal failure,
delirium). Mini-Mental State Examination (MMSE) test was applied to the
patients before and at the 12th, 24th hours; on the first, third, sixth
months after surgery. <br/>Result(s): Extubation time was found to be
shorter in NG (p <.05). Between the groups, rSO<inf>2</inf> and mean
arterial pressure were found to be significantly lower in HG at the time
of T4 measurement (p =.042, p =.038, respectively). MMSE values of the
groups at the first, third, and sixth months were found to be
significantly higher in NG (p =.017, p =.014, p =.002, respectively).
<br/>Conclusion(s): Hyperoxemia application during CABG may be associated
with worse postoperative late-term cognitive functions.<br/>Copyright
&#xa9; 2022 Wiley Periodicals LLC.

<45>
Accession Number
2017808482
Title
New challenges of fetal therapy in Japan.
Source
Journal of Obstetrics and Gynaecology Research. (no pagination), 2022.
Date of Publication: 2022.
Author
Wada S.; Ozawa K.; Sago H.
Institution
(Wada, Ozawa, Sago) Center for Maternal-Fetal, Neonatal and Reproductive
Medicine, National Center for Child Health and Development, Tokyo, Japan
Publisher
John Wiley and Sons Inc
Abstract
Aim: To review new challenges of fetal therapy in Japan after the
establishment of four existing fetal therapies as standard prenatal care
with National Health Insurance coverage over the past 20 years.
<br/>Method(s): Reported studies and our current research activities
related to four fetal therapies newly performed in Japan were reviewed.
<br/>Result(s): Fetoscopic endoluminal tracheal occlusion (FETO) for
congenital diaphragmatic hernia (CDH) aims to occlude the trachea using a
detachable balloon to promote lung growth. Following the recent successful
completion of an international randomized controlled trial for CDH, in
which we participated, FETO is offered for severe left CDH to perform
balloon insertion at 27-29 weeks and removal at 34 weeks of gestation.
Fetal cystoscopy (FC) for low urinary tract obstruction was introduced to
overcome the demerits of vesicoamniotic shunting. FC may provide a proper
diagnosis by visual observation of the urethra and physiological treatment
of the posterior urethral valve. The effectiveness of open fetal surgery
for myelomeningocele (MMC), direct surgery with laparotomy and
hysterotomy, for ameliorating hindbrain herniation and the motor function
was demonstrated, but it was also associated with substantial maternal and
fetal risks. Fetal aortic valvuloplasty (FAV), ultrasound-guided fetal
aortic balloon dilation for critical aortic stenosis with evolving
hypoplastic left heart syndrome may improve left heart development and
maintain biventricular circulation. Feasibility and safety studies for FC,
MMC open fetal surgery, and FAV are currently ongoing. <br/>Conclusion(s):
Clinical research on FETO, FC, MMC open fetal surgery, and FAV has
proceeded with careful preparations in Japan.<br/>Copyright &#xa9; 2022
Japan Society of Obstetrics and Gynecology.

<46>
Accession Number
638202792
Title
Uniportal Video-Assisted Thoracic Surgery in a Pediatric Hospital: Early
Results and Review of the Literature.
Source
Journal of Laparoendoscopic and Advanced Surgical Techniques. 32(6) (pp
713-720), 2022. Date of Publication: 01 Jun 2022.
Author
Ugolini S.; Coletta R.; Lo Piccolo R.; Dell'otto F.; Voltolini L.;
Gonfiotti A.; Morabito A.
Institution
(Ugolini, Coletta, Lo Piccolo, Dell'otto, Morabito) Department Of
Pediatric Surgery, Meyer Children's Hospital Academic Centre, Florence,
Italy
(Coletta) School Of Environment And Life Science, University Of Salford,
Salford, United Kingdom
(Dell'otto, Morabito) Department Of Neurosciences Psychology Drug Research
And Child Health (NEUROFARBA), University Of Florence, Florence, Italy
(Voltolini, Gonfiotti) Department Of Thoracic Surgery, University Hospital
Careggi, Florence, Italy
(Voltolini, Gonfiotti) Department Of Experimental And Clinical Medicine
(DMSC), University Of Florence, Florence, Italy
Publisher
Mary Ann Liebert Inc.
Abstract
Background: Uniportal video-assisted thoracic surgery (U-VATS) is an
implemented technique in adult surgery that may aid to extend offer the
benefits of thoracoscopy to a wide number of pediatric patients.
<br/>Material(s) and Method(s): Consecutive cases treated between July
2019 and July 2021 were retrospectively analyzed. Simultaneously, a
MEDLINE systematic search was conducted. <br/>Result(s): Twelve patients
(median age 13 years, median weight 44.5 kg) underwent 4 major procedures
(n = 2 lobectomy, n = 2 segmentectomy) and 11 minor procedures (n = 1
bronchogenic cyst resection, n = 4 apical wedge resections and pleurodesis
for pneumothorax, n = 4 wedge resections for lung nodules, and n = 2
debridement for empyema). The median observed operative time was 77
minutes. We recorded one conversion to biportal VATS. No intraoperative
complications or 30-day morbidity-mortality was reported. A rate of 40%
adverse postoperative events was observed (Clavien-Dindo grade I-IVa).
Visual analog scale for postoperative pain recorded a median value of 0 on
days 1, 2, and 3. The systematic review provided 15 full-text articles
reporting 76 pediatric interventions (4 major and 72 minor procedures);
among them, 1 biportal conversion, 3 mild postoperative complications, and
1 redo surgery are presented. <br/>Conclusion(s): As emerged from the
literature review, U-VATS remains scarcely adopted by pediatric surgeons.
Its feasibility is supported by the four reported major lung resections
plus the four cases added on by our series. Thanks to a more rapid
learning curve over conventional VATS, the uniportal technique could be
accessible to a wider number of centers. <br/>Copyright &#xa9; 2022, Mary
Ann Liebert, Inc., publishers.

<47>
Accession Number
638204810
Title
Radial artery versus saphenous vein versus right internal thoracic artery
for coronary artery bypass grafting.
Source
European journal of cardio-thoracic surgery : official journal of the
European Association for Cardio-thoracic Surgery. (no pagination), 2022.
Date of Publication: 09 Jun 2022.
Author
Gaudino M.; Audisio K.; Di Franco A.; Alexander J.H.; Kurlansky P.;
Boening A.; Chikwe J.; Devereaux P.J.; Diegeler A.; Dimagli A.; Flather
M.; Lamy A.; Lawton J.S.; Tam D.Y.; Reents W.; Rahouma M.; Girardi L.N.;
Hare D.L.; Fremes S.E.; Benedetto U.
Institution
(Gaudino, Audisio, Di Franco, Rahouma, Girardi) Department of
Cardiothoracic Surgery, Weill Cornell Medicine, NY, NY, United States
(Alexander) Duke Clinical Research Institute, Duke University Medical
Center, Durham, NC, United States
(Kurlansky) Department of Surgery, Center for Innovation and Outcomes
Research, Columbia University Medical Center, NY, NY, United States
(Boening) Department of Cardiovascular Surgery, Justus-Liebig University
Giesen, Giesen, Germany
(Chikwe) Department of Cardiac Surgery in the Smidt Heart Institute at
Cedars-Sinai Medical Center, Los Angeles, CA, USA
(Devereaux, Lamy) Population Health Research Institute,McMaster
University, Hamilton, Ontario, Canada
(Diegeler, Reents) Department Cardiac Surgery, Cardiovascular Center Bad,
Bad Neustadt/Saale, Germany
(Dimagli, Benedetto) Bristol Heart Institute, University of Bristol,
Bristol, United Kingdom
(Flather) Norwich Medical School, University of East Anglia, Norwich,
United Kingdom
(Lawton) Division of Cardiac Surgery, Department of Surgery, Johns Hopkins
University School of Medicine, Baltimore, MD, United States
(Tam, Fremes) Schulich Heart Centre Sunnybrook Health Sciences Centre,
University of Toronto, Toronto, Canada
(Hare) University of Melbourne, Melbourne, VIC, Australia
Publisher
NLM (Medline)
Abstract
OBJECTIVES: We used individual patient data from four of the largest
contemporary coronary bypass surgery trials to evaluate differences in
long-term outcomes when radial artery, right internal thoracic artery, or
saphenous vein graft are used to complement the left internal thoracic
artery-to-left anterior descending graft. <br/>METHOD(S): Primary outcome
was all-cause mortality. Secondary outcome was a composite of major
adverse cardiac and cerebrovascular events (all-cause mortality,
myocardial infarction, and stroke). Propensity score matching and Cox
regression were used to reduce the effect of treatment selection bias and
confounders. <br/>RESULT(S): 10,256 patients (1510 right internal thoracic
artery; 1385 radial artery; 7361 saphenous vein graft) were included. The
matched population consisted of 1776 propensity score-matched triplets.
Mean follow-up was 7.9+/-0.1, 7.8+/-0.1, and 7.8+/-0.1years in the right
internal thoracic artery, radial artery, and saphenous vein graft cohorts
respectively. All-cause mortality was significantly lower in the radial
artery vs the saphenous vein graft (HR 0.62, 95% CI: 0.51-0.76, p=0.003)
and the right internal thoracic artery group (HR 0.59, 95% CI 0.48-0.71,
p=0.001). Major adverse cardiac and cerebrovascular events rate was also
lower in the radial artery group vs the saphenous vein graft (HR 0.78, 95%
CI 0.67-0.90, p=0.04) and the right internal thoracic artery group (HR
0.75, 95% CI 0.65-0.86, p=0.02). Results were consistent in the
Cox-adjusted analysis and solid to hidden confounders. <br/>CONCLUSION(S):
In this pooled analysis of four large coronary bypass surgery trials, the
use of the radial artery was associated with better clinical outcomes when
compared to saphenous vein graft and right internal thoracic
artery.<br/>Copyright &#xa9; The Author(s) 2022. Published by Oxford
University Press on behalf of the European Association for Cardio-Thoracic
Surgery. All rights reserved.

<48>
Accession Number
2015377356
Title
Is this the prime time for transradial access left ventricular
endomyocardial biopsy?.
Source
Interventional Cardiology: Reviews, Research, Resources. 16 (no
pagination), 2021. Date of Publication: 2021.
Author
Tyler Z.; Guttmann O.P.; Savvatis K.; Jones D.; O'Mahony C.
Institution
(Tyler, Guttmann, Savvatis, Jones, O'Mahony) St Bartholomew's Hospital,
London, United Kingdom
(Guttmann, Savvatis, O'Mahony) UCL Centre for Heart Muscle Disease,
Institute of Cardiovascular Science, University College London, London,
United Kingdom
Publisher
Radcliffe Medical Media
Abstract
Left ventricular endomyocardial biopsy (EMB) is an essential tool in the
management of myocarditis and is conventionally performed via transfemoral
access (TFA). Transradial access EMB (TRA-EMB) is a novel alternative and
the authors sought to determine its safety and feasibility by conducting a
systematic review of the literature. Medline was searched in 2020, and
cohort demographics, procedural details and complications were extracted
from selected studies. Four observational studies with a combined total of
496 procedures were included. TRA-EMB was most frequently performed with a
sheathless MP1 guide catheter via the right radial artery. The most common
complication was pericardial effusion (up to 11% in one study), but
pericardial drainage for tamponade was rare (one reported case). Death and
mitral valve damage have not been reported. TRA-EMB was successful in
obtaining samples in 99% of reported procedures. The authors concluded
that TRA-EMB is a safe and feasible alternative to TFA-EMB and the most
common complication is uncomplicated pericardial effusion.<br/>Copyright
&#xa9; 2021 Radcliffe Group Ltd. All rights reserved.

<49>
Accession Number
2010440751
Title
Erdheim-Chester Disease With Extensive Pericardial Involvement: A Case
Report and Systematic Review.
Source
Cardiology Research. 11(2) (pp 118-128), 2020. Date of Publication: 2020.
Author
Sanchez-Nadales A.; Anampa-Guzman A.; Navarro-Motta J.
Institution
(Sanchez-Nadales, Navarro-Motta) Department of Medicine, Advocate Illinois
Masonic Medical Center, Chicago, IL, United States
(Anampa-Guzman) Sociedad Cientifica de San Fernando, Faculty of Medicine,
Universidad Na- cional Mayor de San Marcos, Lima, Peru
(Sanchez-Nadales) Alejandro Sanchez-Nadales, Department of Medicine,
Advocate Illinois Masonic Medical Center, Chicago, IL, United States
Publisher
Elmer Press
Abstract
Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis
characterized by systemic xanthogranulomatous infiltration. We described
the case of a female adult presenting with pericardial effusion.
Pericardial infiltration is the most frequent cardiac manifestation of ECD
and is the one discussed in this article. We found that the majority of
patients with pericardial infiltration needed a cardiovascular procedure.

<50>
[Use Link to view the full text]
Accession Number
2010440234
Title
Efficacy of Allopurinol in Cardiovascular Diseases: A Systematic Review
and Meta-Analysis.
Source
Cardiology Research. 11(14) (pp 226-232), 2020. Date of Publication:
August 2020.
Author
Khanal S.; Basyal B.; Munir S.; Minalyan A.; Khan R.; Alraies C.; Fischman
D.L.; Ullah W.
Institution
(Ullah, Khanal, Basyal, Munir, Minalyan) Abington Jefferson Health, United
States
(Khan) Medstar Union Memorial Hospital, Baltimore, United States
(Alraies) Detroit Medical Center, DMC Heart Hospital, United States
(Fischman) Thomas Jefferson University, Philadelphia, United States
(Ullah) Abington Jefferson Health, United States
Publisher
Elmer Press
Abstract
Background: Given current evidence, the use of allopurinol for the
prevention of major cardiovascular events (acute cardiovascular syndrome
(ACS) or cardiovascular mortality) in patients undergoing coronary artery
bypass graft (CABG), after index ACS or heart failure remains unknown.
<br/>Method(s): Multiple databases were queried to identify studies
comparing the efficacy of allopurinol in patients undergoing CABG, after
ACS or heart failure. The unadjusted odds ratio (OR) was calculated using
a random effect model. <br/>Result(s): A total of nine studies comprising
850 patients (allopurinol 480, control 370) were identified. The pooled OR
of periprocedural ACS (OR: 0.25, 95% confidence interval (CI): 0.06 -
0.96, P = 0.05) and cardiovascular mortality (OR: 0.22, 95% CI: 0.07 -
0.71, P = 0.01) was significantly lower in patients receiving allopurinol
during CABG compared to patients in the control group. The overall number
needed to treat (NNT) to prevent one ACS event was 11 (95% CI: 7 28),
while the NNT to prevent one death was 24 (95% CI: 13 - 247). By contrast,
the odds of cardiovascular mortality in the allopurinol group were not
significantly different from the control group in patients on long-term
allopurinol after ACS or heart failure (OR: 0.33, 95% CI: 0.01 - 8.21, P =
0.50) and (OR: 1.12, 95% CI: 0.39 - 3.20, P = 0.83), respectively.
Similarly, the use of allopurinol did not reduce the odds of recurrent ACS
events at 2 years (OR: 0.32, 95% CI: 0.03 - 3.18, P = 0.33).
<br/>Conclusion(s): Periprocedural use of allopurinol might be associated
with a significant reduction in the odds of ACS and cardiovascular
mortality in patients undergoing CABG. Allopurinol, however, offers no
long-term benefits in terms of secondary prevention of ACS or mortality.
Larger scale studies are needed to validate our findings.<br/>Copyright
&#xa9; The authors

<51>
Accession Number
2004744322
Title
Complete 2-Year Results Confirm Bayesian Analysis of the SURTAVI Trial.
Source
JACC: Cardiovascular Interventions. 13(3) (pp 323-331), 2020. Date of
Publication: 10 February 2020.
Author
Van Mieghem N.M.; Popma J.J.; Deeb G.M.; Yakubov S.J.; Serruys P.W.;
Windecker S.; Sondergaard L.; Gada H.; Chetcuti S.; Kleiman N.S.; Kodali
S.; George I.; Teefy P.; Kiaii B.; Oh J.K.; Kappetein A.P.; Chang Y.;
Mugglin A.S.; Reardon M.J.; Sorajja P.; Sun B.; Agarwal H.; Langdon T.;
den Heijer P.; Bentala M.; O'Hair D.; Bajwa T.; Byrne T.; Caskey M.;
Paulus B.; Garrett E.; Stoler R.; Hebeler R.; Khabbaz K.; Lim D.S.;
Bladergroen M.; Fail P.; Feinberg E.; Rinaldi M.; Skipper E.; Chawla A.;
Hockmuth D.; Makkar R.; Cheng W.; Aji J.; Bowen F.; Schreiber T.; Henry
S.; Hengstenberg C.; Bleiziffer S.; Harrison J.K.; Hughes C.; Joye J.;
Gaudiani V.; Babaliaros V.; Thourani V.; Dauerman H.; Schmoker J.;
Skelding K.; Casale A.; Kovac J.; Spyt T.; Seshiah P.; Smith J.M.; McKay
R.; Hagberg R.; Matthews R.; Starnes V.; O'Neill W.; Paone G.; Hernandez
Garcia J.M.; Such M.; Moris de la Tassa C.; Llosa Cortina J.C.; Carrel T.;
Whisenant B.; Doty J.; Resar J.; Conte J.; Aharonian V.; Pfeffer T.; Ruck
A.; Corbascio M.; Blackman D.; Kaul P.; Kliger C.; Brinster D.; Leya F.;
Bakhos M.; Sandhu G.; Pochettino A.; Piazza N.; de Varennes B.; van Boven
A.; Boonstra P.; Waksman R.; Bafi A.; Asgar A.; Cartier R.; Kipperman R.;
Brown J.; Lin L.; Rovin J.; Sharma S.; Adams D.; Katz S.; Hartman A.;
Al-Jilaihawi H.; Williams M.; Crestanello J.; Lilly S.; Ghani M.;
Bodenhamer R.M.; Rajagopal V.; Kauten J.; Mumtaz M.; Bachinsky W.;
Nickenig G.; Welz A.; Olsen P.S.; Yakubov S.; Watson D.; Chhatriwalla A.;
Allen K.; Teirstein P.; Tyner J.; Mahoney P.; Newton J.; Merhi W.; Keiser
J.; Yeung A.; Miller C.; ten Berg J.; Heijmen R.; Petrossian G.; Robinson
N.; Brecker S.; Jahangiri M.; Davis T.; Batra S.; Hermiller J.; Heimansohn
D.; Radhakrishnan S.; Fremes S.; Maini B.; Bethea B.; Brown D.; Ryan W.;
Reardon M.; Kleiman N.; Spies C.; Lau J.; Herrmann H.; Bavaria J.; Horlick
E.; Feindel C.; Neumann F.-J.; Beyersdorf F.; Binder R.; Maisano F.; Costa
M.; Markowitz A.; Tadros P.; Zorn G.; de Marchena E.; Salerno T.; Labinz
M.; Ruel M.; Sup Lee J.; Gleason T.; Ling F.; Knight P.; Robbins M.; Ball
S.; Giacomini J.; Burdon T.; Applegate R.; Kon N.; Schwartz R.; Schubach
S.; Forrest J.; Mangi A.
Institution
(Van Mieghem) Department of Interventional Cardiology, Erasmus University
Medical Centre, Rotterdam, Netherlands
(Popma) Department of Interventional Cardiology, Beth Israel Deaconess
Medical Center, Boston, MA, United States
(Deeb) Cardiac Surgery, University of Michigan, Ann Arbor, MI, United
States
(Yakubov) Interventional Cardiology, OhioHealth Riverside Methodist
Hospital, Columbus, OH, United States
(Serruys) Cardiovascular Science Division of the National Heart and Lung
Institute, Imperial College London, London, United Kingdom
(Windecker) Department of Interventional Cardiology, University Hospital
Bern, Bern, Switzerland
(Sondergaard) The Heart Center, Rigshospitalet, University of Copenhagen,
Copenhagen, Denmark
(Mumtaz) Cardiac Surgery, University of Pittsburgh Medical Center Pinnacle
Health, Harrisburg, PA, United States
(Gada) Interventional Cardiology, University of Pittsburgh Medical Center
Pinnacle Health, Harrisburg, PA, United States
(Chetcuti) Interventional Cardiology, University of Michigan, Ann Arbor,
MI, United States
(Kleiman) Cardiology, Methodist DeBakey Heart and Vascular Center,
Houston, TX, United States
(Kodali, George) Structural Heart and Valve Center, Columbia University
Medical Center, New York, NY, United States
(Teefy) Department of Medicine, Cardiology Division, London Health
Sciences Centre, University Hospital, London, Ontario, Canada
(Kiaii) Department of Cardiovascular and Thoracic Surgery, London Health
Sciences Centre, University Hospital, London, Ontario, Canada
(Oh) Echocardiography Core Laboratory, Mayo Clinic, Rochester, MN, United
States
(Kappetein) Baaken Research Center, Medical Affairs, Medtronic,
Maastricht, Netherlands
(Chang) Clinical, Medtronic, Mounds View, MN, United States
(Mugglin) Paradigm Biostatistics, Anoka, MN, United States
(Reardon) Department of Cardiothoracic Surgery, Methodist DeBakey Heart
and Vascular Center, Houston, TX, United States
Publisher
Elsevier Inc.
Abstract
Objectives: The aim of this study was to report the 2-year results of the
SURTAVI (Surgical Replacement and Transcatheter Aortic Valve Implantation)
trial and confirm the interim Bayesian analysis. <br/>Background(s):
Transcatheter aortic valve replacement (TAVR) with a self-expanding valve
was noninferior to surgery in patients with severe aortic stenosis and
intermediate operative risk using Bayesian statistical methods. Novel
Bayesian designs have been used to shorten the time to primary endpoint
analysis in randomized clinical trials, although the predictive value of
Bayesian analysis compared with frequentist approaches remains debated.
<br/>Method(s): The SURTAVI trial randomized 1,660 patients. An interim
analysis was performed 1 year after the 1,400th patient was treated to
estimate the primary 2-year endpoint of all-cause mortality or disabling
strokes for all patients. <br/>Result(s): The Kaplan-Meier rate for the
complete 2-year primary endpoint was 12.7% in the TAVR group and 12.6% in
the surgery group (0.0% difference; 95% confidence interval: -3.4% to
3.5%), compared with 12.6% with TAVR and 14.0% with surgery (-1.4%
difference; Bayesian credible interval: -5.2% to 2.3%) in the interim
Bayesian analysis. A comparison of individual clinical, hemodynamic, and
quality-of-life endpoints using Bayesian and frequentist methods found no
significant differences. <br/>Conclusion(s): The complete analysis of all
patients with aortic stenosis at intermediate risk for surgery in the
SURTAVI trial confirmed the noninferiority, with respect to the frequency
of all-cause mortality or disabling stroke, of TAVR to surgery, as
determined in the interim Bayesian analysis. Follow-up will extend out to
10 years.<br/>Copyright &#xa9; 2020 American College of Cardiology
Foundation

<52>
Accession Number
632644453
Title
Transcatheter versus surgical aortic valve replacement in renal transplant
patients: A meta-analysis.
Source
Cardiology Research. 11(5) (pp 280-285), 2020. Date of Publication: 2020.
Author
Mir T.; Darmoch F.; Ullah W.; Sattar Y.; Hakim Z.; Pacha H.M.; Fouad L.;
Gardi D.; Glazier J.J.; Zehr K.; Alraies M.C.
Institution
(Mir) Wayne State University/Detroit Medical Center, Detroit, MI, United
States
(Darmoch) Internal Medicine, Beth Israel Deaconess Medical Center/Harvard
School of Medicine, Boston, MA, United States
(Ullah) Internal Medicine, Abington Jefferson Health, 1200 Old York Road,
Abington, PA 19044, United States
(Sattar) Internal Medicine, Icahn School of Medicine, Mount Sinai Elmhurst
Hospital, New York, NY, United States
(Hakim, Gardi, Glazier, Zehr, Alraies) Cardiovascular Medicine, Detroit
Medical Center, Wayne State University, Detroit, MI, United States
(Pacha) University of Texas Health Science Center, McGovern Medical
School, Memorial Hermann Heart and Vascular Institute, Houston, TX, United
States
(Fouad) Detroit Medical Center, Heart Hospital, Detroit, MI, United States
Publisher
Elmer Press
Abstract
Background: The outcome of transcutaneous aortic valve replacement (TAVR)
in patients with kidney transplant is unknown, as majority of these
patients were excluded from the major TAVR clinical trials. We sought to
compare patients with severe aortic stenosis who underwent TAVR versus
surgical aortic valve replacement (SAVR) with a history of kidney
transplant. <br/>Method(s): PubMed, Google Scholar and Cochrane databases
were searched to identify relevant articles. The incidence of all-cause
mortality and acute kidney injury (AKI) was calculated using relative risk
on a random effect model. <br/>Result(s): A total of 1,538 patients (TAVR
328, SAVR 1,210) were included in the study. TAVR was associated with
lower mortality as compared with SAVR at 30 days from the index procedure
(odds ratio (OR) 0.48, 95% confidence interval (CI): 0.25-0.93; P = 0.03).
Oneyear mortality was studied in three studies and showed comparable
mortality in patients undergoing TAVR and SAVR (OR: 0.76, 95% CI:
0.10-5.51; P = 0.78). Compared to SAVR, TAVR carries an identical risk of
AKI (OR: 0.44, 95% CI: 0.10-1.90; P = 0.27). A sensitivity analysis
performed by exclusion of Voudris et al study showed a non-significant
difference in the mortality incidence of two groups at 30 days (OR: 0.72,
95% CI: 0.27-1.91; P = 0.51). <br/>Conclusion(s): In patients with a
history of kidney transplant, TAVR was associated with a comparable risk
of mortality and AKI compared to SAVR.<br/>Copyright &#xa9; 2020 Elmer
Press.

<53>
Accession Number
631934264
Title
Comparing transcatheter aortic valve replacement (AVR) with surgical AVR
in lower risk patients: A comprehensive meta-analysis and systematic
review.
Source
Cardiology Research. 11(3) (pp 168-178), 2020. Article Number: 1046. Date
of Publication: 01 Jun 2020.
Author
Khan M.S.; Mir T.; Ullah W.; Ali Z.; Idris O.; Khan G.; Ur Rashid M.;
Salman; Mehmood M.; Ali S.S.
Institution
(Khan, Salman) Department of Internal Medicine, Mercy St Vincent Medical
Center, Toledo, OH 43608, United States
(Mir) Department of Internal Medicine, Detroit Medical Center, Wayne State
University, Detroit, MI 48201, United States
(Ullah, Ali) Department of Internal Medicine, Abington Jefferson Health,
Abington, PA 19001, United States
(Idris, Mehmood, Ali) Department of Cardiology, Mercy Saint Vincent
Medical Center, Toledo, OH 43608, United States
(Khan) University of Missouri, Kansas City, MO 64110, United States
(Ur Rashid) Department of Internal Medicine, Advent Health, Orlando, FL
32803, United States
(Khan) Department of Internal Medicine, Mercy Saint Vincent Medical
Center, Toledo, OH 43608, United States
Publisher
Elmer Press
Abstract
Background: Transcutaneous aortic valve replacement (TAVR) is a novel
percutaneous procedure for severe aortic stenosis and has been recently
approved by Food and Drug Administration in lower risk patients. We
performed the first ever meta-analysis and literature review of clinical
trials comparing both 30-day and 1-year outcomes in lower risk patients
undergoing TAVR vs. surgical aortic valve replacement (SAVR, having
Society of Thoracic Surgeons score < 4% or equivalent). <br/>Method(s):
Using predefined selection criteria as above, 68 articles were identified.
Seven eligible articles were selected after extensive review. Primary
effect outcomes were 30-day and 1-year all-cause mortality using risk
ratio (RR) with significant P value of < 0.05. <br/>Result(s): A total of
4,859 subjects were included. Risk of 30-day all-cause mortality was 40.1%
less in TAVR group, RR 0.59 (95% confidence interval (CI): 0.38-0.92, P =
0.02) with no significant heterogeneity. Six studies except Schymik et al
also reported 1-year risk. This was, however, not statistically
significant with a 21% decrease in the TAVR group, RR 0.79 (95% CI:
0.57-1.09, P = 0.15). Six studies reported 30-day risk of secondary
outcomes. The risk of 30-day stroke was 36% less in TAVR group, although
this was not statistically significant, RR 0.64 (95% CI: 0.38-1.9, P =
0.10). The risk of acute kidney injury (AKI) stage 2 and above was 56%
less in post-TAVR patients, RR 0.43 (95% CI: 0.35-0.54, P < 0.001) with no
heterogeneity. For vascular complications, RR was high in TAVR group 4.62
(95% CI: 1.42-15.18, P = 0.01). Significant heterogeneity was demonstrated
though (I2 = 81). The risks for permanent pacemaker (PPM) were also higher
in the TAVR group, RR 3.30 (95% CI: 2.04-5.33, P < 0.001) and significant
heterogeneity was observed. After removing Thyregod et al and Partner 3
trial from the analysis, heterogeneity was removed, but the RR was still
high 3.21 (95% CI: 2.54-4.068, P < 0.001). Post-operative incidence of
endocarditis among TAVR patients was low but not statistically
significant. The 30-day risk for infective endocarditis was RR 0.67 (95%
CI: 0.13-3.48, P = 0.63). The 1-year risk was similarly low but not
significant, RR 0.73 (95% CI: 0.28-1.92, P = 0.53). <br/>Conclusion(s):
Among low risk patients, TAVR was found to be superior in short-term
all-cause mortality and 1-year stroke, a result that was statistically
significant for TAVR and close to significance for stroke. TAVR patients
were also less likely to have post-operative bleeding and AKI stage 2 and
beyond. Post-operative incidence of endocarditis among TAVR patients was
low but not statistically significant. However, the rates of PPM and
vascular complications are higher in TAVR patients. The results of TAVR in
low risk population are thus extremely encouraging. However, the issue of
long-term valve durability in this group needs further studies. Also,
caution needs to be exercised while extending the indications to extremely
young patients due to lack of enough studies.<br/>Copyright &#xa9; The
authors.

<54>
Accession Number
630337640
Title
Pre-operative sildenafil for patients with pulmonary hypertension
undergoing mitral valve surgery: A systematic review and meta-analysis.
Source
Cardiology Research. 10(6) (pp 369-377), 2019. Date of Publication: 2019.
Author
Villanueva D.L.E.; Agustin R.D.; Llanes E.J.
Institution
(Villanueva, Agustin, Llanes) Division of Cardiovascular Medicine,
University of the Philippines, Philippine General Hospital, Taft Avenue,
Manila 1000, Philippines
Publisher
Elmer Press
Abstract
Background: Pulmonary hypertension is a usual complication of
long-standing mitral valve disease. Perioperative pulmonary hypertension
is a risk factor for right ventricular failure and is an important cause
of morbidity and mortality in patients with pulmonary hypertension
undergoing mitral valve surgery. Phosphodiesterase-5 inhibitors
particularly sildenafil citrate have proven clinical benefit for pulmonary
arterial hypertension but have shown discordant results in group 2
pulmonary hypertension patients. We sought to determine the effect of
pre-operative sildenafil on the intra-operative hemodynamic parameters of
these patients. <br/>Method(s): Studies were included if they satisfied
the following criteria: 1) Randomized controlled trials; 2) Adult patients
with pulmonary hypertension scheduled for elective mitral valve surgery;
and 3) Reported data on changes in pre-, intra-, and post-operative
hemodynamic parameters. Using PUBMED, Clinical Key, Science Direct, and
Cochrane databases, a search for eligible studies was conducted from
September 1 to December 31, 2018. The quality of each study was evaluated
using the Cochrane Risk of Bias Tool. The primary outcome of interest is
on the effect of pre-operative sildenafil on the improvement of
intra-operative hemodynamic parameters such as systolic pulmonary artery
pressure (sPAP), mean pulmonary arterial pressure, mean arterial pressure,
pulmonary and systemic vascular resistances. We also investigated its
effect on the post-operative mortality, length of cardiopulmonary bypass
time, ventilation time, and inotrope support requirement. Review Manager
5.3 was utilized to perform analysis of random effects for continuous
outcomes. <br/>Result(s): We identified three studies involving 153
patients with pulmonary hypertension undergoing mitral valve surgery,
showing that among those who received pre-operative sildenafil there is a
significant decrease in intra-operative systolic pulmonary arterial
pressure (mean difference -11.19 (95% confidence interval (CI), -20.23 to
-2.15), P < 0.05) and post-operative sPAP (mean difference -13.67 (95% CI,
- 19.56 to - 7.78), P < 0.05) without significantly affecting the mean
arterial pressure (mean difference 1.94 (95% CI, -5.49 to 9.37), P <
0.05). The systemic and pulmonary vascular resistances were not affected
as well. <br/>Conclusion(s): Administration of pre-operative sildenafil to
patients with pulmonary hypertension undergoing mitral valve surgery
decreases intra-operative and post-operative systolic pulmonary arterial
pressure without significantly affecting other systemic hemodynamic
parameters.<br/>Copyright &#xa9; The authors.

<55>
Accession Number
630276908
Title
Efficacy and safety of subcutaneous fellow's stitch using "fisherman's
knot" technique to achieve large caliber (> 10 french) venous hemostasis.
Source
Cardiology Research. 10(5) (pp 303-308), 2019. Date of Publication: 01 Oct
2019.
Author
Kumar P.; Aggarwaal P.; Sinha S.K.; Pandey U.; Razi M.; Sharma A.K.;
Thakur R.; Varma C.M.; Krishna V.
Institution
(Kumar) Department of Cardiology, Rajendra Institute of Medical Science,
Ranchi, Jharkhand, India
(Aggarwaal, Sinha, Pandey, Razi, Sharma, Thakur, Varma, Krishna)
Department of Cardiology, LPS Institute of Cardiology, G.S.V.M. Medical
College, Kanpur, Uttar Pradesh 208002, India
Publisher
Elmer Press
Abstract
Background: Among patients undergoing intervention involving venous
access, various techniques have been implemented to achieve hemostasis in
order to reduce local access site complications, to decrease length of
stay and to facilitate early ambulation. We aimed to assess the efficacy
and safety of fellow's stitch using "fisherman's knot" (figure of Z (FoZ)
technique when compared with conventional manual compression for immediate
closure of large venous sheath (> 10 French (Fr). <br/>Method(s): Between
November 2012 and March 2019, 949 patients underwent various interventions
which involved venous access requiring hemostasis. All the patients were
anticoagulated with heparin during the procedure. In a sequential
allocation, fellow's stitch using "fisherman's knot" (group I: n = 384)
and conventional manual compression (group II: n = 365) were used in
achieving hemostasis at right/left femoral venous access site following
sheath removal (> 12 Fr). A 0-Vicryl suture was used to make one deep
stitch just distal to entry of sheath and one superficial stitch just
proximal to entry site, thereby creating an FoZ. A fisherman's knot was
then tied, and knot was pushed down while sheath was removed. In cases
where immediate hemostasis was not achieved, it was compressed for 2 min
to achieve it. <br/>Result(s): The mean age of 949 patients was 13.1 +/-
8.2 years where male (n = 574; 65%) outnumbered female (n = 375; 35%). In
group I, hemostasis was achieved immediately after tying the knot in 343
(89.3%) patients, while within <= 2 min of light pressure in 41 (10.7%)
patients. Five (1.3%) patients had failure of stitch as suture snapped
during knotting, and hemostasis was achieved by manual compression as per
protocol in group I. The median time to hemostasis (1.1 vs. 14.3 min, P <
0.001), ambulation (3.3 vs. 18.9 h, P < 0.01) and hospital stay (24.6 vs.
36.8 h, P < 0.001) was significantly shorter in group I compared to group
II. The minor vascular access site complications in form of hematoma (n =
6 (1.6%) vs. n = 1 (0.2%); P < 0.001), and thrombosis at femoral vein (n =
4 (1.1%) vs. n = 0 (0%); P < 0.001) were significantly higher in group II
when compared to group I. The differences regarding re-bleeding and
formation of arterio-venous fistula between both the groups were
statistically insignificant. <br/>Conclusion(s): The fellow's stitch using
"fisherman's knot" or "FoZ" suture is a simple, efficacious and safe
technique to achieve an immediate hemostasis after removal of larger
venous sheath (> 10 Fr).<br/>Copyright &#xa9; The authors.

<56>
Accession Number
2010354953
Title
Sex and transcatheter aortic valve implantation: Impact of female sex on
clinical outcomes.
Source
Interventional Cardiology: Reviews, Research, Resources. 14(3) (pp
137-141), 2019. Date of Publication: December 2019.
Author
Laricchia A.; Bellini B.; Romano V.; Khawaja S.; Montorfano M.; Chieffo A.
Institution
(Laricchia) Interventional Cardiology Unit, GVM Care and Research, Maria
Cecilia Hospital, Cotignola, Italy
(Laricchia, Bellini, Romano, Khawaja, Montorfano, Chieffo) Interventional
Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
Publisher
Radcliffe Medical Media
Abstract
Transcatheter aortic valve implantation (TAVI) has emerged as an
alternative treatment for severe symptomatic aortic stenosis in patients
who are not suitable for surgery or are at high surgical risk.
Approximately 50% of patients undergoing TAVI are female and this is
reflected by a higher inclusion rate of women in TAVI trials. However,
women undergoing TAVI have different baseline clinical characteristics in
comparison to men, with fewer comorbidities and a more preserved left
ventricular ejection fraction. This translates into favourable outcomes
after TAVI, despite a higher rate of peri-procedural complications. This
article discusses gender differences in terms of presentation, procedural
characteristics and post-procedural results in patients with aortic
stenosis undergoing TAVI, with particular focus on possible sex-specific
factors affecting outcome.<br/>Copyright &#xa9; 2019 Radcliffe Group Ltd.
All rights reserved.

<57>
Accession Number
622518976
Title
Extended duration dual antiplatelet therapy after percutaneous coronary
intervention in patients with peripheral arterial disease: A
meta-analysis.
Source
Cardiology Research. 9(3) (pp 137-143), 2018. Date of Publication: 01 Jun
2018.
Author
Ling H.; Andrews E.; Ombengi D.; Li F.
Institution
(Ling) Department of Pharmacy Practice, School of Pharmacy, Georgia
Campus- Philadelphia College of Osteopathic Medicine, Suwanee, GA, United
States
(Andrews) Department of Pharmacy Practice, School of Pharmacy, Hampton
University, Hampton, VA, United States
(Ombengi) Department of Clinical Sciences, Medical College of Wisconsin
Pharmacy School, Milwaukee, WI, United States
(Li) Jiangsu Vocational College of Medicine, Yancheng, Jiangsu, China
Publisher
Elmer Press
Abstract
Background: Patients with peripheral arterial disease (PAD) undergoing
percutaneous coronary intervention (PCI) are at elevated risk of ischemic
and bleeding events. However, the optimal duration of dual antiplatelet
therapy (DAPT) after PCI in patients with PAD remains unclear.
<br/>Method(s): A systematic literature search was performed through June
2017 using PubMed, EMBASE and Cochrane databases with the following key
terms: "dual antiplatelet therapy", "P2Y12 inhibitor", "myocardial
infarction", "percutaneous coronary intervention", "stent", "peripheral
arterial disease", and "ankle-brachial index". The analysis was restricted
to randomized trials published in English in patients with PAD receiving
extended DAPT ( > 12-month) after PCI. Overall analysis was performed
using Review Manager 5.3 with the Mantel-Haenszel method. <br/>Result(s):
Two randomized controlled trials involving 895 patients were included in
this review. Compared to the placebo group, there was no statistical
significance in the occurrence of major adverse cardiovascular and
cerebrovascular events (MACCE) in patients receiving extended DAPT (odds
ratio (OR) 0.76, 95% confidence interval (CI) 0.37 - 1.57; P = 0.46). The
results were associated with substantial heterogeneity (I² =
71%, P = 0.07). Extended DAPT was not significantly associated with
increased moderate/severe bleeding events (OR 1.63, 95% CI 0.84 - 3.18; P
= 0.15; I² = 0%, P = 0.59). The extended DAPT was associated
with 82% relative risk reduction in the events of definite/probably stent
thrombosis. <br/>Conclusion(s): Among patients with PAD, extended DAPT
after PCI resulted in a non-significant difference in ischemic and
bleeding events compared to placebo, respectively. The routine use of
extended DAPT in this cohort should be carefully evaluated.<br/>Copyright
&#xa9; The authors.

<58>
Accession Number
618987811
Title
Occurrence and impact of time delay to primary percutaneous coronary
intervention in patients with ST-segment elevation myocardial infarction.
Source
Cardiology Research. 8(5) (pp 190-198), 2017. Date of Publication: 2017.
Author
Shahin M.; Obeid S.; Hamed L.; Templin C.; Gamperli O.; Nietlispach F.;
Maiera W.; Yousif N.; Mach F.; Roffi M.; Windecker S.; Raber L.; Matter
C.M.; Luscher T.F.
Institution
(Shahin, Obeid, Templin, Gamperli, Nietlispach, Maiera, Yousif, Matter,
Luscher) Department of Cardiology, University Heart Center, Zurich,
Switzerland
(Hamed) Department of Internal Medicine, University Hospital Sohag, Egypt
(Mach, Roffi) Cardiovascular Center, Department of Cardiology, University
Hospital Geneva, Switzerland
(Windecker, Raber) Cardiovascular Center, Department of Cardiology,
University Hospital Bern, Switzerland
Publisher
Elmer Press
Abstract
Background: The aim of the study was to evaluate the occurrence, duration
and impact of time delays to primary percutaneous coronary intervention
(pPCI) in ST-segment elevation myocardial infarction (STEMI).
<br/>Method(s): A total of 357 consecutive STEMI patients enrolled in the
prospective Special Program University Medicine ACS (SPUMACS) cohort were
included. In order to identify the causes behind a possible treatment
delay, we constructed four different time points which included: 1)
symptom onset to hospital arrival, 2) hospital arrival to arrival in the
catheterization laboratory, 3) hospital arrival to first balloon
inflation, and 4) time from arrival in the catheterization laboratory to
first balloon inflation in addition to total ischemic time. Patients were
stratified according to a delay > 3 h, > 30 min, > 90 min and > 1 h,
respectively and major adverse events at 0, 30 and 365 days were analyzed.
<br/>Result(s): Resuscitated STEMI patients (23 patients) and STEMI
patients presenting at weekends (101 patients) and to lesser extent at
night hours (100 patients) experienced more time delays than stable
patients and those presenting at office hours. Median door-to-balloon time
averaged 93 min in resuscitated, but 65 min in stable patients. Median
door-to-balloon time at weekends and public holidays was 89 min, but 68
min at office hours. Median time from hospital arrival to cathlab arrival
at weekends and public holidays was 30 min, but 15 min during office
hours. Corresponding times for resuscitated patients was 45 and 15 min in
stable patients. Of note, resuscitated patients were late presenters as
regards time from symptoms onset to hospital arrival with a median time of
180 min compared to 155 min in stable patients. Median total ischemic time
was 225 min for all patients, 223 min at day hours, 239 at night hours,
244 min at weekends, 233 min at office days, 220 min in stable patients
and 273 min in resuscitated patients. Patients with STEMI who arrived > 3
h after symptom onset had a higher rate of myocardial infarction (MI) at 1
year (1.6% vs. 9% in < 3 h; P = 0.008). Furthermore, STEMI patients who
had a delay of > 1 h from cathlab arrival to first balloon inflation had a
higher rate of in hospital reinfarction at 0 day (0.6% vs. 0% in < 1 h; P
= 0.007), MI at 30 days (0.8% vs. 0% in < 1 h; P = 0.001) and MI at 1 year
(1.4% vs. 1.1% in < 1 h; P = 0.012). Similarly, in these patients, cardiac
deaths at 0 day (0.8% vs. 0.6% in < 1 h; P = 0.035) and at 30 days (0.8%
vs. 0.6% in < 1 h; P = 0.035) were higher as were major adverse
cardiovascular events (MACCE) at 0 day (1.4% vs. 0.8% in < 1 h; P =
0.004). <br/>Conclusion(s): Resuscitated STEMI patients and those
presenting at weekends and to lesser extent at night hours experienced
more time delays and longer ischemic time than stable patients and those
presenting at office hours. In STEMI patients, any delay in treatment
increased their risk of MACCE. Efforts should focus on improving patient's
awareness along with minimizing in-hospital transfer to the
catheterization laboratory especially at weekends and in resuscitated
patients.<br/>Copyright &#xa9; The authors.

<59>
Accession Number
2014160216
Title
Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve
Implantation (DapaTAVI) randomized trial.
Source
European Journal of Heart Failure. 24(3) (pp 581-588), 2022. Date of
Publication: March 2022.
Author
Amat-Santos I.J.; Sanchez-Luna J.P.; Abu-Assi E.; Cruz-Gonzalez I.;
Nombela-Franco L.; Munoz-Garci A.J.; Blas S.G.; de la Torre Hernandez
J.M.; Romaguera R.; Sanchez-Recalde A.; Diez-Gil J.L.; Lopez-Otero D.;
Gheorge L.; Ibanez B.; Iniguez-Romo A.; Raposeiras-Roubin S.; Munoz-Garcia
E.; Sanz-Sanchez J.; Pereiro-Montes D.; Gutierrez-Barri A.;
Salgado-Fernandez J.; Veiga-Fernandez G.; Ojeda S.; Tirado G.; Sanchis J.;
Baladron-Zorita C.; Cordoba-Soriano J.G.; Vilalta V.; del Amo F.N.;
Molina-Navarro E.; Peral-Disdier V.; Ruiz-Quevedo V.; Ojeda F.B.; Alonso
J.A.B.; Abellas M.; Moris C.; Diaz-Fernandez J.F.; Blanco-Mata R.;
Regueiro A.; Fernandez-Diaz J.A.; Lezcano J.S.-R.; Garcia B.;
Arzamendi-Aizpurua D.; Feltes G.; Cuellas C.; Bordes P.; Jimenez-Britez
G.D.; Sarnago-Cebada F.; Gil-Ortega M.V.; Borrero J.C.; Reyes R.M.; Alonso
Briales J.H.; Alcaide J.; Lopez-Ledesma B.; Ten Morro F.; Sanchez-Lacuesta
E.; SanMartin-Pena J.C.; Lopez-Pais J.; Calle G.; Flores-Rios X.;
Mendez-Eirin E.; Nunez M.S.; Alvarez M.P.; de Lezo J.S.; Nunez-Gil I.;
Bonanad-Lozano C.; Nunez-Villota J.; Minana-Escriva G.; Valero-Picher E.;
Gonzalez-D'Gregorio J.; Fernandez-Cisnal A.; Santos S.; Arana J.R.D.;
Barrero A.; Sanz-Patino E.; Mazuecos J.J.; Gallardo-Lopez A.;
Carrillo-Suarez X.; Grau E.F.; Fernandez-Nofrerias E.; Lozano A.P.;
Alvarez M.L.; Franco-Pelaez J.A.; Talavera S.G.; Molina-Jimenez M.;
Morcuende-Gonzalez A.; Millan-Segovia R.; Pascual-Sastre M.;
Maristany-Daudert J.; Ramallal-Martinez R.; Sanchez-Elvira G.;
Bazal-Chacon P.; Bowden G.Y.; de la Fuente Perdomo B.; Loureiro R.E.;
Gonzalez-Ferreiro R.; Melendo-Viu M.; Ocampo-Miguez J.; Cobas-Paz R.;
Queija B.C.; Rioboo-Leston L.; Cespon-Fernandez M.; Dominguez-Erquicia P.;
Ledo-Pineiro A.; Camacho-Freire S.; Astorga-Burgo J.C.; Cepas P.L.; de
Miguel J.A.D.; Gracia M.C.F.; Ferreira I.; Calago A.; Palma R.;
Asmarats-Serra L.; Lopez-Benito M.; Garcia-Fernandez A.G.;
Fernandez-Vazquez F.; de Prado A.P.; Mainar V.; Ruiz-Nodar J.M.;
Valencia-Martin J.; Pineda-Rocamora J.; Torres-Mezcua F.J.; Quiles-Granado
J.M.; Lozano-Palencia T.; Sandin-Rollan M.; Ajo-Ferrer R.; Ajo-Ferrer M.;
Gonzalez-Trevilla A.A.; Gomez-Blazquez I.T.; Garcia-Tejada J.;
Huertas-Nieto S.; Maneiro-Melon N.M.; Olazabal-Valiente A.P.; Alfonso F.
Institution
(Amat-Santos, Sanchez-Luna, Munoz-Garci, Lopez-Otero, Ibanez) CIBERCV,
Madrid, Spain
(Amat-Santos, Sanchez-Luna) Cardiology Department, Hospital Clinico
Universitario, Valladolid, Spain
(Abu-Assi, Melendo-Viu, Iniguez-Romo, Raposeiras-Roubin) Department of
Cardiology, Hospital Alvaro Cunqueiro, Vigo, Spain
(Cruz-Gonzalez) Cardiology Department, Hospital Clinico Universitario,
Salamanca, Spain
(Nombela-Franco) Cardiology Department, Hospital Clinico San Carlos,
Madrid, Spain
(Munoz-Garci) Cardiology Department, Hospital Virgen de la Victoria,
Malaga, Spain
(Blas) Cardiology Department, Hospital Clinico Universitario, Valencia,
Spain
(de la Torre Hernandez) Cardiology Department, Hospital Universitario
Marques de Valdecilla, Santander, Spain
(Romaguera) Cardiology Department, Hospital Universitario de Bellvitge,
Barcelona, Spain
(Sanchez-Recalde) Cardiology Department, Hospital Universitario Ramon y
Cajal, Madrid, Spain
(Diez-Gil) Cardiology Department, Hospital Universitario La Fe, Valencia,
Spain
(Lopez-Otero) Cardiology Department, Hospital Clinico Universitario de
Santiago de Compostela, Madrid, Spain
(Gheorge) Cardiology Department, Hospital Universitario Puerta del Mar,
Cadiz, Spain
(Ibanez) IIS-Department of Cardiology, Hospital Fundacion Jimenez Diaz,
Madrid, Spain
(Ibanez, Raposeiras-Roubin) Centro Nacional de Investigaciones
Cardiovasculares (CNIC), Madrid, Spain
Publisher
John Wiley and Sons Ltd
Abstract
Aims: Despite aortic stenosis (AS) relief, patients undergoing
transcatheter aortic valve implantation (TAVI) are at increased risk of
developing heart failure (HF) within first months of intervention.
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have been shown to
reduce the risk of HF hospitalization in individuals with diabetes
mellitus, reduced left ventricular ejection fraction and chronic kidney
disease. However, the effect of SGLT-2 inhibitors on outcomes after TAVI
is unknown. The Dapagliflozin after Transcatheter Aortic Valve
Implantation (DapaTAVI) trial is designed to assess the clinical benefit
and safety of the SGLT-2 inhibitor dapagliflozin in patients undergoing
TAVI. <br/>Method(s): DapaTAVI is an independent pragmatic, controlled,
prospective, randomized, open-label blinded endpoint, multicentre trial
conducted in Spain, evaluating the effect of dapagliflozin 10 mg/day on
the risk of death and worsening HF in patients with severe AS undergoing
TAVI. Candidate patients should have prior history of HF admission plus
>=1 of the following criteria: (i) diabetes mellitus, (ii) left
ventricular ejection fraction <=40%, or (iii) estimated glomerular
filtration rate between 25 and 75 ml/min/1.73 m². A total of
1020 patients will be randomized (1:1) to dapagliflozin vs. no
dapagliflozin. Key secondary outcomes include: (i) incidence rate of
individual components of the primary outcome; (ii) cardiovascular
mortality; (iii) the composite of HF hospitalization or cardiovascular
death; and (iv) total number of HF rehospitalizations. <br/>Conclusion(s):
DapaTAVI will determine the efficacy and safety of dapagliflozin in a
broad spectrum of frail patients after AS relief by TAVI.<br/>Copyright
&#xa9; 2021 European Society of Cardiology.

<60>
[Use Link to view the full text]
Accession Number
2018654034
Title
Coronary Revascularization for Patients with Diabetes Mellitus.
Source
Annals of Surgery. 275(6) (pp 1058-1066), 2022. Date of Publication: 01
Jun 2022.
Author
El-Andari R.; Bozso S.J.; Fialka N.M.; Kang J.J.H.; Nagendran J.
Institution
(El-Andari, Fialka) Faculty of Medicine and Dentistry, University of
Alberta, Edmonton, AB, Canada
(Bozso, Kang, Nagendran, Nagendran) Division of Cardiac Surgery,
Department of Surgery, University of Alberta, Edmonton, AB, Canada
Publisher
Lippincott Williams and Wilkins
Abstract
Objective:This systematic review and meta-Analysis aims to review the
contemporary literature comparing CABG and PCI in diabetic patients
providing an up-To-date perspective on the differences between the
interventions. <br/>Background(s):Diabetes is common and diabetic patients
are at a 2-To-4-fold increased risk of developing coronary artery disease.
Approximately 75% of diabetic patients die of cardiovascular disease.
Previous literature has identified CABG as superior to PCI for
revascularization in diabetic patients with complex coronary artery
diseas. <br/>Method(s):PubMed and Medline were systematically searched for
articles published from January 1, 2015 to April 15, 2021. This systematic
review included all retrospective, prospective, and randomized trial
studies comparing CABG and PCI in diabetic patients. 1552 abstracts were
reviewed and 25 studies were included in this review. The data was
analyzed using the RevMan 5.4 software. <br/>Result(s):Diabetic patients
undergoing CABG experienced significantly reduced rates of 5-year
mortality, major adverse cardiovascular and cerebrovascular events,
myocardial infarction, and required repeat revascularization. Patients who
underwent PCI experienced improved rates of stroke that trended toward
significance. <br/>Conclusion(s):Previous literature regarding coronary
revascularization in diabetic patients has consistently demonstrated
superior outcomes for patients undergoing CABG over PCI. The development
of 1st and 2nd generation DES have narrowed the gap between CABG and PCI,
but CABG continues to be superior. Continued investigation with large
randomized trials and retrospective studies including long term follow-up
comparing CABG and 2nd generation DES is necessary to confirm the optimal
intervention for diabetic patients.<br/>Copyright &#xa9; 2022 Lippincott
Williams and Wilkins. All rights reserved.

<61>
Accession Number
2015521647
Title
A randomized controlled comparison of three modes of ventilation during
cardiopulmonary bypass on oxygenation in pediatric patients with pulmonary
hypertension undergoing congenital heart surgeries.
Source
Egyptian Journal of Anaesthesia. 38(1) (pp 193-200), 2022. Date of
Publication: 2022.
Author
Gado A.A.; Hefnawy S.M.; Abdelrahim A.M.; Alberry M.A.W.A.A.; Madkour
M.A.E.F.
Institution
(Gado, Hefnawy, Abdelrahim, Alberry, Madkour) Anesthesia and Intensive
Care Department, Faculty of Medicine, Cairo University, Giza, Egypt
Publisher
Taylor and Francis Ltd.
Abstract
Background: Several studies have attempted to improve post bypass
oxygenation, decrease extravascular total lung water volume, utilizing
continuous positive airway pressure (CPAP) and high-frequency ventilation
(HFV) during cardiopulmonary bypass (CPB). <br/>Aim(s): To assess the
influence of various ventilation modes during CPB on direct pulmonary
artery systolic pressure and post bypass oxygenation in pediatric patients
with moderate to severe pulmonary hypertension undergoing corrective
cardiac surgeries. <br/>Method(s): Included in the study were 24 patients
aged 4 months to 6 years, suffering from moderate to severe pulmonary
hypertension, undergoing elective corrective cardiac surgeries for atrial
septal defect (ASD) or ventricular septal defect (VSD) or atrioventricular
canal defects (AVC) (ASA II and III). Group A patients (n = 8) received
high-frequency positive pressure ventilation during cardiopulmonary
bypass, Group B patients (n = 8) received continuous positive, while group
C patients (n = 8) disconnected from the ventilation (passive deflation)
(control group). <br/>Result(s): There was no statistically significant
difference regarding the pulmonary artery systolic pressure (PASP) and
pulmonary artery systolic pressure to systemic systolic blood pressure
(PASP/SSBP Ratio) at t1, t2, and t3 between the three groups.
<br/>Conclusion(s): After cadiopulmonary bypass, no significant changes in
pulmonary artery pressure was observed in pediatric patients, regardless
of the ventilation mode utilized during cardiopulmonary bypass.
Conversely, the pulmonary outcomes; delivered Oxygen (DA-aO2), arterial
oxygen tension (paO2) and paO2/FiO2 (p/f ratio) and lung ultrasound (LUS)
were significantly improved when comparing continuous positive airway
pressure (CPAP) with high frequency positive pressure ventilation (HFPPV)
and passive deflation during cardiopulmonary bypass.<br/>Copyright &#xa9;
2022 The Author(s). Published by Informa UK Limited, trading as Taylor &
Francis Group.

<62>
Accession Number
2015481451
Title
Effects of rhomboid intercostal plane block for postoperative analgesia
after thoracoscopic surgery compared with local anesthetic infiltration: A
randomized clinical trial.
Source
Egyptian Journal of Anaesthesia. 38(1) (pp 179-184), 2022. Date of
Publication: 2022.
Author
Toulan H.F.; Abdelrazik R.A.
Institution
(Toulan, Abdelrazik) Department of Anesthesiology, Intensive Care, and
Pain Management, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Publisher
Taylor and Francis Ltd.
Abstract
Background: The efficacy of pain control is a crucial element of improved
recovery following thoracic surgery. Inadequate analgesia may extend the
interval of hospitalization, besides raising medical costs. Fascial plane
blocks are quickly becoming a feasible as well as a safe alternative to
epidural analgesia for abdominal and thoracic pain. Rhomboid intercostal
block (RIB) is a novel, simple block utilized in a region that is
described as a triangle of auscultation on the scapula's medial edge. This
study attempted to determine the impact of RIB on postoperative pain
following thoracoscopic surgery compared to local anesthetic (LA)
infiltration. <br/>Method(s): The current research is a randomized,
controlled trial on 60 subjects undergoing video-assisted thoracic
surgery. Participants were randomly divided into two groups. All subjects
received standard general anesthesia protocol, which included the
insertion of a double-lumen endotracheal tube as well as mechanical
ventilation. At the end of the operation in the RIB group, an injection of
20 ml bupivacaine (0.25%) was administered below the rhomboid major muscle
guided by ultrasound. In the LA group, patients received local wound
infiltration. Visual analog scores for pain during coughing and at rest,
total postoperative analgesic consumption, adverse effects, and hospital
stay were recorded. <br/>Result(s): The study group demonstrated
diminished visual analog scores during coughing as well as at rest with
less overall consumption of analgesia compared to the local infiltration
group. <br/>Conclusion(s): Our study showed that ultrasound guided RIB
provides better pain relief and less postoperative opioid consumption
after thoracoscopic surgeries compared to local anesthetic
infiltration.<br/>Copyright &#xa9; 2022 The Author(s). Published by
Informa UK Limited, trading as Taylor & Francis Group.

<63>
Accession Number
2010476930
Title
Anti-M antibody and ABO blood grouping discrepancy: a report of three
cases with review of literature.
Source
Hematology, Transfusion and Cell Therapy. 44(2) (pp 288-290), 2022. Date
of Publication: 01 Apr 2022.
Author
Ferdowsi S.; Mohammadi S.; Ahmadnezhad M.; Herfat F.; Rezvani A.; Eshghi
P.; Oodi A.
Institution
(Ferdowsi, Mohammadi, Ahmadnezhad, Herfat, Rezvani, Eshghi, Oodi) Blood
Transfusion Research Center, High Institute for Research and Education in
Transfusion Medicine, Tehran, Iran, Islamic Republic of
(Mohammadi) Hematology, Oncology and Stem Cell Transplantation, Research
Center, Tehran University of Medical Sciences, Tehran, Iran, Islamic
Republic of
Publisher
Elsevier Editora Ltda

<64>
Accession Number
637704237
Title
Optic nerve ultrasound and cardiopulmonary bypass: A pilot study.
Source
Saudi Journal of Anaesthesia. 16(2) (pp 188-193), 2022. Date of
Publication: April-June 2022.
Author
Wakimoto M.; Patrick J.; Yamaguchi Y.; Roth C.; Corridore M.; Tobias J.
Institution
(Wakimoto) Department of Anesthesiology, Osaka Police Hospital, Osaka,
Japan
(Patrick) Heritage College of Osteopathic Medicine, Athens Campus, Athens,
OH, United States
(Patrick) Ohio University, Athens, Greece
(Yamaguchi) Division of Critical Care, Yokohama City University Medical
Center, Yokohama, Japan
(Roth, Corridore, Tobias) Department of Anesthesiology and Pain Medicine,
Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205,
United States
(Corridore, Tobias) Department of Anesthesiology and Pain Medicine, Ohio
State University, Columbus, OH, United States
Publisher
Wolters Kluwer Medknow Publications
Abstract
Introduction: Despite advances in surgical, anesthetic, perfusion, and
postoperative care, adverse neurological consequences may occur following
cardiac surgery and cardiopulmonary bypass (CPB). Consequences of the
physiologic effects of CPB may alter the blood-brain barrier,
autoregulation, and intracranial pressure (ICP) in the immediate
postoperative period. <br/>Method(s): We evaluated the effects of cardiac
surgery and CPB on the central nervous system by measuring the optic nerve
sheath diameter (ONSD) by using ultrasound as a surrogate marker of ICP.
ONSD was measured after anesthetic induction and endotracheal intubation
(time 1), after separation from CPB (time 2), and at the completion of the
surgical procedure prior to leaving the OR (time 3). <br/>Result(s): The
study cohort included 14 patients, ranging in age from newborn to 6 years.
When comparing the Fontan group (n = 5) to the non-Fontan group (n = 9),
four elevated ONSD observations were recorded for the Fontan patients
during the study period, including one at time 1, one at time 2, and two
at time 3. In Fontan versus non-Fontan patients, ONSD was greater at all
three time points compared to non-Fontan. The change in the ONSD from time
1 to time 2 was greater (+0.2 mm vs. -0.1 mm), and the mean value at time
2 was significantly higher (4.2 vs. 3.5 mm, P = 0.048).
<br/>Conclusion(s): Patients with Fontan physiology may be more prone to
higher levels of baseline intracranial pressure due to elevated systemic
venous pressure and decreased cardiac output. Alternatively, the
chronically high central venous pressures may artificially elevate ONSD
without clinical changes in ICP, necessitating the development of separate
normative values based on the type of congenital heart
disease.<br/>Copyright &#xa9; 2022 Saudi Journal of Anesthesia.

<65>
[Use Link to view the full text]
Accession Number
2017549711
Title
Early Experience with the HeartMate Percutaneous Heart Pump from the
SHIELD II Trial.
Source
ASAIO Journal. 68(4) (pp 492-497), 2022. Date of Publication: 01 Apr 2022.
Author
Kapur N.K.; Jorde U.P.; Sharma S.; Pyo R.T.; Rajagopal V.; Lotun K.;
Kimmelstiel C.; Kuo H.-C.; Zhang Z.; Ying S.-W.; West N.E.J.; Kandzari
D.E.
Institution
(Kapur, Kimmelstiel) Tufts Medical Center, Cardiology Department, 800
Washington Street, Box no. 80, Boston, MA 02111, United States
(Jorde, Pyo) Montefiore Medical Center, Cardiology Department, Bronx, NY,
United States
(Rajagopal, Kandzari) Piedmont Heart Institute, Cardiology Department,
Atlanta, GA, United States
(Sharma) Mount Sinai Hospital, Cardiology Department, New York, NY, United
States
(Lotun) Cardiology Department, University of Arizona, Tucson, AZ, United
States
(Kuo, Zhang, Ying, West) Abbott Vascular, Santa Clara, CA, United States
Publisher
Lippincott Williams and Wilkins
Abstract
The HeartMate Percutaneous Heart Pump (PHP) is a novel circulatory support
catheter delivering a self-expanding 24 French impeller across the aortic
valve. The SHIELD II trial compares outcomes among heart failure patients
undergoing high-risk percutaneous coronary intervention (HR-PCI) with the
PHP versus Impella systems. The trial was halted in 2017 due to device
malfunctions. We aimed to describe procedural, hemodynamic, and clinical
outcomes among HR-PCI patients treated with PHP as part of the SHIELD II
trial roll-in phase. Procedural, hemodynamic, and 90 day outcomes were
assessed among patients undergoing HR-PCI with a left ventricular ejection
fraction <=35% and last patent coronary conduit, unprotected left main
disease, or significant three vessel disease. The primary endpoint was the
90 day composite of cardiovascular death, myocardial infarction, stroke,
repeat revascularization, major bleeding, new/worsening aortic
regurgitation, and severe hypotension. Among 75 roll-in phase patients,
PHP support duration was 101 +/- 53 minutes with 2.5 +/- 1.4 coronary
lesions treated per patient. Compared with predevice values, the PHP
system increased cardiac power and mean arterial pressure. Maximum
recorded device flows were 0.4-6.2 L/minute with 26% (n = 19/73) and 9.6%
(n = 7/73) of patients achieving peak flows above 3.5 or 5.0 L/minute,
respectively. Five PHP device malfunction events (6.7%) were observed. At
90 days, the composite endpoint occurred in 24.3% (18/74) of patients.
Early PHP experience demonstrated successful device performance in the
majority of enrolled patients; however, unexpected malfunctions led to
device revision. Completion of the SHIELD II trial will be required to
confirm the safety and efficacy of this iteration of the PHP system in
HR-PCI.<br/>Copyright &#xa9; ASAIO 2021.

<66>
Accession Number
2016536197
Title
A Systematic Review of Ebstein's Anomaly with Left Ventricular
Noncompaction.
Source
Journal of Cardiovascular Development and Disease. 9(4) (no pagination),
2022. Article Number: 115. Date of Publication: April 2022.
Author
Thareja S.K.; Frommelt M.A.; Lincoln J.; Lough J.W.; Mitchell M.E.;
Tomita-Mitchell A.
Institution
(Thareja, Lough) Department of Cell Biology, Neurobiology, and Anatomy,
Medical College of Wisconsin, Milwaukee, WI 53226, United States
(Thareja, Mitchell, Tomita-Mitchell) Department of Surgery, Division of
Congenital Heart Surgery, Medical College of Wisconsin, Milwaukee, WI
53226, United States
(Frommelt, Lincoln, Mitchell, Tomita-Mitchell) Department of Pediatrics,
Division of Pediatric Cardiology, Children's Wisconsin, Milwaukee, WI
53226, United States
(Frommelt, Lincoln, Mitchell, Tomita-Mitchell) Herma Heart Institute,
Children's Wisconsin, Milwaukee, WI 53226, United States
Publisher
MDPI
Abstract
Traditional definitions of Ebstein's anomaly (EA) and left ventricular
noncompaction (LVNC), two rare congenital heart defects (CHDs), confine
disease to either the right or left heart, respectively. Around 15-29% of
patients with EA, which has a prevalence of 1 in 20,000 live births,
commonly manifest with LVNC. While individual EA or LVNC literature is
extensive, relatively little discussion is devoted to the joint appearance
of EA and LVNC (EA/LVNC), which poses a higher risk of poor clinical
outcomes. We queried PubMed, Medline, and Web of Science for all
peer-reviewed publications from inception to February 2022 that discuss
EA/LVNC and found 58 unique articles written in English. Here, we
summarize and extrapolate commonalities in clinical and genetic
understanding of EA/LVNC to date. We additionally postulate involvement of
shared developmental pathways that may lead to this combined disease.
Anatomical variation in EA/LVNC encompasses characteristics of both CHDs,
including tricuspid valve displacement, right heart dilatation, and left
ventricular trabeculation, and dictates clinical presentation in both age
and severity. Disease treatment is non-specific, ranging from symptomatic
management to invasive surgery. Apart from a few variant associations,
mainly in sarcomeric genes MYH7 and TPM1, the genetic etiology and
pathogenesis of EA/LVNC remain largely unknown.<br/>Copyright &#xa9; 2022
by the authors. Licensee MDPI, Basel, Switzerland.

<67>
Accession Number
2018012594
Title
Effect of Xuebijing injection on myocardium during cardiopulmonary bypass:
A prospective, randomized, double blind trial.
Source
World Journal of Clinical Cases. 10(13) (pp 4110-4118), 2022. Date of
Publication: 06 May 2022.
Author
Jin Z.-H.; Zhao X.-Q.; Sun H.-B.; Zhu J.-L.; Gao W.
Institution
(Jin, Zhao, Sun, Zhu, Gao) Department of Anesthesiology, The 2nd
Affiliated Hospital of Harbin Medical University, Heilongjiang, Harbin
150001, China
Publisher
Baishideng Publishing Group Inc
Abstract
BACKGROUND Cardiopulmonary bypass (CPB) is an essential procedure for
maintaining the blood supply to vital organs in patients undergoing
cardiac surgery. However, perioperative cardiac injury related to CPB
remains a severe complication in these patients. Cardiac protection is
important for patients undergoing CPB. AIM To evaluate the potential
cardioprotective efficacy of the Chinese medicine preparation Xuebijing
injection (XBJ) in patients undergoing CPB. METHODS Sixty patients
undergoing cardiac surgery with CPB were randomly allocated to the XBJ and
control groups (saline). XBJ was administered intravenously three times:
12 h prior to surgery, at the beginning of the surgery, and 12 h after the
second injection. Cardiac function was evaluated by echocardiography 48 h
after surgery. Circulating inflammation and oxidative-stress-related
markers were measured. Clinical outcomes related to intensive care unit
(ICU) stay were recorded. RESULTS Compared to control treatment, XBJ was
associated with improved PaO<inf>2</inf>/FiO<inf>2</inf> and cardiac
systolic function, but reduced troponin I and creatine kinase fraction
after surgery (all P < 0.05). The circulating concentrations of tumor
necrosis factor-alpha, interleukin (IL)-1beta and IL-8 in the XBJ group
were significantly lower than those in the control group (all P < 0.05),
whereas the circulating concentration of IL-10 was significantly higher in
the XBJ group (P < 0.05). In addition, the lengths of ICU stay and
hospitalization after surgery tended to be shorter in the XBJ group than
in the control group, although the differences were not significant.
CONCLUSION Perioperative administration of XBJ was associated with
attenuated cardiac injury during CPB, likely via anti-inflammatory and
antioxidative mechanisms<br/>Copyright &#xa9; The Author(s) 2022.
Published by Baishideng Publishing Group Inc. All rights reserved

<68>
Accession Number
2017681278
Title
Temporal Trends in Self-Expandable Transcatheter Aortic Valve Replacement
in South America: A Systematic Review and Meta-Analysis.
Source
Value in Health Regional Issues. 30 (pp 148-160), 2022. Date of
Publication: July 2022.
Author
Boissonnet C.P.; Wisner J.N.; Giorgi M.A.; Carosella L.; Brescacin
Castillejo C.; Pissinis J.; Guetta J.N.
Institution
(Boissonnet, Giorgi, Guetta) Health Economics and Technology Assessment
Unit, Instituto Universitario CEMIC, Buenos Aires, Argentina
(Boissonnet, Giorgi, Guetta) Centro de Educacion Medica e Investigaciones
Clinicas "Norberto Quirno" CEMIC, Buenos Aires, Argentina
(Boissonnet, Giorgi, Carosella, Guetta) Cardiology Section, Department of
Internal Medicine, Centro de Educacion Medica e Investigaciones Clinicas
"Norberto Quirno" CEMIC, Buenos Aires, Argentina
(Wisner) Invasive Cardiology Section, Centro de Educacion Medica e
Investigaciones Clinicas "Norberto Quirno" CEMIC, Buenos Aires, Argentina
(Giorgi) Department of Pharmacology, Instituto Universitario CEMIC, Buenos
Aires, Argentina
(Brescacin Castillejo, Pissinis) Department of Internal Medicine, Centro
de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" CEMIC,
Buenos Aires, Argentina
Publisher
Elsevier Inc.
Abstract
Objectives: This study aimed to estimate temporal trends in clinical
presentation and short-term outcomes of transcatheter aortic valve
replacement (TAVR) with self-expandable prostheses in South America
through a systematic review and meta-analysis of observational data.
<br/>Method(s): We comprehensively searched for articles published in
peer-reviewed medical journals and for abstracts presented in medical
conferences of the region from September 1, 2008, to June 29, 2020. We
included single-center studies on self-expandable TAVR populations with >=
10 patients from South America. <br/>Result(s): A total of 28 cohorts from
6 countries pooling 1780 patients were included in a random-effects
meta-analysis. Pooled estimates of age changed during time (period
2011-2015, 81.6 years; 95% confidence interval [CI] 80.7-82.4; period
2016-2018, 80.6 years; 95% CI 79.8-81.3; period 2019: 78.5 years; 95% CI
77.0-80.0; P = .0003); no other temporal trends in patient characteristics
were ascertained. Temporal trends in short-term mortality pooled estimates
were in-hospital mortality (11.8% [95% CI 8.2-16.7] for the period
2011-2015, 6.6% [95% CI 4.5-9.6] for the period 2016-2018, and 4.4% [95%
CI 1.9-9.8] for the period 2019 [P = .007]) and 30-day mortality (12.8%
[95% CI 7.7-20.4], 9.7% [95% CI 7.0-13.3], and 5.7% [95% CI 2.8-11.3],
respectively [P =.044]). These associations between reporting year of the
study and lower mortality remained after adjusting by age and surgical
risk (multivariate meta-regression). <br/>Conclusion(s): In studies
reported between 2011 and 2019 in South America, we demonstrated a clear
time trend toward reduction of short-term mortality after self-expandable
TAVR, independently of age and surgical risk of populations. These
findings are relevant to the local reassessment of cost-effectiveness of
TAVR.<br/>Copyright &#xa9; 2022 International Society for Health Economics
and Outcomes Research

<69>
Accession Number
2017122012
Title
Perioperative Presentations of Kounis Syndrome: A Systematic Literature
Review.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 36(7) (pp 2070-2076),
2022. Date of Publication: July 2022.
Author
Dai B.; Cavaye J.; Judd M.; Beuth J.; Iswariah H.; Gurunathan U.
Institution
(Dai, Cavaye, Judd, Beuth, Iswariah, Gurunathan) Faculty of Medicine,
University of Queensland, Brisbane, Australia
(Judd) Royal Brisbane and Women's Hospital, Brisbane, Australia
(Beuth, Gurunathan) Department of Anaesthesia, The Prince Charles
Hospital, Brisbane, Australia
(Iswariah) Department of Surgery, The Prince Charles Hospital, Brisbane,
Australia
Publisher
W.B. Saunders
Abstract
Kounis syndrome commonly is described as a complex multisystem phenomenon
mainly affecting coronary arteries, resulting in coronary vasospasm in the
context of an allergic manifestation. This article reviews the literature
regarding perioperative presentations of the syndrome. A systematic search
in MEDLINE and Embase databases was performed for case reports through
June 16, 2021, on Kounis syndrome triggered by medications administered in
the perioperative setting. The authors' search resulted in 35
perioperative reports of Kounis syndrome, with the majority of the cases
occurring in men between 40 and 80 years of age, manifesting within 20
minutes following the administration of the suspected trigger. Chest pain
and ischemic changes on the electrocardiograph were the most frequent
presentations, while intravenous antibiotics and neuromuscular blocking
agents were the most common triggers. In most instances, the patients had
a good recovery following the event. Coronary vasospasm is often less
frequently recognized as a form of allergic manifestation in the
perioperative setting. Many potential triggers, such as antibiotics and
neuromuscular blocking agents, are routinely administered during surgery.
Awareness of this condition, early diagnosis, and effective management of
this condition can lead to good outcomes.<br/>Copyright &#xa9; 2022
Elsevier Inc.

<70>
Accession Number
2014514097
Title
One-year hemodynamic performance of three cardiac aortic bioprostheses: A
randomized comparative clinical trial.
Source
Journal of Clinical Medicine. 10(22) (no pagination), 2021. Article
Number: 5340. Date of Publication: November-2 2021.
Author
Montero-cruces L.; Carnero-alcazar M.; Reguillo-lacruz F.J.;
Cobiella-carnicer F.J.; Perez-camargo D.; Campelos-fernandez P.;
Maroto-castellanos L.C.
Institution
(Montero-cruces, Carnero-alcazar, Reguillo-lacruz, Cobiella-carnicer,
Perez-camargo, Campelos-fernandez, Maroto-castellanos) Department of
Cardiac Surgery, Cardiovascular Institute, Hospital Clinico San Carlos,
Madrid 28940, Spain
Publisher
MDPI
Abstract
Background: We aimed to compare 1 year the hemodynamic in-vivo performance
of three biological aortic prostheses (Carpentier Perimount Magna EaseTM,
Crown PRTTM, and TrifectaTM). <br/>Method(s): The sample used in this
study comes from the "BEST-VALVE" clinical trial, which is a phase IV
single-blinded randomized clinical trial with the three above-mentioned
prostheses. <br/>Result(s): 154 patients were included. Carpentier
Perimount Magna EaseTM (n = 48, 31.2%), Crown PRTTM (n = 51, 32.1%) and
TrifectaTM (n = 55, 35.7%). One year after the surgery, the mean aortic
gradient and the peak aortic velocity was 17.5 (IQR 11.3-26) and 227.1
(IQR 202.0-268.8) for Carpentier Perimount Magna EaseTM, 21.4 (IQR
14.5-26.7) and 237.8 (IQR 195.9-261.9) for Crown PRTTM, and 13 (IQR
9.6-17.8) and 209.7 (IQR 176.5-241.4) for TrifectaTM, respectively.
Pairwise comparisons demonstrated improved mean gradients and maximum
velocity of TrifectaTM as compared to Crown PRTTM. Among patients with
nominal prosthesis sizes <=21, the mean and peak aortic gradient was
higher for Crown PRTTM compared with TrifectaTM, and in patients with an
aortic annulus measured with metric Hegar dilators less than or equal to
22 mm. <br/>Conclusion(s): One year after surgery, the three prostheses
presented a different hemodynamic performance, being TrifectaTM superior
to Crown PRTTM.<br/>Copyright &#xa9; 2021 by the authors. Licensee MDPI,
Basel, Switzerland.

<71>
[Use Link to view the full text]
Accession Number
635311249
Title
Cardiac Resynchronization Therapy with or Without Defibrillation in
Patients with Nonischemic Cardiomyopathy: A Systematic Review and
Meta-Analysis.
Source
Circulation: Arrhythmia and Electrophysiology. 14(6) (pp E008991), 2021.
Date of Publication: 01 Jun 2021.
Author
Patel D.; Kumar A.; Black-Maier E.; Morgan R.L.; Trulock K.; Wilner B.;
Nemer D.; Donnellan E.; Tarakji K.G.; Cantillon D.J.; Varma N.; Saba S.F.;
Al-Khatib S.M.; Wilkoff B.L.; Rickard J.W.
Institution
(Patel, Kumar, Trulock, Wilner, Nemer, Donnellan, Tarakji, Cantillon,
Varma, Wilkoff, Rickard) Heart and Vascular Institute Cleveland Clinic,
OH, United States
(Black-Maier, Al-Khatib) Duke Clinical Research Institute, Duke University
Medical System, Durham, NC, United States
(Morgan) Department of Health Research Methods, Evidence and Impact,
McMaster University, Hamilton, ON, Canada
(Saba) Heart and Vascular Institute, Department of Medicine, University of
Pittsburgh Medical Center, PA, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Background: Cardiac resynchronization therapy (CRT) represents a major
medical advance in patients with heart failure with electrical
dyssynchrony to improve symptoms, reduce hospitalization, and increase
survival both in the presence and absence of implantable
cardioverter-defibrillator therapy. However, among CRT-eligible patients
with nonischemic cardiomyopathy (NICM), the benefit of defibrillator
therapy in addition to CRT remains unclear. A systematic review and
meta-Analysis comparing outcomes of patients with NICM and heart failure
who underwent CRT with implantable cardioverter-defibrillator (CRT-D)
versus CRT-pacemaker only (CRT-P) was, therefore, performed.
<br/>Method(s): A literature search from inception through February 2020
was conducted in PubMed and Cochrane Review Databases for all studies
reporting outcomes of CRT-D versus CRT-P in CRT-eligible patients with
NICM. Studies reporting nonstratified outcomes, including patients with
ischemic cardiomyopathy, were excluded. The primary end point of interest
was all-cause mortality. A random-effects model using hazards ratio (HR)
was used to calculate a cumulative HR for all-cause mortality. The Grading
of Recommendations Assessment, Development, and Evaluation approach
assessed the certainty of evidence across outcomes. <br/>Result(s): Of a
total of 1478 potential citations, the search yielded 8 citations that met
inclusion and exclusion criteria. There was one randomized controlled
trial which included a subgroup of 645 CRT-eligible patients with NICM
(322 with CRT-D and 323 with CRT-P). Seven observational studies
representing 9944 CRT-eligible patients with NICM (6865 CRT-D implantation
and 3079 with CRT-P) were included in a pooled meta-Analysis. The
cumulative adjusted HR for all-cause mortality for CRT-D versus CRT-P was
0.92 (95% CI, 0.83-1.03); I²=0 though with low certainty of
evidence. There may be little difference in infection and cardiac
mortality between CRT-D versus CRT-P devices (HR, 0.82 [95% CI, 0.29-2.20]
moderate certainty of evidence and HR, 0.68 [95% CI, 0.37-1.25], low
certainty of evidence, respectively). <br/>Conclusion(s): In this
meta-Analysis, the addition of defibrillator therapy was not significantly
associated with a reduction in all-cause mortality in CRT-eligible
patients with NICM.<br/>Copyright &#xa9; 2021 Lippincott Williams and
Wilkins. All rights reserved.

<72>
[Use Link to view the full text]
Accession Number
634815058
Title
Bariatric Surgery and Cardiovascular Outcomes in Patients with Obesity and
Cardiovascular Disease: A Population-Based Retrospective Cohort Study.
Source
Circulation. 143(15) (pp 1468-1480), 2021. Date of Publication: 13 Apr
2021.
Author
Doumouras A.G.; Wong J.A.; Paterson J.M.; Lee Y.; Sivapathasundaram B.;
Tarride J.-E.; Thabane L.; Hong D.; Yusuf S.; Anvari M.
Institution
(Doumouras, Lee, Hong, Anvari) Division of General Surgery, McMaster
University, Hamilton, ON, Canada
(Wong, Yusuf) Department of Medicine, McMaster University, Hamilton, ON,
Canada
(Paterson) Department of Family Medicine, McMaster University, Hamilton,
ON, Canada
(Tarride, Thabane) Department of Health Research Methods, Evidence, and
Impact, Faculty of Health Sciences, McMaster University, Hamilton, ON,
Canada
(Tarride) Center for Health Economics and Policy Analysis, McMaster
University, Hamilton, ON, Canada
(Doumouras, Paterson, Sivapathasundaram, Hong, Anvari) ICES, Toronto, ON,
Canada
(Wong, Thabane, Yusuf) Population Health Research Institute, Hamilton
Health Sciences and McMaster University, ON, Canada
(Paterson) Institute of Health Policy, Management, and Evaluation,
University of Toronto, ON, Canada
(Tarride) Programs for Assessment of Technology in Health, The Research
Institute of St Joe's Hamilton, St Joseph's Healthcare, Hamilton, ON,
Canada
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: Bariatric surgery has been shown to significantly reduce
cardiovascular risk factors. However, whether surgery can reduce major
adverse cardiovascular events (MACE), especially in patients with
established cardiovascular disease, remains poorly understood. The present
study aims to determine the association between bariatric surgery and MACE
among patients with cardiovascular disease and severe obesity.
<br/>METHOD(S): This was a propensity score-matched cohort study using
province-wide multiple-linked administrative databases in Ontario, Canada.
Patients with previous ischemic heart disease or heart failure who
received bariatric surgery were matched on age, sex, heart failure
history, and a propensity score to similar controls from a primary care
medical record database in a 1:1 ratio. The primary outcome was the
incidence of extended MACE (first occurrence of all-cause mortality,
myocardial infarction, coronary revascularization, cerebrovascular events,
and heart failure hospitalization). Secondary outcome included 3-component
MACE (myocardial infarction, ischemic stroke, and all-cause mortality).
Outcomes were evaluated through a combination of matching via propensity
score and subsequent multivariable adjustment. <br/>RESULT(S): A total of
2638 patients (n=1319 in each group) were included, with a median
follow-up time of 4.6 years. The primary outcome occurred in 11.5%
(151/1319) of the surgery group and 19.6% (259/1319) of the controls
(adjusted hazard ratio [HR], 0.58 [95% CI, 0.48-0.71]; P<0.001). The
association was notable for those with heart failure (HR, 0.44 [95% CI,
0.31-0.62]; P<0.001; absolute risk difference, 19.3% [95% CI,
12.0%-26.7%]) and in those with ischemic heart disease (HR, 0.60 [95% CI,
0.48-0.74]; P<0.001; absolute risk difference, 7.5% [95% CI, 4.7%-10.5%]).
Surgery was also associated with a lower incidence of the secondary
outcome (HR, 0.66 [95% CI, 0.52-0.84]; P=0.001) and cardiovascular
mortality (HR, 0.35 [95% CI, 0.15-0.80]; P=0.001). <br/>CONCLUSION(S):
Bariatric surgery was associated with a lower incidence of MACE in
patients with cardiovascular disease and obesity. These findings require
confirmation by a large-scale randomized trial.<br/>Copyright &#xa9; 2021
American Heart Association, Inc.

<73>
Accession Number
637634737
Title
Hybrid revascularization vs. coronary bypass for coronary artery disease:
a systematic review and meta-analysis.
Source
The Journal of cardiovascular surgery. 63(3) (pp 353-368), 2022. Date of
Publication: 01 Jun 2022.
Author
Hinojosa-Gonzalez D.E.; Bueno-Gutierrez L.C.; Salan-Gomez M.;
Tellez-Garcia E.; Ramirez-Mulhern I.; Sepulveda-Gonzalez D.; Ramonfaur D.;
Roblesgil-Medrano A.; Flores-Villalba E.
Institution
(Hinojosa-Gonzalez, Bueno-Gutierrez, Salan-Gomez, Tellez-Garcia,
Ramirez-Mulhern, Sepulveda-Gonzalez, Roblesgil-Medrano) School of Medicine
and Health Sciences TecSalud ITESM, Monterrey, Mexico
(Ramonfaur) Harvard Medical School, MA, Boston, United States
(Flores-Villalba) School of Medicine and Health Sciences TecSalud ITESM,
Monterrey, Mexico
(Flores-Villalba) School of Engineering and Sciences TecSalud ITESM,
Monterrey, Mexico
(Flores-Villalba) Laboratorio Nacional de Manufactura Aditiva y Digital
(MADIT), Apodaca, Monterrey, Mexico
Publisher
NLM (Medline)
Abstract
INTRODUCTION: Coronary artery bypass graft is the mainstay of treatment
for multivessel coronary artery disease and is superior to percutaneous
coronary intervention. Combined approaches such as hybrid coronary
revascularization integrate coronary artery bypass grafting with
percutaneous coronary intervention during the same procedure or weeks
apart. These attempt to improve surgical morbidity and long-term outcomes.
EVIDENCE ACQUISITION: Per PRISMA criteria, a systematic review of keywords
"Hybrid Revascularization," "Hybrid Coronary Revascularization,"
"Surgical," "Surgery," "Treatment," "CABG," "HCR" and "PCI" was conducted
in PubMed, EMBASE and SCOPUS. Studies comparing this technique's
performance on either single or two-stage approach against traditional
multiple vessel coronary artery bypass grafting were screened and analyzed
for our review. EVIDENCE SYNTHESIS: Twenty-two studies totaling 6981
participants were ultimately included for analysis. Mean differences in
operative time, bleeding, ventilator time and length of stay were
significantly lower in the hybrid coronary revascularization group. Odds
ratios in transfusions and in-hospital myocardial infarction were also
lower in the hybrid coronary revascularization group. Results for
in-hospital and all-cause mortality, major adverse cardiac events (MACE),
stroke, reintervention, and complete revascularization were not
significantly different. <br/>CONCLUSION(S): Our analysis shows hybrid
coronary revascularization is a feasible alternative to traditional
coronary artery bypass grafting. Short-and long-term outcomes including
mortality, MACE, and postoperative morbidity are similar between both
groups, while hybrid approaches are associated with decreased
perioperative morbidity.

<74>
Accession Number
2015929588
Title
The effects of vitamin D supplementation on postoperative atrial
fibrillation after coronary artery bypass grafting in patients with
vitamin D deficiency.
Source
Journal of Cardiac Surgery. 37(7) (pp 2219-2224), 2022. Date of
Publication: July 2022.
Author
Talasaz A.H.; Salehiomran A.; Heidary Z.; Gholami K.; Aryannejad H.;
Jalali A.; Daei M.
Institution
(Talasaz, Salehiomran, Aryannejad, Jalali) Tehran Heart Center, Tehran
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Heidary) Department of Clinical Pharmacy, Faculty of Pharmacy, Mashhad
University of Medical Sciences, Mashhad, Iran, Islamic Republic of
(Gholami) Department of Clinical Pharmacy, School of Pharmacy, Tehran
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Daei) Department of Clinical Pharmacy, Faculty of Pharmacy, Alborz
University of Medical Sciences, Alborz, Iran, Islamic Republic of
Publisher
John Wiley and Sons Inc
Abstract
Introduction: Postoperative atrial fibrillation (POAF) as a common
complication of coronary artery bypass grafting (CABG) surgery is
associated with increased mortality and morbidity rates. Vitamin D
deficiency increases the prevalence of POAF; however, the effects of
vitamin D supplementation on the incidence of POAF have not yet been
completely elucidated. <br/>Method(s): In this prospective, open-label,
randomized clinical trial the level of 25-hydroxy vitamin D (25(OH) D) was
measured in patients undergoing CABG surgery. Patients with vitamin D
insufficiency (defined as 25(OH) D level < 30 ng/ml) were included and
randomly assigned to control group to receive either the general standard
of care (Group A) or to study group to receive the general standard of
care plus oral vitamin D<inf>3</inf>, 600,000 IU 5 days before surgery
(Group B). The primary outcome of our study was the occurrence of POAF
during the first 5 days after CABG surgery. <br/>Result(s): Totally, 93
patients in group B and 103 patients in group A completed the study. The
occurrence of POAF was significantly lower in group B as compared to group
A (9.68% vs. 20.39%, p =.038). The length of intensive care unit (ICU)
stay and hospital stay were reduced in group B patients (2.21 vs. 3.86
days, p <.001 and 7.40 vs. 9.58 days, p =.022, respectively).
<br/>Conclusion(s): Our study demonstrated that vitamin D supplementation
reduces the incidence of POAF, duration of ICU, and hospital stay
following CABG surgery.<br/>Copyright &#xa9; 2022 Wiley Periodicals LLC.

<75>
Accession Number
2014808521
Title
Comparison of Two Noninvasive Ventilation Strategies (NHFOV Versus NIPPV)
as Initial Postextubation Respiratory Support in High-Risk Infants After
Congenital Heart Surgery.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 36(7) (pp 1962-1966),
2022. Date of Publication: July 2022.
Author
Wu H.-L.; Lei Y.-Q.; Lin W.-H.; Huang S.-T.; Chen Q.; Zheng Y.-R.
Institution
(Wu, Lei, Lin, Huang, Chen, Zheng) Department of Cardiac Surgery, Fujian
Branch of Shanghai Children's Medical Center, Fuzhou, China
(Wu, Lei, Lin, Huang, Chen, Zheng) Fujian Children's Hospital, Fuzhou,
China
(Wu, Lei, Lin, Huang, Chen, Zheng) Fujian Maternity and Child Health
Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China
(Wu, Lei, Lin, Huang, Chen, Zheng) Fujian Key Laboratory of Women and
Children's Critical Diseases Research, Fujian Maternity and Child Health
Hospital, Fuzhou, China
Publisher
W.B. Saunders
Abstract
Objective: This study aimed to compare the effects of nasal high-frequency
oscillatory ventilation (NHFOV) and noninvasive positive-pressure
ventilation (NIPPV) as the initial postextubation therapies on preventing
extubation failure (EF) in high-risk infants younger than three months
after congenital heart surgery (CHS). <br/>Design(s): This was a
single-center, randomized, unblinded clinical trial. <br/>Setting(s): The
study was performed in a teaching hospital. <br/>Participant(s): Between
January 2020 and January 2021, a total of 150 infants underwent CHS in the
authors' hospital. <br/>Intervention(s): Infants younger than three months
with a high risk for extubation failure who were ready for extubation were
randomized to either an NHFOV therapy group or an NIPPV therapy group, and
received the corresponding noninvasive mechanical ventilation to prevent
EF. Measurements: Primary outcomes were reintubation, long-term
noninvasive ventilation (NIV) support (more than 72 hours), and the time
in NIV therapy. The secondary outcomes were adverse events, including
mild-moderate hypercapnia, severe hypercapnia, severe hypoxemia, treatment
intolerance, signs of discomfort, unbearable dyspnea, inability to clear
secretions, emesis, and aspiration. <br/>Main Result(s): Of 92 infants, 45
received NHFOV therapy, and 47 received NIPPV therapy after extubation.
There were no significant differences between the NHFOV and the NIPPV
therapy groups in the incidences of reintubation, long-term NIV support,
and total time under NIV therapy. No significant difference was found of
the severe hypercapnia between the two groups, but NHFOV treatment
significantly decreased the rate of mild-moderate hypercapnia (p < 0.05).
Other outcomes were similar in the two groups. <br/>Conclusion(s): Among
infants younger than three months after CHS who had undergone extubation,
NIPPV therapy and NHFOV therapy were the equivalent NIV strategies for
preventing extubation failure, and NHFOV therapy was more effective in
avoiding mild-moderate hypercapnia.<br/>Copyright &#xa9; 2021 Elsevier
Inc.

<76>
Accession Number
2018675080
Title
UTILITY OF ROUTINE EGD BEFORE TEE IN PATIENTS WITH CIRRHOSIS: A SYSTEMATIC
REVIEW.
Source
Gastrointestinal Endoscopy. Conference: DDW 2022 Digestive Disease Week.
San Diego United States. 95(6 Supplement) (pp AB42), 2022. Date of
Publication: June 2022.
Author
Swar B.; St. Laurent C.W.; Nadeem M.; Ali I.A.
Publisher
Elsevier Inc.
Abstract
DDW 2022 Author Disclosures: Bishr Swar: NO financial relationship with a
commercial interest <br/> Caleb St. Laurent: NO financial relationship
with a commercial interest <br/> Mahum Nadeem: NO financial relationship
with a commercial interest <br/> Ijlal Akbar Ali: NO financial
relationship with a commercial interest Background and Aim:
Gastroenterologists are routinely consulted by cardiologists for clearance
before performing a transesophageal echocardiogram (TEE) due to concerns
for variceal rupture leading to life threatening bleeding. Literature is
controversial on whether TEE is safe in this population and whether
endoscopy prior to TEE has any significant benefit. We designed this
systematic review to determine how endoscopy prior to TEE in patients with
esophagogastric varices affects patient outcomes in terms of major and
minor bleeding. <br/>Method(s): We searched PubMed/MEDLINE and EMBASE
database up to October 15, 2021. Detailed searches of the databases were
performed using keywords that include: esophagus varices, stomach varices,
varices, transesophageal echocardiography, echo, etc and 599 studies were
found. Title and abstracts and subsequent full text review was performed
by two independent reviewers. <br/>Result(s): 12 retrospective and
observational studies comprising 1,618 patients met the inclusion
criteria. Pooled incidence of major bleeding (described as Hgb drop of >2
or overt GI bleed) within this population is 0.37% (n = 6) regardless if
they received an endoscopy immediately prior to TEE or not. Incidence of
minor bleeding (defined as bleeding not meeting major criteria) was 1.11%
(n = 18). The overall bleeding risk within the studied population was
therefore 1.48% (n = 24). Due to the small number of events in studies
that recorded timing of endoscopy, metanalysis was not adequately powered
for significant findings. Pooled odds ratio was 2.18 (95% CI 0.22-21.07)
for risk of bleeding event in patients receiving endoscopy prior to TEE.
<br/>Discussion(s): Our systematic review indicates that TEE in patients
with varices is generally safe with an incidence of major and minor
bleeding being 1.48%. Notably, reports of major complications within the
general population have varied from 0.2 and 0.4% and up to 1.4% in cardiac
surgery cohorts. The incidence of major bleeding, specifically, (0.37%) is
at or below the level of major complication risk observed in the general
population. Thus, TEE is relatively safe in this population and an EGD
prior to TEE may not be needed in every patient with varices who requires
a TEE. We hope this can reduce the burden of EGDs on gastroenterologists
and could reduce time spent, cost and length of stay in the hospital.
However, further studies need to be performed to verify these results.
Unfortunately, there were not enough events to provide sufficient power in
our metanalysis. Only 4 studies documented specific timing of endoscopy
prior to TEE pointing out that more well-designed studies are needed to
draw certain conclusions on the basis of metanalysis. (No Image
Selected)<br/>Copyright &#xa9; 2022

<77>
Accession Number
638196508
Title
IMPACT OF NON-INVASIVE VENTILATION IMMEDIATELY AFTER EXTUBATION ON
CLINICAL AND FUNCTIONAL OUTCOMES IN PATIENTS SUBMITTED TO CORONARY ARTERY
BYPASS GRAFTING: CLINICAL TRIAL.
Source
European Respiratory Journal. Conference: International Congress of the
European Respiratory Society, ERS 2021. Virtual. 58(SUPPL 65) (no
pagination), 2021. Date of Publication: September 2021.
Author
Cordeiro A.L.; Silva C.; Lima K.; Santana M.; Guimaraes A.; Forestieri P.;
Forgiarini L.A.
Institution
(Cordeiro, Silva, Lima, Santana) Faculdade Nobre, Feira De Santana (BA),
Brazil
(Guimaraes) Instituto Nobre de Cardiologia, Feira De Santana (BA), Brazil
(Forestieri) Federal University of Sao Paulo, Sao Paulo, Brazil
(Forgiarini) Universidade La Salle, Canoas, Brazil
Publisher
European Respiratory Society
Abstract
Objective: Assess the impact of immediate NIV after extubation on
oxygenation and functional capacity of patients undergoing to CABG.
<br/>Method(s): Randomized clinical trial. Patients were assessed before
and after surgery using the Functional Independence Measure(FIM),
six-minute walk test(6MWT) and peripheral muscle strength(MRC). On the
first day after the surgery, two groups formed immediate NIV(NIVI) and
conventional NIV(NIVC). Hemogasometry was collected before and after NIV.
Complication rates were also assessed. NIVI performed ventilation after
one hour of orotracheal extubation, at NIVC performed NIV on the first
postoperative day, 24 hours after extubation. After discharge, the above
variables were reevaluated. <br/>Result(s): 79 patients were evaluated,
46(58.22%) men, mean age 65+/-9 years. NIVI reduced the reintubation rate,
only 1 (3%) compared to NIVC with 5 (12%) patients, p=0.01. In the
post-Intervention the inspired oxygen fraction (FiO2) was 0.43+/-0.07 in
the conventional group and 0.30+/-0.10 in the intervention group, p=0.01.
The post- intervention PaO2/FiO2 ratio was 191+/-45 and NIVI 266+/-29(p
<0.001) and one day later in the NIVC it was 210+/-39 and NIVI 279+/-37(p
<0.001). VNII lost 51+/-36 meters in the 6MWT compared to the NIVC that
lost 95+/-40 meters(p <0.01). <br/>Conclusion(s): NIVI after extubation of
patients undergoing to CABG, reduced the loss of functional capacity,
improved blood gases and decreased the rate of reintubation.

<78>
Accession Number
638196315
Title
VENTILATORY MUSCLE STRENGTH SIX MONTHS AFTER CORONARY ARTERY BYPASS
GRAFTING IN PATIENTS SUBMITTED TO INSPIRATORY MUSCULAR TRAINING BASED ON
THE ANAEROBIOSIS THRESHOLD: CLINICAL TRIAL.
Source
European Respiratory Journal. Conference: International Congress of the
European Respiratory Society, ERS 2021. Virtual. 58(SUPPL 65) (no
pagination), 2021. Date of Publication: September 2021.
Author
Cordeiro A.L.; Almeida L.; Leite J.; Mascarenhas H.; Guimaraes A.;
Forgiarini L.A.; Petto J.
Institution
(Cordeiro, Almeida, Leite, Mascarenhas) Faculdade Nobre, Feira De Santana
(BA), Brazil
(Guimaraes) Instituto Nobre de Cardiologia, Feira De Santana (BA), Brazil
(Forgiarini) La Salle University, Canoas, Brazil
(Petto) Escola Bahiana de Medicina e Saude Publica, Salvador, Brazil
Publisher
European Respiratory Society
Abstract
Objective: To test the hypothesis that IMT based on AT modifies
inspiratory muscle strength and pulmonary function six months after CABG.
<br/>Method(s): This is a controlled and randomized clinical trial. In the
preoperative period, maximum inspiratory pressure(MIP), maximum expiratory
pressure(MEP), vital capacity and peak expiratory flow were evaluated. On
the first postoperative day, patients were randomized to two groups: IMT
based on AT(IMT-AT) where the load was prescribed through the glycemic and
conventional threshold(IMT-C) that performed the training with load based
on 40% of MIP. They were trained until the day of hospital discharge, at
that time and six months later they were evaluated again. <br/>Result(s):
A total of 42 patients completed pulmonary function tests in six months
after cardiac surgery, with 21 in each group. Statistical difference was
found between the TMI-AT and the TMI-C on MIP (difference between the
means of -5cmH2; 95% CI=- 8.21to-1.79) and CV (difference between the
means of -2ml/kg;95%CI=-3.87to-0.13) up to six months of follow-up. No
difference was found between groups in the other variables analyzed.
<br/>Conclusion(s): We conclude that inspiratory muscle training based on
the anaerobic threshold promoted recovery of inspiratory muscle strength
and vital capacity, after six months of coronary artery bypass grafting,
when compared to conventional training.

<79>
Accession Number
638196285
Title
INSPIRATORY MUSCLE TRAINING IN PATIENTS IN THE POSTOPERATIVE OF CARDIAC
SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS[MGN1][MOU2] > [MGN1]Pre ou
pos cirurgia, ou ambos? [MOU2]Apenas no pre-operatorio.
Source
European Respiratory Journal. Conference: International Congress of the
European Respiratory Society, ERS 2021. Virtual. 58(SUPPL 65) (no
pagination), 2021. Date of Publication: September 2021.
Author
Cordeiro A.L.; Oliveira L.
Institution
(Cordeiro, Oliveira) Faculdade Nobre, Feira De Santana (BA), Brazil
Publisher
European Respiratory Society
Abstract
Introduction: Cardiac surgery is associated with worsening pulmonary
function and respiratory muscle strength, reducing functional capacity and
increasing hospital stay. In this sense, Inspiratory Muscle Training (IMT)
appears as a resource to reduce the impact of cardiac surgery.
<br/>Objective(s): Review the evidence about IMT in patients in
postoperative of cardiac surgery[MGN1] [MOU2] . <br/>Method(s): We
conducted this systematic review used the databases Ovid, LILACS, CINAHL,
Pubmed and CENTRAL. Randomized clinical trials that addressed IMT after
cardiac surgery were selected. The outcomes assessed were maximum
inspiratory pressure (MIP), maximum expiratory pressure (MEP), tidal
volume (TV), peak expiratory flow (PEF), functional capacity and length of
hospital stay. The mean difference between groups and the respective 95%
confidence intervals were calculated and used to quantify the effect of
continuous outcomes. Results[MGN3]: Eight studies were selected. The IMT
was superior to the control over MIP 15.77 cmH2O (95% CI 5.95 to 25.49),
MEP 15.87 cmH2O (95% CI 1.16 to 30.58), PEF 40.98 L / min (95% CI 4.64 to
77), 32), TV 184.75ml (95% CI 19.72a349.77), hospital stay -1.25 days (95%
CI -1.77a-0.72), but without impact on functional capacity 29.93 meters
(95% CI % -27.59a87.45). <br/>Conclusion(s): Based on the results
presented, inspiratory muscle training was beneficial as a form of
treatment[MGN5] [MOU6] for patients after cardiac surgery.

<80>
Accession Number
638195703
Title
Thoracic surgery practice shift during the novel Coronavirus Disease 2019
(COVID19) pandemic.
Source
European Respiratory Journal. Conference: International Congress of the
European Respiratory Society, ERS 2021. Virtual. 58(SUPPL 65) (no
pagination), 2021. Date of Publication: September 2021.
Author
Hardavella G.; Babaliari E.; Karampinis I.; Bellou E.; Keramida E.; Sepsas
E.; Demertzis P.
Institution
(Hardavella, Bellou, Keramida, Sepsas, Demertzis) 9th Department of
Respiratory Medicine, 'Sotiria' Athens' Chest Diseases Hospital, Athens,
Greece
(Babaliari) Emergency, Outpatient, Inpatient and Ambulatory Care,
'Sotiria' Athens Chest Diseases Hospital, Athens, Greece
(Karampinis) Department of Thoracic Surgery, General Oncology Hospital
Agiioi Anargyroi, Athens, Greece
Publisher
European Respiratory Society
Abstract
Introduction: The COVID-19 pandemic has affected the entire lung cancer
services including the thoracic surgical practice. <br/>Aim(s): To provide
an insight into the impact of national outbreak of COVID19 on thoracic
surgical practice in a tertiary referral centre. Materials/Methods:
Retrospective review of hospital records/electronic databases for thoracic
surgery during the COVID19 pandemic (2020) and comparison with previous
year. <br/>Result(s): During the pandemic, a total number of 591 thoracic
surgery procedures were performed versus 1020 in 2019 (40% decrease) which
has been attributed to the overall decreased number of referrals and the
hospital transformation into a COVID19 referral centre. During the
pandemic, 44% of surgical procedures were major thoracic surgery for lung
cancer treatment with curative intent as opposed to 30% in 2019, 37% were
of diagnostic purpose(versus 35% in 2019) and 19% was general thoracic
surgery including minor procedures(versus 35% in 2019). In 2020 there has
been a noticeable shift towards complex thoracic oncology operations with
curative intent in accordance with the centre's expertise and adaptation
to COVID19 lung cancer guidelines. The departmental income was reduced by
26% despite the 40% decrease in overall activity due to increased costing
of complex procedures. The graphical representation of monthly procedures
is inversely proportional to the national pandemic curve and lockdowns.
<br/>Conclusion(s): The pandemic has impacted the number and complexity of
thoracic surgery cases with a statistically significant trend towards
major oncological surgery and a decrease in minor procedures. The
departmental income was not significantly affected.

<81>
Accession Number
638195452
Title
Merging new data with preferences:Does thoracoscopic paravertebral block
catheter placement before thoracic surgery enhances patient's recovery? A
prospective cohort study.
Source
European Respiratory Journal. Conference: International Congress of the
European Respiratory Society, ERS 2021. Virtual. 58(SUPPL 65) (no
pagination), 2021. Date of Publication: September 2021.
Author
Lioumpas D.; Stamatatos I.; Anagostopoulos G.; Tsagkarakis F.; Xekalakis
D.; Katsadonis A.; Michos T.; Bouboulis K.; Eleutheroulis N.; Tzatzadakis
N.
Institution
(Lioumpas, Stamatatos, Bouboulis, Eleutheroulis, Tzatzadakis) Thoracic
Surgery Department, Nikaia General Hospital, Athens, Greece
(Anagostopoulos, Tsagkarakis, Xekalakis, Katsadonis) General Surgery
Department, Nikaia General Hospital, Athens, Greece
(Michos) Thoracic Surgery Department, Kat General Hospital, Athens, Greece
Publisher
European Respiratory Society
Abstract
Background: Emerging studies demonstrate accumulating benefits of improved
analgesic efficacy of paravertebral blocks (PVB) prior to surgery. We
evaluate outcomes of intraoperative PVB catheter placement under direct
thoracoscopic vision, before and after surgery, in terms of postoperative
pain and quality of recovery (QoR). <br/>Method(s): Using a systematic
random sampling technique, we conducted a prospective cohort study of
fifty-eight (58) patients who underwent uniportal Video Assisted Thoracic
Surgery (uVATS) for of all causes, between 2017- 2020. Patients were
randomly allocated into two groups. Group A (n=28) received a PVB
continuous infusion catheter prior to surgery, while group B (n=30) at the
end of surgery. Patients with history of chronic pain and prior surgical
procedures were excluded from the study. <br/>Result(s): The mean age of
study participants was 45 3 years (SD 15 7), approximately a third [22
(38%)] were women while median time of surgery was 103+/-35 min. The
postoperative numerical score (NRS) at rest were significantly lowered in
group A. Time to first analgesic request was significantly shorter in
group B in the first 24h (75% vs 25%) and in the 24-48-h period (60% vs
7%) p value < 0.001. There was no difference between groups in duration of
hospital stay (LoS). The reported primary block failure rate was 3.1%
<br/>Conclusion(s): Our study supports the available data in favor of the
superiority of PVB catheter placement before surgery as a safe and
effective analgesic method reducing post-operative pain scores and opioid
consumption.

<82>
Accession Number
638195036
Title
Collateral impact of COVID19 pandemic on lung cancer services in a
tertiary referral centre.
Source
European Respiratory Journal. Conference: International Congress of the
European Respiratory Society, ERS 2021. Virtual. 58(SUPPL 65) (no
pagination), 2021. Date of Publication: September 2021.
Author
Hardavella G.; Babaliari E.; Bellou E.; Karampinis I.; Keramida E.; Bracka
I.; Demertzis P.
Institution
(Hardavella, Bellou, Keramida, Bracka, Demertzis) 9th Department of
Respiratory Medicine, 'Sotiria' Athens Chest Diseases Hospital, Athens,
Greece
(Babaliari) Emergency, Outpatient, Inpatient and Ambulatory Care,
'Sotiria' Athens Chest Diseases Hospital, Athens, Greece
(Karampinis) Department of Thoracic Surgery, General Oncology Hospital,
Agioi Anargyroi, Athens, Greece
Publisher
European Respiratory Society
Abstract
Introduction: The COVID-19 pandemic has been predicted to significantly
affect overall patients with lung cancer and healthcare systems.
<br/>Aim(s): To investigate the impact of COVID-19 pandemic on lung cancer
diagnostic and treatment services in a tertiary referral centre.
<br/>Material(s) and Method(s): Targeted retrospective review of all
hospital records and electronic databases for diagnostic/therapeutic
procedures for lung cancer&systemic treatments/ immunotherapies during the
pandemic (03/2020-12/2020) and comparison with previous year
(03/2019-12/2020). <br/>Result(s): Our Trust is a tertiary referral centre
for Respiratory Medicine. During the pandemic, 257 active lung cancer
outpatient cases were recorded versus 784 (03.2019-12.2019) resulting in a
68% decrease. Diagnostic/therapeutic bronchoscopies sustained a 39%
decrease, thoracic surgery cases decreased by 42% and
chemotherapies/immunotherapies were reduced by 12%. Compellingly, the
graphical monthly breakdown of outpatients/procedures/treatments is
inversely proportional to the pandemic curve and state lockdowns. Despite
the significant decrease in outpatient cases (including new referrals) the
decrease is systemic treatments was significantly less accounting for the
extent of disease recurrences requiring second line treatment.
Interestingly, systemic treatments' costs have increased by 24% despite
the 12% decrease in their numbers which is attributed to the increased use
of immunotherapy as 2nd line treatment in disease recurrences.
<br/>Conclusion(s): The COVID19 pandemic poses implications in our Trust's
lung cancer services including costs and follows a pattern that is
inversely proportional to the pandemic curve.

<83>
Accession Number
638194940
Title
Impact of the COVID19 pandemic on patterns of respiratory, thoracic
oncology and thoracic surgery outpatient care.
Source
European Respiratory Journal. Conference: International Congress of the
European Respiratory Society, ERS 2021. Virtual. 58(SUPPL 65) (no
pagination), 2021. Date of Publication: September 2021.
Author
Hardavella G.; Babaliari E.; Bellou E.; Karampinis I.; Keramida E.;
Demertzis P.
Institution
(Hardavella, Bellou, Keramida, Demertzis) Department of Respiratory
Medicine, 'Sotiria' Athens' Chest Diseases Hospital, Athens, Greece
(Babaliari) Outpatients' Department,'Sotiria' Athens' Chest Diseases
Hospital, Athens, Greece
(Karampinis) Department of Thoracic Surgery, General Oncology Hospital,
Agioi Anargyroi, Athens, Greece
Publisher
European Respiratory Society
Abstract
Introduction: The COVID-19 pandemic has dramatically changed how
outpatient care is delivered in health care practices. <br/>Aim(s): To
provide an insight into the impact of COVID19 pandemic on outpatient care
in a tertiary respiratory centre. Materials/Methods: Retrospective review
of outpatient records and electronic databases during the pandemic
(03/2020-12/2020) and comparison with previous year (03/2019-12/2019).
<br/>Result(s): During the pandemic 15,897 outpatient visits were recorded
versus 33,895 in 2019 (53% decrease) with a mean age 64.7 (age range 22-82
years). The biggest decrease in outpatient visits during the pandemic was
noted in interstitial lung disease(ILD) clinics (-75%) and general
respiratory outpatients (-72%) which are mainly self referrals/primary
care referrals for persistent respiratory symptoms not subsiding with
first line of treatment. Thoracic oncology outpatients visits decreased by
62% during the pandemic, COPD by 59%, asthma by 56%, OSA by 52%. Thoracic
surgery outpatients was amongst the least affected outpatient pathways
with a 30% reduction of outpatient visits. The monthly breakdown of visits
was inversely proportional to the national pandemic curve and the
intermittent state lockdowns. <br/>Conclusion(s): The pandemic and
intermitted lockdowns changed the threshold for general respiratory
referrals with more people remaining under the community care. The most
immunocompromised groups of patients (ILD, thoracic oncology patients) did
not seek outpatient care preferring to either transfer their care to other
centres or remaining under community care until progression.

<84>
Accession Number
638193994
Title
Landiolol vs Esmolol on hemodynamic response during weaning of
post-operative ICU patients with heart failure.
Source
European Respiratory Journal. Conference: International Congress of the
European Respiratory Society, ERS 2021. Virtual. 58(SUPPL 65) (no
pagination), 2021. Date of Publication: September 2021.
Author
Anifanti M.; Iona I.; Tsikritsaki K.; Chrysikos S.; Kalogeromitros A.;
Koukoulitsios G.
Institution
(Anifanti, Iona, Tsikritsaki, Kalogeromitros, Koukoulitsios) ICU, General
Hospital of Athens 'G. Gennimatas', Athens, Greece
(Chrysikos) 5th Respiratory Medicine department, ''Sotiria'' Chest
diseases hospital, Athens, Greece
Publisher
European Respiratory Society
Abstract
Introduction: Weaning and tracheal extubation of postoperative ICU
patients is a stressful procedure that triggers the sympathetic nervous
system leading to a potential deterioration of cardiac performance in
patients with left ventricular dysfunction. This study was conducted to
compare the efficacy and safety of Landiolol, a novel
ultra-shortacting-beta-1 blocker, with those of Esmolol in cardiovascular
response during the extubation of patients with heart failure Methods:
Thirty-nine patients with heart failure [LVEF (%): 36.6+/-7.6, NYHA Class
III/IV (n): 32/9] were randomly divided into two groups: Landiolol group
of 19 patients and Esmolol group of 20 patients. Landiolol infusion at the
rate of 4 mug/Kg/min and Esmolol infusion at the rate of 100/Kg/min was
started as soon as the weaning procedure began. Heart rate (HR), systolic
arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial
pressure (MAP), and cardiac rhythm was recorded every minute up to 30 min
after the extubation of the trachea Results: Mean age, LVEF, NYHA Class,
Acute Physiology and Chronic Health Evaluation II, and Sequential Organ
Failure Assessment score were similar between the two groups. Landiolol
produced a more rapid and substantial decrease in HR than Esmolol
(-40+/-20 vs.-30+/-16 bpm) without any hemodynamics deterioration. A
significant reduction of MAP was recorded in the Esmolol group.
<br/>Conclusion(s): Landiolol more rapidly and more potent reduced the HR
than Esmolol. Significant reduction of MAP was recorded only in the
Esmolol group.

<85>
Accession Number
638193837
Title
Enhanced recovery after surgery decreases pain in thoracic surgery.
Source
European Respiratory Journal. Conference: International Congress of the
European Respiratory Society, ERS 2021. Virtual. 58(SUPPL 65) (no
pagination), 2021. Date of Publication: September 2021.
Author
Hentati A.; Ayed A.B.; Jdidi J.; Chaari Z.; Abid W.; Ammar A.; Hlima G.B.;
Frikha I.
Institution
(Hentati, Ayed, Jdidi, Chaari, Abid, Ammar, Hlima, Frikha) Habib Bourguiba
University Hospital, Sfax, Tunisia
Publisher
European Respiratory Society
Abstract
Objectives: Enhanced recovery after surgery (ERAS) is the application of
simple measures in the postoperative care with the aim of reducing
morbidity and mortality, and accelerating rehabilitation and hospital
discharge. The evidence of ERAS benefits in thoracic surgery remains
limited due to the selectivity of the type of surgical resection and
thoracic pathology in published studies. This study was designed to
evaluate the effectiveness of postoperative care using the ERAS protocol
compared to traditional one in thoracic surgery. Materiel and Methods:
This is a prospective randomized controlled study, conducted between
December 2015 and August 2017 at the department of Thoracic and
Cardiovascular Surgery of the Habib Bourguiba University Hospital in Sfax,
Tunisia. <br/>Result(s): One hundred patients undergoing thoracic surgery
were randomly allocated to ERAS group or control group. The following
complication rates were lower in the ERAS group: Lack of re-expansion
(14.63% vs 16.10%: p=0.72), pleural effusion (0% vs 10.86%, p=0.05) and
prolonged air leak (17.07% vs 30.43%, p=0.14). The level of pain decreased
significantly in the ERAS group from postoperative H3 (p=0.006). This
difference was significant at H6 (p=0.001), H24 (p=0.05), H48 (p=0.01),
discharge (p=0.002) and after 15 days (p=0.01) with a decreased analgesic
consumption. The length of hospital stay was shorter in the ERAS group
(median 6 days vs 7 days, p= 0.17). <br/>Conclusion(s): The ERAS protocol
can reduce post operative pain. This study provides an ERAS protocol,
applicable to any thoracic surgery pathology, approach or type of
resection.

<86>
[Use Link to view the full text]
Accession Number
2018713663
Title
Risk factors for hospital readmission in adult patients with heart failure
with reduced ejection fraction: A systematic review.
Source
JBI Evidence Synthesis. 18(8) (pp 1641-1700), 2020. Date of Publication:
06 Aug 2020.
Author
Schjodt I.; Liljeroos M.; Larsen P.; Johnsen So.P.; Stromberg A.; Logstrup
B.B.
Institution
(Schjodt, Logstrup) Department of Cardiology, Aarhus University Hospital,
Aarhus, Denmark
(Liljeroos, Stromberg) Department of Health, Medicine and Caring Sciences,
Linkoping University, Linkoping, Sweden
(Liljeroos) Centre for Clinical Research Sormland, Uppsala University,
Eskilstuna, Sweden
(Larsen) Health Sciences Research Center, University College Lillebaelt,
Odense, Denmark
(Johnsen) Danish Center for Clinical Health Services Research, Department
of Clinical Medicine, Aalborg University, Aalborg, Denmark
(Stromberg) Department of Cardiology, Linkoping University Hospital,
Linkoping, Sweden
(Logstrup) Department of Clinical Medicine, Aarhus University, Aarhus,
Denmark
Publisher
Lippincott Williams and Wilkins
Abstract
Objective:The objective of this review was to identify and synthesize
evidence on risk factors associated with hospital readmission within the
first year after heart failure hospitalization among patients with heart
failure with reduced left ventricular ejection fraction.Introduction:Heart
failure is associated with a high risk of hospital readmission.
Readmissions are associated with higher mortality and health care costs.
It is a high health care priority to identify vulnerable patients with
heart failure who may potentially benefit from targeted personalized care
interventions aiming to reduce readmissions.Inclusion criteria:This review
considered studies including adult patients who had heart failure with a
reduced left ventricular ejection fraction <= 40% who were discharged
after a heart failure hospitalization. The authors included studies with
experimental and observational designs evaluating risk factors for i)
all-cause hospital readmission, ii) heart failure hospital readmission,
and iii) composite outcomes within seven, 15, 30, 60, 90, 180, and 365
days after hospital discharge. Composite outcomes included end points
where all-cause readmission and/or heart failure readmission were part of
a defined end point (i.e. all-cause readmission or mortality; heart
failure readmission or mortality; cardiovascular readmission;
cardiovascular readmission or mortality; and readmission, mortality, or
cardiac transplant). Studies reporting all-cause readmission and/or heart
failure readmission as a primary outcome, secondary outcome, or part of a
composite outcome were included. <br/>Method(s):PubMed, Embase, CINAHL,
Cochrane CENTRAL, PsycINFO, OpenGrey, MedNar, DART-Europe, ProQuest
Dissertations and Theses, and the Grey Literature Report in Public Health
were searched to find both published and unpublished studies in English,
Swedish, Norwegian, or Danish from 2000 to June 2018. Study selection,
critical appraisal, data extraction, and data synthesis followed the JBI
approach for systematic reviews. Statistical pooling was not possible due
to clinical and methodological heterogeneity of the studies included and
the lack of risk factors reported more than once. A narrative summary of
the findings was performed. <br/>Result(s):Fifty-Two studies, including
one randomized controlled trial and 51 cohort studies with a total of
128,186 participants, were included. Risk factors for readmission were
reported for 30-day outcome in 16 studies, 60-day in three studies, 90-day
in 15 studies, 180-day in 12 studies, and 365-day outcome in 15 studies.
Based on multivariable analyses from 43 cohort studies and results from
one randomized controlled trial, the authors identified several factors
associated with higher risk of all-cause readmission, heart failure
readmission, and composite outcomes (e.g. readmission or death) within 30,
60, 90, 180, and 365 days after discharge for a heart failure
hospitalization. <br/>Conclusion(s):This review provides a comprehensive
overview of factors associated with a clinical outcome after a heart
failure hospitalization in patients with heart failure with left
ventricular ejection fraction <= 40%. Owing to the heterogeneity of
variables investigated and the lack of comparability of findings, the
clinical impact of the identified risk factors remains uncertain. This
review highlights research gaps and the need for a standardized way to
define and measure all-cause readmission, heart failure readmission, and
composite end points in clinical research to improve study quality and
enable comparison of findings between studies.<br/>Copyright &#xa9; 2021
Lippincott Williams and Wilkins. All rights reserved.

<87>
[Use Link to view the full text]
Accession Number
2018713662
Title
Effect of intrathecal morphine plus patient-controlled analgesia with
morphine versus patient-controlled analgesia with morphine alone on total
morphine dose 24 hours post-surgery: A systematic review.
Source
JBI Evidence Synthesis. 18(8) (pp 1611-1640), 2020. Date of Publication:
28 Aug 2020.
Author
Pitre L.; Garbee D.; Tipton J.; Schiavo J.; Pitt A.
Institution
(Pitre, Garbee, Tipton, Pitt) School of Nursing, Louisiana State
University Health Sciences Center, New Orleans, United States
(Pitre, Garbee, Tipton, Schiavo, Pitt) Louisiana Centre for Promotion of
Optimal Health Outcomes: A JBI Centre of Excellence
(Schiavo) School of Dentistry, Louisiana State University Health Sciences
Center, New Orleans, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Objective:The objective of this review was to evaluate the effects of
preoperative intrathecal morphine (ITM) in addition to patient-controlled
analgesia with morphine (PCAM) versus PCAM without preoperative ITM on
total morphine dose in the first 24 hours postoperatively in adult
patients undergoing abdominal or thoracic
surgery.Introduction:Postoperative pain is a significant problem for
patients undergoing major abdominal and thoracic surgery. Intrathecal
morphine can reduce postoperative pain and reduce intravenous (IV)
morphine requirements during the first 24 hours after surgery; however,
the amount of IV morphine dose reduction achieved has not been well
established. This knowledge could help anesthesia providers determine if
ITM is an appropriate analgesic option for patients.Inclusion
criteria:This review included studies with participants 18 years of age or
older receiving general anesthesia for abdominal or thoracic surgery.
Studies were included that used the intervention of preoperative ITM in
addition to PCAM versus PCAM without preoperative ITM. Total morphine dose
in milligrams during the first 24 hours after surgery was the outcome of
interest. <br/>Method(s):A search of PubMed and CINAHL was conducted for
studies published between January 1984 and October 2018 using the key
terms intrathecal, morphine, postoperative, pain, patient-controlled
analgesia and general anesthesia. Index terms and keywords from identified
articles were used to search CINAHL, Cochrane Central Register of
Controlled Trials (CENTRAL), Embase, ClinicalTrials.gov, Ovid MEDLINE,
ProQuest Dissertations and Theses/Nursing and Allied Health Databases, and
Scopus. The reference lists of articles that underwent critical appraisal
were searched for additional studies. Methodological quality was assessed
using the JBI Critical Appraisal Checklist for Randomized Controlled
Trials. Two independent reviewers assessed each selected article. Study
results were pooled in statistical meta-Analysis using the JBI System for
the Unified Management, Assessment and Review of Information, and two
studies were described in narrative form. Differences in IV morphine dose
between the ITM plus PCAM and PCAM alone groups were calculated to produce
the weighted mean difference (WMD) utilizing a 95% confidence interval
(CI). Heterogeneity was assessed using chi²and
I²values. Subgroup analysis was conducted on two studies that
included IV non-opioid analgesia in addition to ITM and PCAM for
postoperative analgesia. <br/>Result(s):Seven RCTs with a total sample
size of 352 patients were included in this review. Five studies that
evaluated postoperative total morphine dose in milligrams with and without
preoperative ITM were included for statistical meta-Analysis, with 277
participants from four countries. Total morphine dose was significantly
reduced in patients who received ITM (WMD =-24.44 mg, 95% CI-28.70
to-20.18 mg) compared to PCAM without ITM. Subgroup analysis of two
studies involving 112 participants using IV acetaminophen in addition to
ITM and PCAM indicated no additional benefit after ITM was already
administered (WMD =-25.93, 95% CI-32.05 to-19.80 mg). Two studies with 75
participants were described narratively because total morphine dose was
reported as median rather than mean values. <br/>Conclusion(s):In this
review, ITM provided a significant decrease in overall total morphine dose
during the first 24 hours after surgery in abdominal surgery patients. The
addition of IV non-opioids to the postoperative analgesia protocol showed
no additional reduction in postoperative IV morphine dose between
groups.Systematic review registration number:PROSPERO
CRD42018100613.<br/>Copyright &#xa9; 2021 Lippincott Williams and Wilkins.
All rights reserved.

<88>
Accession Number
2018671776
Title
Differences Among Clinical Trials and Registries on Surgical and
Percutaneous Coronary Interventions.
Source
Annals of Thoracic Surgery. (no pagination), 2022. Date of Publication:
2022.
Author
Chadow D.; Audisio K.; Perezgrovas-Olaria R.; Cancelli G.; Robinson N.B.;
Rahouma M.; Soletti G.; Angiolillo D.J.; Metkus T.S.; Gaudino M.F.L.
Institution
(Chadow, Audisio, Perezgrovas-Olaria, Cancelli, Robinson, Rahouma,
Soletti, Gaudino) Department of Cardiothoracic Surgery, Weill Cornell
Medicine, New York, New York
(Angiolillo) Division of Cardiology, University of Florida College of
Medicine, Jacksonville, Florida
(Metkus) Division of Cardiology, Department of Medicine, Johns Hopkins
University School of Medicine, Baltimore, Maryland
(Metkus) Division of Cardiac Surgery, Department of Surgery, Johns Hopkins
University School of Medicine, Baltimore, Maryland
Publisher
Elsevier Inc.
Abstract
Background: A need exists for systematic evaluation of the differences in
baseline characteristics and early outcomes between patients enrolled in
randomized controlled trials (RCTs) and clinical practice for coronary
artery bypass grafting (CABG) and percutaneous coronary intervention
(PCI). <br/>Method(s): Systematic searches were conducted to identify RCTs
comparing CABG vs PCI and CABG or PCI registries. Sixteen predefined
baseline characteristics and 30-day mortality were extracted from the
included studies. Pooled proportion and mean with 95% CI were calculated
for binary and continuous outcomes, respectively, by using the random
effects model. <br/>Result(s): Fourteen RCTs and 10 registries including
more than 2 million patients were included. Registry patients who
underwent CABG had a higher prevalence of hypertension, smoking, reduced
left ventricular ejection fraction, and prior myocardial infarction, but a
lower prevalence of single-vessel disease when compared with CABG-treated
patients included in RCTs. Regarding PCI, hypertension, hyperlipidemia,
left main coronary artery disease, triple-vessel coronary disease, and
NYHA functional class <IV were significantly more prevalent among patients
in RCTs, whereas age, reduced left ventricular ejection fraction, and
smoking were more represented among PCI registry patients. Thirty-day
mortality was higher in registries for both PCI-treated and CABG-treated
patients. <br/>Conclusion(s): There were significant differences in
baseline characteristics and 30-day mortality between patients enrolled in
RCTs comparing CABG vs PCI and CABG and PCI registries. However, results
were mixed, and the discrepancy was less than seen in other
fields.<br/>Copyright &#xa9; 2022 The Society of Thoracic Surgeons

<89>
Accession Number
2018669768
Title
TAVI with the ACURATE neo transcatheter heart valve in special
populations: A systematic review.
Source
Hellenic Journal of Cardiology. (no pagination), 2022. Date of
Publication: 2022.
Author
Koliastasis L.; Doundoulakis I.; Kokkinidis D.G.; Milkas A.; Drakopoulou
M.; Benetos G.; Latsios G.; Synetos A.; Aggeli K.; Tousoulis D.; Tsioufis
K.; Toutouzas K.
Institution
(Koliastasis, Doundoulakis, Drakopoulou, Benetos, Latsios, Synetos,
Aggeli, Tousoulis, Tsioufis, Toutouzas) First Department of Cardiology,
National and Kapodistrian University, "Hippokration" Hospital, Athens,
Greece
(Koliastasis, Milkas) Athens Naval and Veterans Hospital, Athens, Greece
(Doundoulakis) Department of Cardiology, 424 General Military Training
Hospital, Thessaloniki, Greece
(Kokkinidis) Section of Cardiovascular Medicine, Yale University School of
Medicine, Yale New Haven Hospital, New Haven, CT, United States
Publisher
Hellenic Cardiological Society
Abstract
The ACURATE neo transcatheter aortic valve is a self-expanding device
suitable for both transfemoral and transapical approach, but specific
groups of patients are under-represented in clinical trials. We aim to
provide a comprehensive systematic review on TAVI with ACURATE neo in
those special populations. TAVI in bicuspid aortic valve, TAVI in patients
with small aortic annulus, TAVI for pure aortic regurgitation and
valve-in-valve procedures, were systematically reviewed. The primary
endpoint was device success as defined by VARC-2 criteria. The secondary
endpoints were safety and performance outcomes according to VARC-2
consensus document.ACURATE neo exhibited similar outcomes in bicuspid vs
tricuspid aortic valve except for pre and post-dilatation rates in one
observational study. Lower mean aortic gradient and higher pre-dilatation
rates with comparable safety outcomes were described for ACURATE neo when
compared to Lotus and Evolut-R for bicuspid aortic valve stenosis. 2
studies compared ACURATE in small aortic annuli. ACURATE neo showed lower
transvalvular gradients and lower patient prosthesis mismatch rates
compared to Sapien 3 and when compared to Evolut R/ Evolut PRO/ Portico,
results were similar except for pre-dilatation rates. 3 studies
investigated ACURATE neo for pure aortic regurgitation and one for
valve-in-valve procedure and demonstrated safety and efficacy, with the
exception of malposition events in patients designated for higher valve
deployment in the valve-in-valve implantation study.ACURATE neo valve may
be a feasible and safe option for patients with bicuspid anatomy, small
aortic annulus, previously implanted bioprosthetic aortic valve and pure
aortic regurgitation. Registration number: Available at
https://osf.io/aus26 (DOI 10.17605/OSF.IO/AUS26).<br/>Copyright &#xa9;
2022 Hellenic Society of Cardiology

<90>
Accession Number
638185934
Title
Gerbode defect-Percutaneous closure of three cases and a brief review of
literature.
Source
Journal of Indian College of Cardiology. 12(2) (pp 71-75), 2022. Date of
Publication: April-June 2022.
Author
Roy M.; Gangopadhyay D.; Saha S.; Sukla S.; Sinha P.
Institution
(Roy, Gangopadhyay, Saha, Sinha) Department of Pediatric Cardiology, NH
RTIICS, 931 Jawpur Road, Kolkata 700 074, India
(Sukla) Department of Pediatric Cardiology, Max Super Speciality Hospital,
New Delhi, India
Publisher
Wolters Kluwer Medknow Publications
Abstract
Gerbode defect is very rare cardiac abnormality accounting for <1% of
cardiac defects. Historically treated by open heart surgery, many authors
have now popularized the concept of percutaneous closure of such defects
by various devices. We report three such cases and provide a brief review
of the literature.<br/>Copyright &#xa9; 2022 Wolters Kluwer Medknow
Publications. All rights reserved.

<91>
Accession Number
2017012924
Title
A Systematic Review of Adherence to Immunosuppression among Pediatric
Heart Transplant Patients.
Source
Journal of Cardiovascular Development and Disease. 9(5) (no pagination),
2022. Article Number: 165. Date of Publication: May 2022.
Author
Nassetta K.; Hussain T.; Gambetta K.; Le K.; O'dwyer L.C.; Badawy S.M.
Institution
(Nassetta) Department of Pediatrics, Ann and Robert H. Lurie Children's
Hospital of Chicago, 225 E. Chicago Avenue, Chicago, IL 60611, United
States
(Hussain) Department of Internal Medicine, Northwestern University McGaw
Medical Center, 251 E. Huron St., Ste. 16-738, Chicago, IL 60611, United
States
(Gambetta) Division of Cardiology, Ann and Robert H. Lurie Children's
Hospital of Chicago, 225 E. Chicago Avenue, Chicago, IL 60611, United
States
(Le) Department of Pharmacy, Ann and Robert H. Lurie Children's Hospital
of Chicago, 225 E. Chicago Avenue, Chicago, IL 60611, United States
(O'dwyer) Galter Health Sciences Library & Learning Center, Northwestern
University Feinberg School of Medicine, 320 E. Superior Street, Chicago,
IL 60611, United States
(Badawy) Division of Hematology, Oncology, and Stem Cell Transplant, Ann
and Robert H. Lurie Children's Hospital of Chicago, 225 E. Chicago Avenue,
Chicago, IL 60611, United States
(Badawy) Department of Pediatrics, Northwestern University Feinberg School
of Medicine, 225 E. Chicago Avenue, Chicago, IL 60611, United States
Publisher
MDPI
Abstract
After pediatric heart transplant, commitment to lifelong immunosuppression
is crucial to maintaining graft health. However, a review of the current
literature surrounding adherence to immunosuppression in pediatric heart
transplant patients is lacking. This systematic review aims to summarize
the current landscape of adherence to immunosuppression in pediatric heart
transplant patients. We conducted searches in PubMed MEDLINE, Embase,
CENTRAL register of Controlled Trials (Wiley), and Scopus, from inception
to March 2020. Studies were eligible if they outlined an aspect of
adherence to immunosuppression and the measurement of adherence was
performed with an objective or otherwise validated measure of adherence
(e.g., drug levels, adherence questionnaires). The titles/abstracts of 880
articles were reviewed. After initial screening, 106 articles underwent
full text review. As such, 14 articles were included in the final review.
Baseline adherence estimates varied greatly, with most values between 40%
and 70%. Nonadherence to immunosuppression is associated with worse
outcomes (rejection, hospitalization, mortality), impaired quality of
life, and mental health concerns in pediatric heart transplant patients.
As nonadherence to immunosuppression is common and associated with worse
outcomes, there is a need for further development and evaluation of
interventions in this space.<br/>Copyright &#xa9; 2022 by the authors.
Licensee MDPI, Basel, Switzerland.

<92>
Accession Number
2018058154
Title
Vitamin C and the risk of atrial fibrillation: Mendelian randomization
study may be misleading.
Source
Clinical Nutrition. 41(6) (pp 1446-1447), 2022. Date of Publication: June
2022.
Author
Hemila H.; Chalker E.
Institution
(Hemila) Department of Public Health, University of Helsinki, POB 41,
Helsinki, Finland
(Chalker) Biological Data Science Institute, Australian National
University, Canberra, ACT, Australia
Publisher
Churchill Livingstone

<93>
Accession Number
2017746468
Title
Immune Response to SARS-CoV-2 Vaccine among Heart Transplant Recipients: A
Systematic Review.
Source
Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary
Medicine. 16 (no pagination), 2022. Date of Publication: 2022.
Author
Shoar S.; Prada-Ruiz A.C.C.; Patarroyo-Aponte G.; Chaudhary A.; Sadegh
Asadi M.
Institution
(Shoar) Department of Clinical Research, Scientific Collaborative
Initiative, Houston, TX, United States
(Prada-Ruiz) Division of Pediatric Cardiology, Department of Pediatrics,
University of Texas Health Science Center at Houston, Houston, TX, United
States
(Patarroyo-Aponte) Division of Pulmonary and Critical Care Medicine,
Department of Internal Medicine, McGovern Medical School, University of
Texas Health Science Center at Houston, Houston, TX, United States
(Chaudhary) Department of Internal Medicine, Griffin Hospital, Derby, CT,
United States
(Sadegh Asadi) Division of Cardiology, Department of Medicine, University
of Maryland School of Medicine, Baltimore, MD, United States
Publisher
SAGE Publications Ltd
Abstract
Background: Heart transplant (HTX) recipients are at a significantly
higher risk of adverse clinical outcomes, due to chronic immunosuppression
and co-existence of other chronic conditions, when contracting the
SARS-CoV-2 infection. Although vaccination against SARS-CoV-2 is currently
the most promising measure for the prevention of severe Coronavirus
Disease 2019 (COVID-19) among solid organ transplant recipients, the
extent of immune response and its protective efficacy among patients
receiving HTX has not been sufficiently studied. <br/>Method(s): We
performed a systematic review of the literature by inquiring
PubMed/Medline to identify original studies among HTX recipients, who had
received at least one dose of the SARS-CoV-2 vaccine. Data on the measured
humoral or cellular immune response was collected from all the eligible
studies. Factors associated with a poor immune response were further
investigated within these studies. <br/>Result(s): A total of 12 studies
comprising 563 HTX recipients were included. The average age of the study
participants was 60.8 years. Sixty four percent of the study population
were male. Ninety percent of the patients had received an mRNA vaccine
(Pfizer/ BNT162b2 or Moderna/mRNA-1273). A positive immune response to
SARS-CoV-2 vaccine was variably reported in 0% to 100% of the patients.
Older age (> 65 years), vaccine dose (first, second, or third), time since
HTX to the first dose of the vaccine, the time interval between the latest
dose of the vaccine and measurement of the immune response, and the type
of immunosuppressive regimen were all indicated as potential determinants
of a robust immune response to the SARS-CoV-2 vaccination.
<br/>Conclusion(s): HTX recipients demonstrate a weaker immune response to
the vaccination against SARS-CoV-2 compared to the general population.
Older age, anti-metabolite agents such as mycophenolate mofetil, and
vaccination during the first year following the HTX have been indicated as
potential determinants of a poor immune response.<br/>Copyright &#xa9; The
Author(s) 2022.

<94>
Accession Number
2017704059
Title
Prehabilitation of elderly frail or pre-frail patients prior to elective
surgery (PRAEP-GO): study protocol for a randomized, controlled, outcome
assessor-blinded trial.
Source
Trials. 23(1) (no pagination), 2022. Article Number: 468. Date of
Publication: December 2022.
Author
Schaller S.J.; Kiselev J.; Loidl V.; Quentin W.; Schmidt K.; Morgeli R.;
Rombey T.; Busse R.; Mansmann U.; Spies C.; Marschall U.; Eckardt-Felmberg
R.; Landgraf I.; Schwantes U.
Institution
(Schaller, Kiselev, Schmidt, Morgeli, Spies) Department of Anesthesiology
and Operative Intensive Care Medicine (CVK/CCM), Charite -
Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin
and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin 10117, Germany
(Loidl, Mansmann) Institute for Medical Information Processing, Biometry,
and Epidemiology - IBE, Ludwig-Maximilians-Universitat Munchen, Munich,
Germany
(Quentin, Rombey, Busse) Department of Health Care Management, Technische
Universitat Berlin, Berlin, Germany
Publisher
BioMed Central Ltd
Abstract
Background: Frailty is expressed by a reduction in physical capacity,
mobility, muscle strength, and endurance. (Pre-)frailty is present in up
to 42% of the older surgical population, with an increased risk for peri-
and postoperative complications. Consequently, these patients often suffer
from a delayed or limited recovery, loss of autonomy and quality of life,
and a decrease in functional and cognitive capacities. Since frailty is
modifiable, prehabilitation may improve the physiological reserves of
patients and reduce the care dependency 12 months after surgery.
<br/>Method(s): Patients >= 70 years old scheduled for elective surgery or
intervention will be recruited in this multicenter, randomized controlled
study, with a target of 1400 participants with an allocation ratio of 1:1.
The intervention consists of (1) a shared decision-making process with the
patient, relatives, and an interdisciplinary and interprofessional team
and (2) a 3-week multimodal, individualized prehabilitation program
including exercise therapy, nutritional intervention, mobility or balance
training, and psychosocial interventions and medical assessment. The
frequency of the supervised prehabilitation is 5 times/week for 3 weeks.
The primary endpoint is defined as the level of care dependency 12 months
after surgery or intervention. <br/>Discussion(s): Prehabilitation has
been proven to be effective for different populations, including
colorectal, transplant, and cardiac surgery patients. In contrast,
evidence for prehabilitation in older, frail patients has not been clearly
established. To the best of our knowledge, this is currently the largest
prehabilitation study on older people with frailty undergoing general
elective surgery. Trial registration: ClinicalTrials.gov NCT04418271.
Registered on 5 June 2020. Universal Trial Number (UTN):
U1111-1253-4820<br/>Copyright &#xa9; 2022, The Author(s).

<95>
Accession Number
2017662314
Title
Corticosteroids in patients undergoing cardiac surgery: A meta-analysis of
12,559 patients.
Source
Perfusion (United Kingdom). (no pagination), 2022. Date of Publication:
2022.
Author
Chen L.; Xiang F.; Hu Y.
Institution
(Chen, Xiang, Hu) Department of Pharmacy, The Second Affiliated Hospital
of Wenzhou Medical University, Wenzhou, China
Publisher
SAGE Publications Ltd
Abstract
Objective: Corticosteroids can attenuate the inflammatory response to
cardiopulmonary bypass, but their benefits on clinical outcomes are
unclear. We conducted a meta-analysis to evaluate whether corticosteroid
therapy affects outcomes in patients undergoing cardiac surgery.
<br/>Method(s): We searched PubMed, Embase, EBSCO and Cochrane databases
from 1 January 2010 to 14 March 2022 for randomized controlled trials
(RCTs) that assessed corticosteroid versus non- corticosteroid therapy in
patients undergoing cardiac surgery. The primary outcome was in-hospital
mortality. Secondary outcomes were renal failure, infection, delirium,
intensive care unit (ICU) and hospital stay. <br/>Result(s): Four RCTs
including 12,559 patients (6265 randomized to corticosteroid therapy and
6294 to non-corticosteroid therapy) were included. One-hundred and 92 of
6265 patients (3.1%) randomized to the corticosteroid group versus 221 of
6294 patients (3.5%) randomized to the non-corticosteroid group
experienced death during hospitalization. Compared the control group,
corticosteroid therapy did not significantly reduce in-hospital mortality,
with an RR of 0.87 (0.72-1.06), p =.16. There was no difference in the
incidence of infection (RR 0.78 (0.56-1.10), p =.16), delirium during
hospitalization (RR 1.01 (0.90-1.14), p =.85), or the length of hospital
stay (MD -0.13 (-0.32 to 0.05), p =.17). However, corticosteroid therapy
significantly reduced the risk of renal failure (RR 0.82 (0.67-0.99), p
=.04), and the length of ICU stay (MD -0.41 (-0.65 to -0.17), p <.01).
<br/>Conclusion(s): Corticosteroids did not significantly reduce the rates
of in-hospital mortality, infection, or delirium, but reduce the incidence
of renal failure and the length of ICU stay.<br/>Copyright &#xa9; The
Author(s) 2022.

<96>
Accession Number
638200094
Title
Fraction of Inspired Oxygen During General Anesthesia for Non-Cardiac
Surgery: Systematic Review and Meta-Analysis.
Source
Acta anaesthesiologica Scandinavica. (no pagination), 2022. Date of
Publication: 08 Jun 2022.
Author
Hoybye M.; Lind P.C.; Holmberg M.J.; Bolther M.; Jessen M.K.; Vallentin
M.F.; Hansen F.B.; Holst J.M.; Magnussen A.; Hansen N.S.; Johannsen C.M.;
Enevoldsen J.; Jensen T.H.; Roessler L.L.; Klitholm M.P.; Eggertsen M.A.;
Caap P.; Boye C.; Dabrowski K.M.; Vormfenne L.; Henriksen J.; Karlsson
C.M.; Balleby I.R.; Rasmussen M.S.; Paelestik K.; Granfeldt A.; Andersen
L.W.
Institution
(Hoybye, Holmberg, Jessen, Andersen) Research Center for Emergency
Medicine, Aarhus University Hospital, Denmark
(Hoybye, Holmberg, Jessen, Vallentin, Hansen, Magnussen, Johannsen,
Enevoldsen, Eggertsen, Boye, Vormfenne, Granfeldt, Andersen) Department of
Clinical Medicine, Aarhus University, Denmark
(Lind) Department of Surgical Gastroenterology, Aalborg University
Hospital, Denmark
(Holmberg) Department of Cardiology, Viborg Regional Hospital, Viborg,
Denmark
(Bolther, Holst, Hansen, Klitholm, Caap, Dabrowski, Henriksen, Granfeldt,
Andersen) Department of Anesthesiology and Intensive Care, Aarhus
University Hospital, Denmark
(Vallentin, Andersen) Prehospital Emergency Medical Services, Central
Denmark Region ,Aarhus, Denmark
(Jensen) Department of Internal Medicine, University Hospital of North
Norway, Narvik, Norway
(Roessler) Department of Emergency Medicine, Department of Clinical
Research, University of Southern Denmark, Odense, Denmark
(Karlsson, Rasmussen) Department of Anesthesiology and Intensive Care,
Aalborg University Hospital, Denmark
(Balleby) National Hospital of the Faroe Islands, Torshavn, Faroe Islands
(Paelestik) Department of Anesthesiology and Intensive Care, Viborg
Regional Hospital, Viborg, Denmark
Publisher
NLM (Medline)
Abstract
BACKGROUND: Controversy exists regarding the effects of a high versus a
low intraoperative fraction of inspired oxygen (FiO2 ) in adults
undergoing general anesthesia. This systematic review and meta-analysis
investigated the effect of a high versus a low FiO2 on postoperative
outcomes. <br/>METHOD(S): PubMed and Embase were searched on March 22,
2022 for randomized clinical trials investigating the effect of different
FiO2 levels in adults undergoing general anesthesia for non-cardiac
surgery. Two investigators independently reviewed studies for relevance,
extracted data, and assessed risk of bias. Meta-analyses were performed
for relevant outcomes, and potential effect measure modification was
assessed in subgroup analyses and meta-regression. The evidence certainty
was evaluated using GRADE. <br/>RESULT(S): This review included 25
original trials investigating the effect of a high (mostly 80%) versus a
low (mostly 30%) FiO2 . Risk of bias was intermediate for all trials. A
high FiO2 did not result in a significant reduction in surgical site
infections (OR: 0.91, 95% CI 0.81 to 1.02 [p = 0.10]). No effect was found
for all other included outcomes, including mortality (OR = 1.27, 95% CI:
0.90 to 1.79 [p = 0.18]) and hospital length of stay (mean difference =
0.03days, 95% CI -0.25 to 0.30 [p = 0.84).Results from subgroup analyses
and meta-regression did not identify any clear effect modifiers across
outcomes. The certainty of evidence (GRADE) was rated as low for most
outcomes. <br/>CONCLUSION(S): In adults undergoing general anesthesia for
non-cardiac surgery, a high FiO2 did not improve outcomes including
surgical site infections, length of stay, or mortality. However, the
certainty of the evidence was assessed as low.<br/>Copyright This article
is protected by copyright. All rights reserved.

<97>
Accession Number
638199811
Title
External Support for Saphenous Vein Grafts in Coronary Artery Bypass
Surgery: A Randomized Clinical Trial.
Source
JAMA cardiology. (no pagination), 2022. Date of Publication: 08 Jun 2022.
Author
Goldstein D.J.; Puskas J.D.; Alexander J.H.; Chang H.L.; Gammie J.S.;
Marks M.E.; Iribarne A.; Vengrenyuk Y.; Raymond S.; Taylor B.S.; Yarden
O.; Orion E.; Dagenais F.; Ailawadi G.; Chu M.W.A.; DiMaio J.M.; Narula
J.; Moquete E.G.; O'Sullivan K.; Williams J.B.; Crestanello J.A.; Jessup
M.; Rose E.A.; Scavo V.; Acker M.A.; Gillinov M.; Mack M.J.; Gelijns A.C.;
O'Gara P.T.; Moskowitz A.J.; Bagiella E.; Voisine P.
Institution
(Goldstein) Department of Cardiovascular and Thoracic Surgery, Montefiore
Medical Center, Bronx, NY, United States
(Puskas) Department of Cardiovascular Surgery, Mount Sinai Morningside, NY
(Alexander) Department of Medicine, Division of Cardiology, Duke
University Medical Center, Durham, NC
(Chang, Marks, Raymond, Moquete, O'Sullivan, Rose, Gelijns, Moskowitz,
Bagiella) Department of Population Health Science and Policy, Icahn School
of Medicine at Mount Sinai, NY
(Gammie) Johns Hopkins Heart and Vascular Institute, Johns Hopkins Health
System, Baltimore, MD, United States
(Iribarne) Section of Cardiac Surgery, Dartmouth-Hitchcock Medical Center,
NH, Lebanon
(Vengrenyuk) Division of Cardiology, Icahn School of Medicine at Mount
Sinai, Mount Sinai Hospital, NY
(Taylor) Division of Cardiac Surgery, University of Maryland School of
Medicine, Baltimore, United States
(Yarden, Orion) Vascular Graft Solutions Ltd, Tel Aviv, Israel
(Dagenais, Voisine) Department of Surgery, Institut de Cardiologie et
Pneumologie de Quebec, Quebec City, QC, Canada
(Ailawadi) Department of Cardiac Surgery, University of Michigan, Ann
Arbor, United States
(Chu) Division of Cardiac Surgery, Western University, London Health
Sciences Centre, London, ON, Canada
(DiMaio, Mack) Cardiothoracic Surgery, Baylor Scott & White Health, Plano,
TX, United States
(Narula) Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, NY
(Williams) Cardiovascular Surgery, WakeMed Health and Hospitals, Raleigh,
NC, United States
(Crestanello) Department of Cardiovascular Surgery, Mayo Clinic,
Rochester, MN
(Jessup) American Heart Association, Dallas, TX, United States
(Scavo) Cardiovascular and Thoracic Surgery, Lutheran Medical Group, Ft
Wayne, IN
(Acker) Division of Cardiovascular Surgery, University of Pennsylvania,
Hospital of the University of Pennsylvania, Philadelphia, United States
(Gillinov) Department of Thoracic and Cardiovascular Surgery, Cleveland
Clinic, Cleveland, OH, United States
(O'Gara) Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
Publisher
NLM (Medline)
Abstract
Importance: Intimal hyperplasia and subsequent saphenous vein graft
failure may have significant adverse clinical effects in patients
undergoing coronary artery bypass surgery. External support of saphenous
vein grafts has the potential to prevent vein graft dilation and hence
slow the rate of intimal hyperplasia and increase long-term vein patency.
<br/>Objective(s): To determine efficacy, as measured by intimal
hyperplasia, and safety of an external saphenous vein graft support device
in patients undergoing a coronary bypass graft procedure. <br/>Design,
Setting, and Participant(s): This within-patient randomized, open-label,
multicenter study was conducted at 17 Cardiothoracic Surgical Trials
Network centers in North America. Between January 2018 and February 2019,
224 patients with multivessel coronary artery disease undergoing isolated
bypass surgery were enrolled. For each patient, 1 of 2 vein grafts was
randomized to receive external support or no support.
<br/>Intervention(s): External vein graft support or no support. <br/>Main
Outcomes and Measures: The primary efficacy end point was intimal
hyperplasia area assessed by intravascular ultrasound at 12 months
postrandomization for each study graft. Secondary confirmatory end points
were lumen diameter uniformity assessed by angiography and graft failure
(>=50% stenosis) by quantitative coronary angiography. Major cardiac and
cerebrovascular events were collected through month 12. <br/>Result(s):
Among 224 patients (mean [SD] age, 65.8 [8.3] years; 178 [79.5%] male),
203 (90.6%) were eligible for intravascular ultrasound, of which 85
(41.9%) had at least 1 study graft occluded or severely diseased at 12
months (55 supported, 56 unsupported). After imputation of data missing
because of graft occlusion or severe disease, the estimated mean (SE)
intimal hyperplasia area was 5.11 (0.16) mm2 in supported grafts and 5.79
(0.20) mm2 in unsupported grafts (P=.07). In a sensitivity analysis of 113
patients with both grafts imaged, the mean intimal hyperplasia area was
4.58 (0.18) mm2 and 5.12 (0.23) mm2 in supported and unsupported grafts,
respectively (P=.04). By 12 months, 5 patients (2.2%) died and 16 patients
(7.1%) experienced a major cardiac or cerebrovascular event.
<br/>Conclusions and Relevance: The 12-month difference in intimal
hyperplasia area between supported and unsupported grafts did not achieve
statistical significance. Cumulative mortality and major cardiac or
cerebrovascular events rates were similar to those in other randomized
coronary artery bypass trials. Further investigation to assess the effect
of external graft support devices on long-term graft patency and clinical
outcomes is warranted. Trial Registration: ClinicalTrials.gov Identifier:
NCT03209609.

<98>
Accession Number
2018481498
Title
Effects of structured intraoperative briefings on patient outcomes:
Multicentre before-And-After study.
Source
British Journal of Surgery. 109(1) (pp 136-144), 2022. Date of
Publication: 01 Jan 2022.
Author
Tschan F.; Keller S.; Semmer N.K.; Timm-Holzer E.; Zimmermann J.; Huber
S.A.; Wrann S.; Hubner M.; Banz V.; Prevost G.A.; Marschall J.; Candinas
D.; Demartines N.; Weber M.; Beldi G.
Institution
(Tschan, Keller, Timm-Holzer, Zimmermann, Huber) Institute for Work and
Organizational Psychology, University of Neuchatel, Neuchatel, Switzerland
(Semmer) Department of Psychology, University of Berne, Berne, Switzerland
(Wrann, Weber) Department of Surgery, Triemli Hospital, Zurich,
Switzerland
(Hubner, Demartines) Department of Visceral Surgery, University Hospital
Lausanne (CHUV), Lausanne, Switzerland
(Banz, Prevost, Candinas, Beldi) Department of Visceral Surgery and
Medicine, Berne University Hospital, University of Berne, Berne,
Switzerland
(Prevost) Department of Surgery, Kantonsspital Graubunden, Chur,
Switzerland
(Marschall) Department of Infectious Diseases, University Hospital Berne,
Berne, Switzerland
Publisher
Oxford University Press
Abstract
Background: Operations require collaboration between surgeons, anaesthetia
professionals, and nurses. The aim of this study was to determine whether
intraoperative briefings influence patient outcomes. <br/>Method(s): In a
before-And-After controlled trial (9 months baseline; 9 months
intervention), intraoperative briefings were introduced in four general
surgery centres between 2015 and 2018. During the operation, the
responsible surgeon (most senior surgeon present) briefed the surgical
team using the StOP? protocol about: progress of the operation (Status),
next steps (Objectives), possible problems (Problems), and encouraged
asking questions (?). Differences between baseline and intervention were
analysed regarding surgical-site infections (primary outcome), mortality,
unplanned reoperations, and duration of hospital stay (secondary
outcomes), using inverse probability of treatment (IPT) weighting based on
propensity scores. <br/>Result(s): In total, 8256 patients underwent
surgery in the study. Endpoint data were available for 7745 patients (93.8
per cent). IPT-weighted and adjusted intention-To-Treat analyses showed no
differences in surgical-site infections between baseline and intervention
(9.8 versus 9.6 per cent respectively; adjusted difference (AD)-0.15 (95
per cent c.i.-1.45 to 1.14) per cent; odds ratio (OR) 0.92, 95 per cent
c.i. 0.83 to 1.15; P = 0.797), but there were reductions in mortality (1.6
versus 1.1 per cent; AD-0.54 (-1.04 to-0.03) per cent; OR 0.60, 0.39 to
0.92; P = 0.018), unplanned reoperations (6.4 versus 4.8 per cent; AD-1.66
(-2.69 to-0.62) per cent; OR 0.72, 0.59 to 0.89; P = 0.002), and fewer
prolonged hospital stays (21.6 versus 19.8 per cent; AD-1.82 (-3.48
to-0.15) per cent; OR 0.87, 0.77 to 0.98; P = 0.024). <br/>Conclusion(s):
Short intraoperative briefings improve patient outcomes and should be
performed routinely.<br/>Copyright &#xa9; 2021 The Author(s) 2021.
Published by Oxford University Press on behalf of BJS Society Ltd.

<99>
[Use Link to view the full text]
Accession Number
2017581286
Title
A holistic investigation of the global outcomes of spontaneous
pneumothorax during 1980-2021, including the COVID-19 pandemic A
bibliometric approach.
Source
Medicine (United States). 101(11) (no pagination), 2022. Article Number:
e29113. Date of Publication: 18 Mar 2022.
Author
Baldemir R.; Ulger G.
Institution
(Baldemir, Ulger) Anesthesiology and Reanimation Clinic, Ankara Ataturk
Chest Diseases and Thoracic Surgery Training and Research Hospital,
University of Health Sciences, Ankara, Turkey
Publisher
Lippincott Williams and Wilkins
Abstract
Background: During coronavirus pandemic, despite the increase in the
number of studies on spontaneous pneumothorax (SP), there is not enough
bibliometric study in the literature. In this study, it was aimed to
analyze scientific articles published on SP. <br/>Method(s): Studies
published on SP between 1980 and 2021 were obtained from the Web of
Science database and analyzed using statistical and bibliometric methods.
Spearman correlation coefficient was used for correlation studies. The
exponential smoothing estimator was used to forecast publication trend for
coming years. Network visualization maps were used to analyze citations
and identify trending topics. <br/>Result(s): A total of 2422 publications
were found. 1403 (57.9%) of these publications were articles. The articles
on SP have increased with a non-linear trend in recent years. The top 5
contributors to the literature were USA (231, 16.4%), Japan (161, 11.4%),
United Kingdom (98, 6.9%), France (81, 5.7%), and Taiwan (78, 5.5%). The
top 3 most active institutions were National Taiwan University Hospital
(22, 1.5%), Catholic University Korea (19, 1.3%), and National Taiwan
University (19, 1.3%). The top 3 journals that published the most articles
were Chest (51), Annals of Thoracic Surgery (46), and Journal of Thoracic
Disease (45). The most studied subjects were primary SP, recurrence,
thoracoscopy, pleurodesis, video-assisted thoracoscopic surgery, COVID-19,
video-assisted thoracic surgery, chest tube(s), and secondary spontaneous
pneumothorax. According to trend topics analysis, the keywords studied in
recent years are COVID-19, chest tubes, pneumonia, subcutaneous emphysema,
risk factors, dyspnea, primary SP, FLCN gene, tension pneumothorax,
uniportal, postoperative recurrence, secondary spontaneous pneumothorax,
chronic obstructive pulmonary disease, and uniportal. <br/>Conclusion(s):
In this comprehensive bibliometric study, we summarized 1403 articles
about SP, which has an increasing trend in the number of articles during
the COVID-19 pandemic process. This article can be a useful resource for
clinicians and scientists through presenting a summary of worldwide
studies related to SP, including the ones during COVID-19
pandemic.<br/>Copyright &#xa9; 2022 the Author(s).

<100>
Accession Number
2017766572
Title
Hybrid coronary revascularization versus coronary artery bypass grafting
for multivessel coronary artery disease: A systematic review and
meta-analysis.
Source
International Journal of Cardiology. 359 (pp 20-27), 2022. Date of
Publication: 15 Jul 2022.
Author
Dixon L.K.; Akberali U.; Di Tommaso E.; George S.J.; Johnson T.W.; Bruno
V.D.
Institution
(Dixon) Bristol Medical School, Public Health Science, University of
Bristol, Bristol, United Kingdom
(Akberali, Di Tommaso, George, Johnson, Bruno) Bristol Medical School,
Translational Health Science, University of Bristol, Bristol, United
Kingdom
(Johnson, Bruno) Bristol Heart Institute, University Hospitals of Bristol
and Weston NHS Foundation Trust, Bristol, United Kingdom
Publisher
Elsevier Ireland Ltd
Abstract
Background: Hybrid coronary revascularization (HCR) combines the benefits
of a left internal mammary artery to left anterior descending artery
anastomosis, via a mini thoracotomy, with percutaneous coronary
intervention (PCI) for other diseased coronaries. <br/>Aim(s): The aim of
this meta-analysis is to compare the short- and long-term outcomes of HCR
with those of coronary artery bypass grafting (CABG) for multi-vessel
coronary artery disease (MCAD). <br/>Method(s): We performed a
meta-analysis with a primary outcome of short-term mortality and secondary
outcomes of mid-term survival, length of hospital stay, stroke, renal
failure and mid-term MACE rate. <br/>Result(s): 3399 patients (HCR = 1164,
CABG = 2235) were included, with no significant difference in short-term
mortality between groups (OR = 1.50, 95% CI = [0.90,2.49], p = 0.11),
although a higher mortality rate was seen in the HCR group (0.73% vs
0.64%). The average length of stay in intensive care unit was
significantly shorter following HCR than CABG (mean difference = -15.52 h,
CI = [-22.47,-8.59], p0.001) and overall hospital stay was also shorter in
this group, although not statistically significant (mean difference =
-3.15 days, 95% CI = [-6.55, 0.25], p = 0.07). HCR was associated with a
reduced odds of blood transfusion (OR = 0.34, 95% CI = [0.22,0.54], p <
0.001). There was not a significant difference in mid-term survival (OR =
0.86, 95% CI = [0.62,1.21], p = 0.39) or MACE rate (OR = 0.82, 95% CI =
[0.55,1.23], p = 0.34). No differences were found between HCR and CABG for
post-operative stroke (OR = 1.36, 95% CI = [0.87, 2.13], p = 0.16) or
renal failure (OR = 0.71, 95% CI = [0.43,1.16], p = 0.14).
<br/>Conclusion(s): HCR has a higher incidence of short-term mortality
compared to CABG in patients with MCAD, although this difference is not
statistically significant. Similar rates of mid-term survival and other
short term post-operative complications were found between the two groups.
HCR has a shorter ICU stays and reduced requirement for blood
transfusion.<br/>Copyright &#xa9; 2022 Elsevier B.V.

<101>
[Use Link to view the full text]
Accession Number
2017431269
Title
Implementation of Vancomycin Therapeutic Monitoring Guidelines: Focus on
Bayesian Estimation Tools in Neonatal and Pediatric Patients.
Source
Therapeutic Drug Monitoring. 44(2) (pp 241-252), 2022. Date of
Publication: 01 Apr 2022.
Author
Han J.; Sauberan J.; Tran M.T.; Adler-Shohet F.C.; Michalik D.E.; Tien
T.H.; Tran L.; Do D.H.; Bradley J.S.; Le J.
Institution
(Han, Tran, Le) University of California, San Diego, Skaggs School of
Pharmacy and Pharmaceutical Sciences, MC 0657, 9500 Gilman Drive, San
Diego, CA 92093, United States
(Sauberan) Neonatal Research Institute, SHARP Mary Birch Hospital for
Women and Newborns, San Diego, United States
(Tran, Adler-Shohet) Children's Hospital of Orange County, Orange, United
States
(Michalik) MemorialCare Miller Children's and Women's Hospital Long Beach,
Long Beach, CA, United States
(Tien) University Medical Center, Ho Chi Minh City, Vietnam
(Do) Canyon Crest Academy, San Diego, United States
(Bradley) Division of Infectious Diseases, University of California at San
Diego, San Diego, CA, United States
(Bradley) Rady Children's Hospital-San Diego, San Diego, CA, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Background:The 2020 consensus guidelines for vancomycin therapeutic
monitoring recommend using Bayesian estimation targeting the ratio of the
area under the curve over 24 hours to minimum inhibitory concentration as
an optimal approach to individualize therapy in pediatric patients. To
support institutional guideline implementation in children, the objective
of this study was to comprehensively assess and compare published
population-based pharmacokinetic (PK) vancomycin models and available
Bayesian estimation tools, specific to neonatal and pediatric patients.
<br/>Method(s):PubMed and Embase databases were searched from January 1994
to December 2020 for studies in which a vancomycin population PK model was
developed to determine clearance and volume of distribution in neonatal
and pediatric populations. Available Bayesian software programs were
identified and assessed from published articles, software program
websites, and direct communication with the software company. In the
present review, 14 neonatal and 20 pediatric models were included. Six
programs (Adult and Pediatric Kinetics, BestDose, DoseMeRx, InsightRx,
MwPharm++, and PrecisePK) were evaluated. <br/>Result(s):Among neonatal
models, Frymoyer et al and Capparelli et al used the largest PK samples to
generate their models, which were externally validated. Among the
pediatric models, Le et al used the largest sample size, with multiple
external validations. Of the Bayesian programs, DoseMeRx, InsightRx, and
PrecisePK used clinically validated neonatal and pediatric models.
<br/>Conclusion(s):To optimize vancomycin use in neonatal and pediatric
patients, clinicians should focus on selecting a model that best fits
their patient population and use Bayesian estimation tools for therapeutic
area under the -curve-targeted dosing and monitoring.<br/>Copyright &#xa9;
2022 Lippincott Williams and Wilkins. All rights reserved.

<102>
Accession Number
2016950524
Title
An Overview about Radiography of Pulmonary Ground Glass Opacity.
Source
NeuroQuantology. 20(5) (pp 1154-1167), 2022. Date of Publication: 2022.
Author
Zaki R.S.; Dawoud O.A.; Ahmed A.F.; Salem A.F.
Institution
(Zaki, Dawoud, Ahmed, Salem) Department of Radiodiagnosis, Faculty of
Medicine, Zagazig University, Egypt
Publisher
Anka Publishers
Abstract
Background: Pulmonary ground-glass opacity (GGO) is defined as hazy
opacity that does not obscure underlying bronchial structures or pulmonary
vessels at computed tomography (CT). Pathologically, GGO may be caused by
partial airspace filling, interstitial thickening with inflammation,
oedema, fibrosis, neoplastic proliferation, the normal respiratory
condition or increased pulmonary capillary blood volume. Recently, It has
received considerable attention because it may indicate an early
underlying lung cancer, which in most cases presents as bronchioloalveolar
carcinoma (BAC) and adenocarcinoma with a predominant BAC
component.<br/>Copyright &#xa9; 2022, Anka Publishers. All rights
reserved.

<103>
Accession Number
2016638371
Title
Bioprosthetic Aortic Valve Degeneration: a Review from a Basic Science
Perspective.
Source
Brazilian Journal of Cardiovascular Surgery. 37(2) (pp 239-250), 2022.
Date of Publication: 2022.
Author
Velho T.R.; Pereira R.M.; Fernandes F.; Guerra N.C.; Ferreira R.; Nobre A.
Institution
(Velho, Pereira, Guerra, Ferreira, Nobre) Cardiothoracic Surgery
Department, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte,
Lisboa, Portugal
(Velho) Innate Immunity and Inflammation Laboratory, Instituto Gulbenkian
de Ciencia, Oeiras, Portugal
(Fernandes) Department of Biomedical Sciences and Medicine, Universidade
do Algarve, Campus de Gambelas, Faro, Portugal
Publisher
Sociedade Brasileira de Cirurgia Cardiovascular
Abstract
Introduction: The increase in the prevalence of aortic stenosis due to an
aging population has led to an increasing number of surgical aortic valve
replacements. Over the past 20 years, there has been a major shift in
preference from mechanical to bioprosthetic valves. However, despite
efforts, there is still no "ideal" bioprosthesis. It is crucial to
understand the structure, biology, and function of native heart valves to
design more intelligent, strong, durable, and physiological heart valve
tissues. <br/>Method(s): A comprehensive review of the literature was
performed to identify articles reporting the basic mechanisms of
bioprosthetic valve dysfunction and the biology of native valve cells.
Searches were run in PubMed, MEDLINE (the Medical Literature Analysis and
Retrieval System Online), and Google Scholar. Terms for subject heading
and keywords search included "biological heart valve dysfunction",
"bioprosthesis dysfunction", "bioprosthesis degeneration", and "tissue
heart valves". <br/>Result(s): All the relevant findings are summarized in
the appropriate subsections. Structural dysfunction is a logical and
expected consequence of the chemical, mechanical, and immunological
processes that occur during fixation, manufacture, and implantation.
<br/>Conclusion(s): Biological prosthesis valve dysfunction is a
clinically significant process. It has become a major issue considering
the growing rate of bioprosthesis implantation and improved long-term
patient survival. Understanding bioprosthetic aortic valve degeneration
from a basic science perspective is a key point to improve technologic
advances and specifications that lead to a new generation of
bioprostheses.<br/>Copyright &#xa9; 2022, Sociedade Brasileira de Cirurgia
Cardiovascular. All rights reserved.

<104>
[Use Link to view the full text]
Accession Number
635505362
Title
Late Outcomes of the RAPID-TnT Randomized Controlled Trial: 0/1-Hour
High-Sensitivity Troponin T Protocol in Suspected ACS.
Source
Circulation. 144(2) (pp 113-125), 2021. Date of Publication: 13 Jul 2021.
Author
Lambrakis K.; Papendick C.; French J.K.; Quinn S.; Blyth A.; Seshadri A.;
Edmonds M.J.R.; Chuang A.; Khan E.; Nelson A.J.; Wright D.; Horsfall M.;
Morton E.; Karnon J.; Briffa T.; Cullen L.A.; Chew D.P.
Institution
(Lambrakis, Blyth, Seshadri, Chuang, Khan, Morton, Karnon, Chew) College
of Medicine and Public Health, Flinders University of South Australia,
Adelaide, Australia
(Chew) South Australian Health and Medical Research Institute, Adelaide,
Australia
(Papendick, Edmonds, Nelson, Wright, Horsfall) South Australian Department
of Health, Adelaide, Australia
(Papendick, Nelson) School of Medicine, University of Adelaide, Australia
(French) Department of Cardiology, Liverpool Hospital, University of New
South Wales, Sydney, Australia
(Quinn) Department of Statistics, Data Science and Epidemiology, Swinburne
University of Technology, Melbourne, Australia
(Briffa) School of Population and Global Health, University of Western
Australia, Perth, Australia
(Cullen) Emergency and Trauma Centre, Royal Brisbane and Women's Hospital,
Australia
(Cullen) School of Public Health, Queensland University of Technology,
Brisbane, Australia
(Cullen) School of Medicine, University of Queensland, Brisbane, Australia
Publisher
Lippincott Williams and Wilkins
Abstract
Background: High-sensitivity troponin assays are increasingly being
adopted to expedite evaluation of patients with suspected acute coronary
syndromes. Few direct comparisons have examined whether the enhanced
performance of these assays at low concentrations leads to changes in care
that improves longer-term outcomes. This study evaluated late outcomes of
participants managed under an unmasked 0/1-hour high-sensitivity cardiac
troponin T (hs-cTnT) protocol compared with a 0/3-hour masked hs-cTnT
protocol. <br/>Method(s): We conducted a multicenter prospective
patient-level randomized comparison of care informed by unmasked 0/1-hour
hs-cTnT protocol (reported to <5 ng/L) versus standard practice masked
hs-cTnT testing (reported to <=29 ng/L) assessed at 0/3 hours and followed
participants for 12 months. Participants included were those presenting to
metropolitan emergency departments with suspected acute coronary
syndromes, without ECG evidence of coronary ischemia. The primary end
point was time to all-cause death or myocardial infarction using Cox
proportional hazards models adjusted for clustering within hospitals.
<br/>Result(s): Between August 2015 and April 2019, we randomized 3378
participants, of whom 108 withdrew, resulting in 12-month follow-up for
3270 participants (masked: 1632; unmasked: 1638). Among these, 2993
(91.5%) had an initial troponin concentration of <=29 ng/L. Deployment of
the 0/1-hour hs-cTnT protocol was associated with reductions in functional
testing. Over 12-month follow-up, there was no difference in invasive
coronary angiography (0/1-hour unmasked: 232/1638 [14.2%]; 0/3-hour
masked: 202/1632 [12.4%]; P=0.13), although an increase was seen among
patients with hs-cTnT levels within the masked range (0/1-hour unmasked
arm: 168/1507 [11.2%]; 0/3-hour masked arm: 124/1486 [8.3%]; P=0.010). By
12 months, all-cause death and myocardial infarction did not differ
between study arms overall (0/1-hour: 82/1638 [5.0%] versus 0/3-hour:
62/1632 [3.8%]; hazard ratio, 1.32 [95% CI, 0.95-1.83]; P=0.10). Among
participants with initial troponin T concentrations <=29 ng/L, unmasked
hs-cTnT reporting was associated with an increase in death or myocardial
infarction (0/1-hour: 55/1507 [3.7%] versus 0/3-hour: 34/1486 [2.3%];
hazard ratio, 1.60 [95% CI, 1.05-2.46]; P=0.030). <br/>Conclusion(s):
Unmasked hs-cTnT reporting deployed within a 0/1-hour protocol did not
reduce ischemic events over 12-month follow-up. Changes in practice
associated with the implementation of this protocol may be associated with
an increase in death and myocardial infarction among those with newly
identified troponin elevations. Registration: URL:
https://www.anzctr.org.au; Unique identifier:
ACTRN12615001379505.<br/>Copyright &#xa9; 2021 Lippincott Williams and
Wilkins. All rights reserved.

<105>
Accession Number
2017683597
Title
Mechanical or biologic prostheses for mitral valve replacement: A
systematic review and meta-analysis.
Source
Clinical Cardiology. (no pagination), 2022. Date of Publication: 2022.
Author
Yu J.; Qiao E.; Wang W.
Institution
(Yu, Qiao, Wang) Department of Structural Heart Disease, Fu Wai Hospital,
National Center for Cardiovascular Diseases, Chinese Academy of Medical
Sciences, Peking Union Medical College, Beijing, China
Publisher
John Wiley and Sons Inc
Abstract
Either a mechanical or bioprosthetic valve is used in patients undergoing
mitral valve replacement (MVR). However, the optimal mitral prosthesis
remains controversial. The aim of this meta-analysis was thus to compare
outcomes between mechanical mitral valve replacement (MVRm) and
bioprosthetic mitral valve replacement (MVRb) for MVR patients. We
searched Embase, PubMed, Web of Science, and Cochrane Library databases
from January 1, 2000 to October 31, 2021 for studies that directly
compared surgical outcomes of MVRm and MVRb. A total of 22 studies with 35
903 patients were included in the meta-analysis (n = 23 868 MVRm and n =
12 035 MVRb). The MVRm group displayed lower long-term all causes
mortality (HR, 0.84; 95% confidence interval [CI]: 0.77-0.91; p <.0001; I2
= 51%), and fewer mitral reoperation (hazard ratio [HR]: 0.34; 95% CI:
0.23-0.50; p <.00001; I2 = 74%) than MVRb group. However, the MVRm group
was associated with a greater risk of major bleeding events (HR: 1.21; 95%
CI: 1.14-1.29; p <.00001; I2 = 0%), stroke and systemic embolism (HR:
1.20; 95% CI: 1.10-1.32; p <.0001; I2 = 0%) in matched or adjusted data.
No significant difference was observed between MVRm and MVRb on operative
mortality in matched/adjusted group (risk ratios: 0.83; 95% CI: 0.66-1.05;
p =.12; I2 = 0%). The results were consistent with patients aged under 70
years old. Patients who received a MVRm is associated with 16% lower risk
of long-term mortality and 66% lower risk of mitral reoperation, but 20%
greater risk of stroke or systemic embolism, 21% greater risk of major
bleeding compared with MVRb in matched/adjusted studies group, which were
consistent to patients younger than the age of 70 years who underwent
MVR.<br/>Copyright &#xa9; 2022 The Authors. Clinical Cardiology published
by Wiley Periodicals LLC.

<106>
Accession Number
2017231015
Title
Outcomes with revascularization and medical therapy in patients with
coronary disease and chronic kidney disease: A meta-analysis.
Source
Atherosclerosis. 351 (pp 41-48), 2022. Date of Publication: June 2022.
Author
Leszek A.; Poli L.; Zbinden S.; Godoy L.C.; Reny J.-L.; Farkouh M.E.;
Charytan D.M.; Mavrakanas T.A.
Institution
(Leszek, Poli, Zbinden, Reny) Department of Medicine, Geneva University
Hospitals and Faculty of Medicine, Geneva, Switzerland
(Godoy, Farkouh) Peter Munk Cardiac Centre, Heart and Stroke Richard Lewar
Centre, University of Toronto, Toronto, ON, Canada
(Godoy) Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP,
Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
(Charytan) Department of Medicine, New York University Langone Medical
Center & New York University Grossman School of Medicine, New York, NY,
United States
(Mavrakanas) Department of Medicine, McGill University Health Centre,
Montreal, QC, Canada
(Mavrakanas) Research Institute of the McGill University Health Centre,
Montreal, QC, Canada
Publisher
Elsevier Ireland Ltd
Abstract
Background and aims: Chronic kidney disease (CKD) confers a high risk for
poor cardiovascular outcomes. We conducted a systematic review and
meta-analysis to estimate the effects of revascularization as the initial
management strategy compared with medical therapy among patients with CKD
and coronary artery disease. <br/>Method(s): A Medline/PubMed literature
research was conducted to identify randomized studies comparing early
coronary revascularization with optimal medical therapy or medical therapy
alone in patients with CKD (estimated glomerular filtration rate <60
mL/min/1.73 m² or maintenance dialysis). The primary outcome
was myocardial infarction. The secondary outcomes were all-cause mortality
or progression to kidney failure. The risk ratio (RR) was estimated using
a random-effects model. <br/>Result(s): Eleven randomized trials were
included (3422 patients). Revascularization was associated with lower
incidence of myocardial infarction compared with medical therapy in
patients with CKD: RR 0.71 (95% confidence interval [CI] 0.54-0.94;
p=0.02). This result was mainly driven from a significantly lower
incidence of myocardial infarction with early revascularization among
patients with stable coronary artery disease: RR 0.59; 95% CI 0.37-0.93. A
similar incidence of all-cause mortality was observed with both treatment
strategies: RR 0.88 (95% CI 0.72-1.08; p=0.22). A trend towards lower
incidence of all-cause mortality was observed with revascularization in
the subgroup of patients presenting with NSTE-ACS: RR 0.73 (95% CI
0.51-1.04; p=0.08) but not among patients with stable coronary disease.
There was no difference in progression to kidney failure between the two
strategies. <br/>Conclusion(s): Coronary revascularization may be superior
to medical therapy among patients with CKD and coronary
disease.<br/>Copyright &#xa9; 2022

<107>
Accession Number
2016132836
Title
Systematic review of electrophysiology procedures in patients with
obstruction of the inferior vena cava.
Source
Journal of Cardiovascular Electrophysiology. 33(6) (pp 1300-1311), 2022.
Date of Publication: June 2022.
Author
Al-Sinan A.; Chan K.H.; Young G.D.; Martin A.; Sepahpour A.; Sy R.W.
Institution
(Al-Sinan, Chan, Sy) Department of Cardiology, Royal Prince Alfred
Hospital, Sydney, Australia
(Al-Sinan) Department of Cardiology, Waikato Hospital, Hamilton, New
Zealand
(Chan, Sy) Faculty of Medicine and Health, The University of Sydney,
Sydney, Australia
(Young) Department of Cardiology, Royal Adelaide Hospital, Adelaide,
Australia
(Martin) Green Lane Cardiovascular Service, Auckland City Hospital,
Auckland, New Zealand
(Sepahpour) Department of Cardiology, St. George Hospital, Sydney,
Australia
Publisher
John Wiley and Sons Inc
Abstract
Aims: The objective of the study was to conduct a systematic review to
describe and compare the different approaches for performing cardiac
electrophysiology (EP) procedures in patients with interrupted inferior
vena cava (IVC) or equivalent entities causing IVC obstruction.
<br/>Method(s): We conducted a structured search to identify manuscripts
reporting EP procedures with interrupted IVC or IVC obstruction of any
aetiology published up until August 2020. No restrictions were applied in
the search strategy. We also included seven local cases that met inclusion
criteria. <br/>Result(s): The analysis included 142 patients (mean age
48.9 years; 48% female) undergoing 143 procedures. Obstruction of the IVC
was not known before the index procedure in 54% of patients. Congenital
interruption of IVC was the most frequent cause (80%); and, associated
congenital heart disease (CHD) was observed in 43% of patients in this
setting. The superior approach for ablation was the most frequently used
strategy (52%), followed by inferior approach via the azygos or hemiazygos
vein (24%), transhepatic approach (14%), and retroaortic approach (10%).
Electroanatomical mapping (58%), use of long sheaths (41%), intracardiac
echocardiography (19%), transesophageal echocardiography (15%) and remote
controlled magnetic navigation (13%) were used as adjuncts to aid
performance. Ablation was successful in 135 of 140 procedures in which
outcomes were reported. Major complications were only reported in patients
undergoing AF ablation, including two patients with pericardial effusion,
one of whom required surgical repair, and another patient who died after
inadvertent entry into an undiagnosed atrioesophageal fistula from a
previous procedure. <br/>Conclusion(s): The superior approach is most
frequent approach for performing EP procedures in the setting of
obstructed IVC. Transhepatic approach is a feasible alternative, and may
provide a "familiar approach" for transseptal access when it is required.
Adjunctive use of long sheaths, intravascular echocardiography,
electro-anatomical mapping and remote magnetic navigation may be helpful,
especially if there is associated complex CHD. With careful planning, EP
procedures can usually be successfully performed with a low risk of
complications.<br/>Copyright &#xa9; 2022 The Authors. Journal of
Cardiovascular Electrophysiology published by Wiley Periodicals LLC.

<108>
[Use Link to view the full text]
Accession Number
2018654388
Title
Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline.
Source
Journal of Clinical Oncology. 40(12) (pp 1356-1384), 2022. Date of
Publication: 20 Apr 2022.
Author
Daly M.E.; Singh N.; Ismaila N.; Antonoff M.B.; Arenberg D.A.; Bradley J.;
David E.; Detterbeck F.; Fruh M.; Gubens M.A.; Moore A.C.; Padda S.K.;
Patel J.D.; Phillips T.; Qin A.; Robinson C.; Simone C.B.
Institution
(Daly) University of California, Davis, CA, United States
(Singh) Postgraduate Institute of Medical Education & Research,
Chandigarh, India
(Ismaila) American Society of Clinical Oncology (ASCO), 2318 Mill Road,
Suite 800, Alexandria, VA 22314, United States
(Antonoff) MD Anderson Cancer Center, Houston, TX, United States
(Arenberg, Qin) University of Michigan, Ann Arbor, MI, United States
(Bradley) Emory University, Atlanta, GA, United States
(David) University of Southern California, Los Angeles, CA, United States
(Detterbeck) Yale Cancer Center, New Haven, CT, United States
(Fruh) Department of Medical Oncology, Cantonal Hospital of St Gallen, St
Gallen, Switzerland
(Daly, Singh, Ismaila, Antonoff, Arenberg, Bradley, David, Detterbeck,
Fruh, Gubens, Moore, Padda, Patel, Phillips, Qin, Robinson, Simone)
University of Bern, Bern, Switzerland
(Gubens) University of California, San Francisco, CA, United States
(Moore) LUNGevity Foundation, Chicago, IL, United States
(Padda) Department of Medicine, Division of Oncology, Cedars-Sinai Medical
Center, Los Angeles, CA, United States
(Patel) Northwestern University, Feinberg School of Medicine, Chicago, IL,
United States
(Phillips) City of Hope, Lancaster, CA, United States
(Robinson) Washington University, St Louis, MO, United States
(Simone) New York Proton Center, Memorial Sloan Kettering Cancer Center,
New York, NY, United States
Publisher
Lippincott Williams and Wilkins
Abstract
PURPOSETo provide evidence-based recommendations to practicing clinicians
on management of patients with stage III non-small-cell lung cancer
(NSCLC).METHODSAn Expert Panel of medical oncology, thoracic surgery,
radiation oncology, pulmonary oncology, community oncology, research
methodology, and advocacy experts was convened to conduct a literature
search, which included systematic reviews, meta-analyses, and randomized
controlled trials published from 1990 through 2021. Outcomes of interest
included survival, disease-free or recurrence-free survival, and quality
of life. Expert Panel members used available evidence and informal
consensus to develop evidence-based guideline recommendations.RESULTSThe
literature search identified 127 relevant studies to inform the evidence
base for this guideline.RECOMMENDATIONSEvidence-based recommendations were
developed to address evaluation and staging workup of patients with
suspected stage III NSCLC, surgical management, neoadjuvant and adjuvant
approaches, and management of patients with unresectable stage III
NSCLC.Additional information is available at
www.asco.org/thoracic-cancer-guidelines. <br/>Copyright &#xa9; 2022
American Society of Clinical Oncology.

<109>
Accession Number
2018674773
Title
Ischemic Hepatitis Induced by Uremic Cardiac Tamponade in a Patient with
Underlying Hepatitis C with a Review of the Literature.
Source
Case Reports in Gastroenterology. (pp 326-332), 2022. Date of
Publication: 2022.
Author
Alsultan M.K.; Bakr A.; Hassan Q.
Institution
(Alsultan) Department of Nephrology, Al Assad and Al Mouwasat University
Hospitals, Damascus University, Faculty of Medicine, Damascus, Syrian Arab
Republic
(Bakr) Department of Oncology, Al Biruni University Hospital, Damascus
University, Faculty of Medicine, Damascus, Syrian Arab Republic
(Hassan) Department of Nephrology, Al Assad University Hospital, Damascus
University, Faculty of Medicine, Damascus, Syrian Arab Republic
Publisher
S. Karger AG
Abstract
Ischemic hepatitis is a rare cause of acute liver injury (ALI) and is
associated with various etiologies including cardiac failure, trauma,
hemorrhage, and respiratory failure that all result in poor perfusion and
oxygen delivery to the liver. A 30-year-old patient complained of
orthopnea with a history of hepatitis C treatment and is currently on
hemodialysis (HD) due to chronic allograft rejection. Also, he had
previous pericardial effusion (PEFF) due to inadequate dialysis.
Laboratory tests on admission revealed urinary tract infection, HCV PCR
positive, and high blood urea nitrogen. Computed tomography of the chest
showed massive PEFF. Echocardiography revealed a massive PEFF that
measured 3.6 cm on the apical four-chamber window, and the inferior vena
cava diameter was 27 mm with a decreased collapsibility of <=20% in
inspiration. The patient was treated for UTI and started the treatment for
HCV. Also, increased HD sessions with minimal heparinization of the
dialyzer circuit were obtained along with daily monitoring of PEFF by
echocardiography. At first, echocardiography did not reveal frank signs of
cardiac tamponade, but after 2 sessions of HD, the patient developed chest
pain, worsening orthopnea, JVP elevation, and dropping of the systolic BP.
Echocardiography showed specific signs of cardiac tamponade, which
included an increased effusion to 4.4 cm and changes in velocities of the
mitral valve and tricuspid valve during the respiratory cycle by more than
25% and 40%, respectively. The patient was transmitted to ICU, and
pericardiocentesis was obtained. Two days later, asymptomatic ALI was
noticed by elevation of the following tests: ALT, AST, LDH, PT, and INR.
However, ALI exhibits a rapid and spontaneous resolution to nearly normal
tests after 10 days. Although the patient was hemodynamically stable, the
liver injury occurred and might be attributed to ESRD and hypertension
that caused thickened heart walls, diastolic dysfunction, and subsequently
hepatic congestion, in addition to previous liver injury due to HCV. We
present a rare case of ALI caused by uremic pericardial tamponade with an
overview of the current literature with regard to this entity. So, we
emphasize monitoring liver function tests in the context of PEFF,
especially in patients with chronic kidney disease. <br/>Copyright &#xa9;
2022 The Author(s). Published by S. Karger AG, Basel.

<110>
Accession Number
2018488536
Title
Cardiovascular computed tomography in pediatric congenital heart disease:
A state of the art review.
Source
Journal of Cardiovascular Computed Tomography. (no pagination), 2022.
Date of Publication: 2022.
Author
Cohen J.; Asrani P.; Lee S.; Frush D.; Han B.K.; Chelliah A.; Farooqi K.M.
Institution
(Cohen) Department of Pediatrics, Division of Pediatric Cardiology, Icahn
School of Medicine at Mount Sinai, New York, NY, United States
(Asrani, Chelliah, Farooqi) Division of Pediatric Cardiology, Department
of Pediatrics, New York Presbyterian/Columbia University Irving Medical
Center, New York, NY, United States
(Lee) Department of Pediatrics, The Heart Center, Nationwide Children's
Hospital, The Ohio State University, Columbus, OH, United States
(Frush) Division of Pediatric Radiology, Department of Radiology, Medical
Physics Graduate Program, Duke University Medical Center, Durham, NC,
United States
(Han) The Children's Heart Clinic at The Children's Hospitals and Clinics
of Minnesota, Minneapolis, MN, United States
(Chelliah) Division of Pediatric Cardiology, Goryeb Children's Hospital,
Atlantic Health System, Morristown, NJ, United States
Publisher
Elsevier Inc.
Abstract
Cardiac computed tomography (CCT) has increasingly been used in the
assessment of both children and adults with congenital heart disease
(CHD), in part due to advances in CCT technology and an increased
prevalence of adults with palliated CHD. It serves as a complimentary
modality to echocardiography, cardiac magnetic resonance imaging and
cardiac catheterization. CCT can provide unique diagnostic information, is
less invasive and less likely to require sedation compared to other
modalities. Detailed knowledge of individual patient cardiac anatomy,
physiology, surgical repair and possible residual lesions are paramount to
optimal CCT imaging. This comprehensive review details the use of CCT both
pre- and postoperatively for the most common CHD diagnoses. We also aim to
highlight some new and innovative technologies that have become available
and can further optimize CCT imaging for CHD patients.<br/>Copyright
&#xa9; 2022 Society of Cardiovascular Computed Tomography

<111>
Accession Number
2016415611
Title
Chronic kidney disease and transcatheter aortic valve implantation.
Source
Cardiovascular Intervention and Therapeutics. (no pagination), 2022. Date
of Publication: 2022.
Author
Adachi Y.; Yamamoto M.
Institution
(Adachi, Yamamoto) Department of Cardiology, Toyohashi Heart Center, 21-1
Gobutori, Oyamachyo, Aichi, Toyohashi 441-8530, Japan
(Yamamoto) Department of Cardiology, Nagoya Heart Center, Aichi, Nagoya,
Japan
(Yamamoto) Department of Cardiology, Gifu Heart Center, Gifu, Japan
Publisher
Springer Japan
Abstract
Transcatheter aortic valve implantation (TAVI) is an established treatment
option for patients with severe aortic stenosis. Patients with aortic
stenosis have a higher prevalence of chronic kidney disease (CKD). CKD is
generally associated with an increased risk of mortality, cardiovascular
events, and readmission for heart failure; this supports the concept of a
cardio-renal syndrome (CRS). CRS encompasses a spectrum of disorders of
the heart and kidneys, wherein dysfunction in one organ may cause
dysfunction in the other. TAVI treatment is expected to break this
malignant cycle of CRS and improve cardio-renal function after the
procedure. However, several reports demonstrate that patients with CKD
have been associated with poor outcomes after the procedure. In addition,
TAVI treatments for patients with advanced CKD and those with end-stage
renal disease on hemodialysis are considered more challenging. Adequate
management to preserve cardio-renal function in patients undergoing TAVI
may reduce the risk of cardio-renal adverse events and improve the
long-term prognosis. The current comprehensive review article aims to
assess the prognostic impact of CKD after TAVI and seek optimal care in
patients with CKD even after successful TAVI.<br/>Copyright &#xa9; 2022,
The Author(s) under exclusive licence to Japanese Association of
Cardiovascular Intervention and Therapeutics.